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Abstract 
Chronic  myeloid  leukaemia  (CML)  is  a  stem  cell  (SC)  disorder  initiated  by  the 
reciprocal  translocation  between  chromosome  9  and  22,  giving  rise  to  the 
Philadelphia  (Ph)  chromosome  and  the  resulting  expression  of  the  oncogenic 
fusion protein BCR-ABL. The current first line of treatment is imatinib mesylate 
(IM), a tyrosine kinase inhibitor (TKI) that competes with ATP to block ABL kinase 
activity, which in turn prevents tyrosine phosphorylation of downstream molecules 
and selectively induces apoptosis of BCR-ABL cells. However, despite excellent 
cytogenetic  responses,  only  a  minority  of  patients  achieve  complete  molecular 
response (CMR). We have previously identified a population of quiescent (q) Ph
+ 
SC found in chronic phase (CP) CML that are relatively insensitive to IM and other 
TKIs and which may be responsible for the molecular persistence of this disease. 
This  population  may  be  insensitive  because  TKIs  do  not  reach  therapeutic 
concentrations  within  the  cell.  Such  resistance  to  classical  chemotherapeutic 
drugs,  the  phenomenon  of  multidrug  resistance  (MDR),  is  mediated  by  ABC 
transporters.  In  this  study  we  have  investigated  whether  CML  SC  express  the 
clinically relevant ABC transporters and determine their interaction with TKIs. In 
addition, we determined whether the inhibition of these transporters increased the 
efficacy of TKI against CML SC. 
Using CML CD34
+ cells isolated from newly diagnosed patients, normal CD34
+ 
cells and cell lines transduced with specific transporters as controls, the relative 
expression  of  drug  transporters  were  determined  in  CML  CD34
+  cells  and 
intracellular  staining  confirmed  protein  expression.  The  interaction  of  drug 
transporters  with  TKIs  was  assessed  using  a  combination  of  substrate 
displacement assays and radiolabelled assays. The effect of transporter inhibitors     3 
with TKIs on the growth and differentiation of q34
+ and more mature CD34
+ cells 
from CML patients in CP were assessed with regard to cell division, apoptosis and 
BCR-ABL kinase activity. 
When compared to normal CD34
+ cells, CML CD34
+ cells over-expressed ABCG2 
mRNA. In contrast MDR1 expression was reduced in CML CD34
+ cells and MRP1 
was  detected  at  similar  expression  levels  in  both  populations.  All  three  drug 
transporters  were  expressed  at  the  protein  levels  in  CML  CD34
+  cells.  It  was 
determined that at therapeutic concentrations (5 M) IM and nilotinib both inhibited 
ABCG2 and MDR1 and nilotinib also inhibited MRP1. Neither drug was a substrate 
for any of the transporters. In contrast, dasatinib was shown to be a substrate for 
ABCG2  and  MRP1,  but  had  no  effect  on  MDR1.  Therefore  activity  and 
concentration of dasatinib but not IM or nilotinib may be altered by the activity of 
these  proteins.  In  keeping  with  their  inhibitory  activity,  neither  IM  nor  nilotinib 
demonstrated significantly increased efficacy when combined with specific ABC 
transporter inhibitors (FTC or PSC 833). Surprisingly, although dasatinib was a 
substrate for ABCG2 and MRP1, dasatinib did not further increase apoptosis, or 
reduce the qSC population. 
Therefore, although MDR1, MRP1 and ABCG2 were found to be expressed and 
functional in CML CD34
+ cells and to interact with TKI, the co-treatment of TKIs 
with drug transporter inhibitors did not further increase apoptosis, reduce BCR-
ABL  kinase  activity  or  reduce  the  qSC  population.  Therefore,  modulation  of 
individual transporter activity is unlikely to reverse the resistance of this population 
of cells to TKI and will not improve the clinical response to these drugs. 
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1  Introduction 
1.1 Normal haemopoietic stem cell (HSC) and haemopoiesis  
Haemopoiesis is a carefully regulated process which results in the production of 
~10
11 erythrocytes, leukocytes and platelets each day. All of the formed blood cell 
lineages arise from a multi-potent HSC population, which may differentiate through 
a series of intermediate lineage, committed progenitor cells.  
The HSC is a rare cell located in the bone marrow (BM). Based on limiting dilution 
studies  in  non-obese  diabetic-severe  combined  immune  deficient  (NOD-SCID) 
mice, it has been estimated that there are approximately 3x10
6 HSCs in humans 
(Wang  et  al.  1997).  The  HSC  has  two  key  identifying  properties;  its  ability  to 
differentiate into multiple cell types and to self-renew (Shizuru et al. 2005).  Self-
renewal may be symmetrical, resulting in two daughter HSCs, or asymmetrical, 
producing an identical copy of itself and a downstream progenitor. Studies carried 
out  on  mouse  BM  cells  have  identified  three  distinct  HSC  populations  that 
constitute 0.05% of mouse BM cells; long-term HSCs (LT-HSC) which are capable 
of indefinite self-renewal, short-term HSCs (ST-HSC) which have a limited time 
span for self-renewal, and multi-potent progenitors that have little or no detectable 
self-renewal capacity (Morrison et al. 1997). These populations form a hierarchy in 
which the LT-HSC gives rise to ST-HSC, which forms the multi-potent progenitor, 
which then leads to either a lymphoid or myeloid lineage progenitor (Figure 1-1).  
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Figure 1-1 Schematic diagram of the haemopoietic cell hierarchy 
Only LT-HSC and ST-HSC have the capacity for self-renewal, which is lost 
once the cell has become a multi-potent progenitor. These give rise to the 
CLP and CMP, which undergo several proliferation and differentiation steps 
to give rise to mature, terminally differentiated progeny. [LT- long term, ST- 
short  term,  HSC-  haemopoietic  stem  cell,  CMP-  common  myeloid 
progenitor, CLP- common lymphoid progenitor] 
 
For  clinical  and  laboratory  purposes,  HSCs  may  be  isolated  by 
immunophenotyping using CD34, a surface glycoprotein involved in cell adhesion, 
as  the  surrogate  marker  (Berenson  et  al.  1988).  However,  the  isolated  CD34
+ 
population is heterogeneous and only a small minority are true HSCs with multi-
lineage  potential  that  have  indefinite  self-renewal.  These  are  characterised  as Jordanides Niove, 2008    Chapter 1 23 
CD34
+/lin
-/38
low/- (Miller et al. 1999) and are predominantly in the quiescent state 
(i.e. in G0), maintained so by their microenvironment. Another method for obtaining 
enriched  HSC  populations  is  by  exploiting  their  ability  to  efflux  Hoechst  33342 
(Hst). Goodell et al (Goodell et al. 1997) identified the small side population (SP) 
of cells that are Hst low which have the same immature phenotype as the HSC. In 
vitro studies of these primitive cells however, are difficult due to their rarity but also 
due to the unclear mechanism of self-renewal and differentiation which, in culture 
conditions, results in loss of stem cell phenotype with the acquisition of lineage-
specific markers (Weissman 2000).  
1.2 Cancer stem cell (CSC)  
The original hypothesis, known as the “clonal genetic model”, defined cancer as a 
proliferative  disease  that  originated  from  mutated  tumour  cells  that  contributed 
equally to the tumourigenic activity. However, the identification of normal HSCs 
and an improved understanding of haemopoiesis, led to the suggestion that the 
cancer  cells  may  be  organised  as  a  similar  hierarchy,  with  tumours  originating 
from a rare population of functionally distinct CSC. The first definitive evidence for 
the CSC hypothesis and the identification of the leukaemic stem cell (LSC) was 
reported by Bonnet and Dick (Bonnet and Dick 1997). They found that only a small 
defined subset of cells were capable of initiating acute myeloid leukaemia (AML) in 
NOD-SCID mice. These cells, termed SL-IC (SCID leukaemia-initiating cell) were 
identified  as  CD34
+CD38
-,  which  confirmed  that  primitive  cells  rather  than 
committed  progenitor  cells  represented  the  cell  of  origin  for  leukaemic 
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To date, the origin of LSCs is controversial (Figure 1-2). One view is that the LSCs 
are HSCs that have become leukaemic as a result of accumulated mutations. The 
reasoning for this theory is that as HSCs already possess the machinery for self-
renewal  as  well  as  various  developmental  pathways,  they  may  require  fewer 
mutations  to  maintain  the  ability  for  self-renewal  than  the  activation  of  these 
pathways in a more differentiated cell. Secondly, the nature of HSCs to persist for 
long periods of time increases the opportunity for mutations to accumulate in these 
stem cells (as shown by the atomic bomb survivors who developed cancer several 
years post exposure). Evidence for this view is supported by the cells with the 
CD34
+CD38
- phenotype which resembles that of the normal HSC, initiating most 
AML subtypes in NOD/SCID mice (Bonnet and Dick 1997). 
In contrast, LSCs may also be a more restricted or differentiated mature cell that 
has transformed and acquired the stem cell capability of self-renewal. Cozzio et al 
(Cozzio  et  al.  2003)  demonstrated  that  retroviral  transduction  of  the  potent 
leukaemic fusion gene  MLL-ENL can give rise to self-renewal properties in the 
CMP  and  induce  AML  when  transplanted  into  irradiated  mice.  Similarly, 
progenitors  transduced  with  MOZ-TIF2  resulted  in  leukaemia,  yet  in  contrast 
progenitors transduced with BCR-ABL did not (Huntly et al. 2004). This suggests 
that  only  some  leukaemia  oncogenes  can  confer  self-renewing  properties  to 
haemopoietic progenitors.  
Following documentation of the LSC, recent studies have now suggested that the 
CSC concept may also be relevant in solid tumours. Similar to the study by Bonnet 
and Dick (Bonnet and Dick 1997), breast cancer in NOD-SCID mice was initiated 
by the isolation of a phenotypically distinct subset of breast cancer cells (Al-Hajj et Jordanides Niove, 2008    Chapter 1 25 
al. 2003) and brain cancer stem cells were able to generate new tumours in vivo 
(Singh et al. 2004); this field is ever expanding. 
 
Figure 1-2 Origin of LSC 
The LSC may arise by transformation events occurring in the HSC which 
disrupts the normal development and gives rise to the self-renewing LSC. In 
contrast  the  transformation  may  occur  in  the  restricted  progenitors.  The 
mutations in these cells must reactivate the self-renewal properties in order 
to generate the LSC. [LSC-leukaemic stem cell, HSC-haemopoietic stem 
cell] 
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1.3 Chronic myeloid leukaemia (CML) 
One disease that has been established as a CSC driven disease is CML. CML is a 
clonal myeloproliferative  disorder that  is initiated  by the  reciprocal translocation 
between the 3’ end of the C-ABL (Abelson) gene from chromosome 9 and the 3’ 
end  of  the  BCR  (Breakpoint  Cluster  Region)  gene  on  chromosome  22 
(t(9;22)(q34;q11)),  giving  rise  to  the  abnormally  small  chromosome  22  (also 
termed Philadelphia (Ph) chromosome, named so after the city  in which it was 
discovered) (Rowley 1973). The molecular consequence of this translocation is the 
expression  of  the  fusion  gene  BCR-ABL.  Depending  upon  the  site  of  the 
breakpoint  in BCR, two fusion proteins can be  produced, one of 185kD (p185, 
seen in B cell-acute lymphoblastic leukaemia (B-ALL) and one of 210kD (p210). 
The  latter  constitutively  active  tyrosine  kinase  oncoprotein  is  seen  in  >95%  of 
patients with CML (Druker et al. 2001). 
CML  accounts  for  15-20%  of  all  leukaemias  in  adults  with  an  incidence  of 
approximately 1 in 100,000. CML may be diagnosed in all age groups, although 
the median age of onset is 40-60 years, with a slight male predominance of 1.4:1 
(Faderl et al. 1999). The principal cause is unclear, although there is a clear link 
with  exposure  to  ionising  radiation,  as  demonstrated  by  the  atomic  bomb 
survivors. CML typically has three clinical stages, presenting in an initial chronic 
phase (CP), progressing to accelerated phase (AP) and reaching blast crisis (BC) 
in typically 3-5 years, although in some cases the CP transforms rapidly to BC. In 
over  90%  of  cases,  CML  is  diagnosed  in  CP  and  is  characterised  by  an 
abnormally high white blood cell count consisting mainly of mature and immature 
myeloid  cells,  increased  megakaryocytes  in  BM  and  splenomegaly  (Sawyers 
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however, continues to be the basis upon which CML is diagnosed. In many clinical 
centres, the development of highly sensitive quantitative PCR to detect BCR-ABL 
transcripts has become a valuable tool for monitoring responses to therapy (Lion 
et al. 1995). As the disease progresses, additional cytogenetic abnormalities arise. 
During  AP  there  is  an  increase  in  immature  cells  with  additional  cytogenetic 
abnormalities and BC behaves like an acute leukaemia with a very poor prognosis. 
1.3.1 Role of BCR, ABL and the fusion protein BCR-ABL 
The proteins ABL1  and BCR are ubiquitously expressed in non-malignant cells 
and have many cellular regulatory functions (Laneuville 1995). BCR can modulate 
actin  polymerisation  through  RAC  (Diekmann  et  al.  1991),  activate  NF-kB 
(Montaner et al. 1998) and may influence the RAS pathway through interaction 
with the growth factor binding protein 2 (GRB2) (Goga et al. 1995; Ma et al. 1997). 
ABL1  protein  is  predominately  nuclear,  although  it  may  also  be  present  in  the 
cytoplasm  and  modulates  both  cell  cycle  regulation  and  response  to  integrin 
signalling (Van Etten 1999). ABL1 also forms complexes with GRB2 and the CT10 
regulator of kinase-like (CrkL) protein.  
The role of BCR-ABL in the pathogenesis of CML was established in 1990, when 
murine  BM  cells  transfected  with  the  p210  oncoprotein  (p210
BCR-ABL)  were 
transplanted  into  irradiated  recipients,  causing  them  to  develop  a 
myeloproliferative disorder closely resembling CML (Daley et al. 1990). However, 
although necessary, BCR-ABL alone may not be sufficient to cause CML as low 
BCR-ABL transcripts have also been detected in the blood of healthy individuals, 
suggesting that other factors may contribute to the transformation of this disease 
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A consequence of BCR-ABL however, is an increase in cell proliferation. Initially it 
was  assumed  this  was  due  to  the  most  mature  proliferating  cells  in  CP  CML 
causing  the  expansion  of  Ph
+  cells,  known  as  the  “discordant  maturation 
hypothesis”. However, this was refuted with further studies demonstrating that the 
myeloid expansion is a result of increased numbers of primitive CML progenitor 
cells  (Marley  et  al.  1996).  Holyoake  et  al  (Holyoake  et  al.  1999)  have  also 
demonstrated deregulated mechanisms in the quiescent population leading to an 
increase in cell cycling and contributing to increased proliferation.  
BCR-ABL  is  exclusively  localised  to  the  cytoplasm  (in  contrast  to  ABL  which 
shuttles  between  the  nucleus  and  cytoplasm),  resulting  in  the  constitutive 
phosphorylation of several substrates and activation of a range of cytoplasmic and 
nuclear transduction pathways. The substrates include adaptor molecules such as 
CrkL (Oda et al. 1994; Sattler et al. 1996) and GRB2 (Pendergast et al. 1993), 
adhesion proteins and proteins with catalytic function (such as Ras-GAP). These 
in  turn  activate  many  pathways  that  regulate  cell  proliferation  and  apoptosis 
(Figure 1-3).  
The anti-apoptotic phosphatidylinositol-3 kinase (PI3 kinase) pathway is activated 
when it forms a complex with BCR-ABL, Cbl and the adaptor molecules Crk and 
CrkL (Sattler and Salgia 1998). This in turn activates the downstream effector AKT 
kinase,  which  exerts  its  anti-apoptotic  effects  through  phosphorylation  of 
downstream target molecules. AKT can then phosphorylate IkB kinase, inducing 
the degradation of NF-kB inhibitor IkB. The released NF-kB then translocates to 
the  nucleus  allowing  proliferation,  inhibition  of  apoptosis  and  control  of 
differentiation.  In  addition  AKT  can  also  phosphorylate  BAD,  which  is  a  pro-
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Phosphorylation  of  BAD  by  AKT  releases  BCLxL  to  bind  to  BAX  and  hence 
neutralises the pro-apoptotic effects of BAX.  
 
Figure 1-3 Schematic diagram of the main signalling pathways 
activated by BCR-ABL in CML cells 
In  normal  HSCs,  these  pathways  are  normally  activated  by  cytokines, 
promoting  survival,  differentiation  and  proliferation.  In  the  absence  of 
growth  factors,  BCR-ABL  can  bypass  this  requirement  activating  these 
pathways  and  prolonging  survival  by  inhibiting  apoptosis.  The 
phosphorylation of substrates such as CrkL activates many pathways that 
regulate cell proliferation and promote cell survival. Indeed, the constitutive 
phosphorylation of CrkL may be used as a surrogate marker of BCR-ABL 
activity in the laboratory. Phosphorylation of AKT leads to cell survival. The 
phosphorylation  of  IκK  results  in  the  phosphorylation  and  degradation  of 
IκB, releasing NF-κB to translocate to the  nucleus where it can exert its 
anti-apoptotic  and  proliferative  effect.  Similarly  BAD  is  phosphoryated  to 
allow BCLXL to bind to BAX, neutralising its pro-apoptotic effect. BCR-ABL 
also  stabilises  RAS  in  the  active  form,  activating  the  RAF-MEK-ERK 
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Autophosphorylation  of  the  BCR-ABL  oncogene  also  leads  to  the  constitutive 
activation of the RAS pathway via interaction with the small adapter protein GRB2 
(Ma et al. 1997). RAS are a group of guanine nucleotide proteins (G-proteins) that 
can transduce external signals to transcription factors in the nucleus. Activation of 
RAS is achieved by farnesylation of RAS in the cytoplasm. Farnesylated RAS then 
translocates  to  the  cell  membrane  and  interacts  with  regulatory  proteins, 
maintaining a balance between the active and inactive form of RAS. However, the 
association of BCR-ABL with the GRB2/SOS complex (son of sevenless) retains 
RAS in the active form. This results in stimulation of the RAF-MEK-ERK effector 
pathway  and  subsequent  transcriptional  control  of  cell  growth,  proliferation  and 
differentiation (Sawyers et al. 1995).  
Another  mechanism  that  may  cause  deregulated  turnover  and  anti-apoptotic 
phenotype  is  BCR-ABL  induced  growth  factor  independence,  either  through 
ligand-independent  receptor  activation,  such  as  the  JAK/STAT  (JAK-Janus 
Kinases,  STAT-Signal  Transducer  of  Transcription)  pathway  or  autocrine 
production of cytokines. Normally, cytokines such as interleukin-3 (IL-3) activate 
JAK, causing phosphorylation of STAT5 which then translocates to the nucleus 
and upregulates transcription genes such as BCLxL which enhance cell survival, 
proliferation and differentiation (Horita et al. 2000). In the presence of BCR-ABL, 
however, the requirement of cytokines is bypassed such that JAK is activated in 
the absence of exogenous cytokines. In some cases, the constitutive activation of 
STAT5 is not always associated with activation of JAK, but activated via the SRC 
family  haemopoietic  cell  kinase  (HcK),  hence  bypassing  the  requirement  of 
cytokines  for  translocation  and  activation  of  transcription  genes  (Klejman  et  al. 
2002).  Overall,  the  pathways  activated  by  BCR-ABL  lead  to  deregulated 
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In addition to inducing cytokine independent activation of JAK/STAT5 mediated 
signalling  mechanisms,  BCR-ABL  also  activates  the  autocrine  production  of 
growth  factors.  Studies  have  conclusively  confirmed  an  autocrine  loop  for  IL-3, 
granulocyte-colony  stimulating  factor  (G-CSF)  and  granulocyte  macrophage-
colony stimulating factor (GM-CSF), in mouse BM cells transduced with bcr-abl 
expressing retroviral vectors (Zhang and Ren 1998; Abolhoda et al. 1999) and in 
primitive  human  CML  cells  (Jiang  et  al.  1999),  which  in  turn  maintained  cell 
survival and proliferation (Strife et al. 1988; Bedi et al. 1994; Maguer-Satta et al. 
1998; Jiang et al. 1999; Fu et al. 2000; Jiang et al. 2002). The specific activation of 
IL-3  production  following  BCR-ABL  transduction  suggested  that  control  of  IL-3 
expression  was  a  direct  consequence  of  BCR-ABL  activation,  as  cells  with  an 
inactive BCR-ABL kinase did not express IL-3 (Anderson and Mladenovic 1996) 
and, further downstream, increased STAT5 phosphorylation was a direct function 
of IL-3 stimulation (Jiang et al. 1999).  
1.3.2 Historic treatment of CML 
Following the discovery of CML in the 19
th century, initial therapeutic treatments 
included  administering  highly  toxic  arsenic  or  performing  splenectomy,  both  of 
which  had  limited  success.  Subsequently,  the  introduction  of  radiotherapy 
provided a good control of symptoms but did not extend survival. However, this 
remained the standard treatment until the introduction of the oral alkylating agent 
busulphan in the 1950’s, which showed a selective action on haemopoietic tissue 
despite  being  toxic  to  germinal  epithelium,  and  the  antimetabolite  hydroxyurea. 
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In the 1980’s the use of Interferon α (IFNα) was introduced for the treatment of 
CML. Although it restored normal haematological values in a lower proportion of 
patients compared to those treated with busulphan or hydroxyurea, IFNα was able 
to induce Ph
+ reduction in 5-15% cases (Talpaz et al. 1986) and when combined 
with arabinoside (Ara-C), induced a complete haematological response (CHR) of 
66% and major cytogenetic response (MCR) of 41%, with a survival rate of 85.7% 
within three years (Guilhot et al. 1997).  However, this treatment was associated 
with  a  number  of  side  effects  ranging  from  nausea  and  diarrhoea  to 
thrombocytopenia  and  the  majority  of  patients  had  minimal  residual  disease 
(MRD), which ultimately led to IFNα resistance. 
In  addition,  allogeneic  BM  transplantation  was  introduced  at  the  same  time  for 
younger  patients  (<50-55yrs).  This  procedure  has  a  significant  morbidity  and 
mortality of between 20-40%, due to the associated graft-versus-host disease and 
frequent  infections  (Sawyers  1999).  Yet  post-transplant,  there  is  up  to  a  70% 
leukaemia-free survival and to date this remains the only curative treatment (Clift 
and  Anasetti  1997;  Gratwohl  et  al.  1998).  However,  due  to  the  nature  of  the 
transplant and the difficulty in obtaining HLA matched donors only a minority of 
patients are suitable for these transplants. 
1.3.3 Development of a therapeutic drug for CML 
The discovery that the abnormal tyrosine kinase activity of ABL is essential for 
BCR-ABL mediated transformation and pathogenesis of CML made this an ideal 
target for therapeutic intervention. The first demonstration that synthetic inhibitors 
could be engineered to possess selective activity came from the development of a 
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PHOSphorylaTion Inhibitors), the most potent of which were able to selectively 
inhibit  epidermal  growth  factor  (EGF)  cell-dependent  proliferation,  whilst  not 
affecting  the  EGF-independent  proliferation.  Further  development  led  to  the 
generation of AG 490, the first synthetic compound that could inhibit proliferation in 
vivo  and  in  vitro.  Working  independently,  Ciba-Geigy  (now  known  as  Novartis) 
identified  the  phenylamino-pyrimidine  compounds  as  being  selective  inhibitors 
against the platelet derived growth factor-receptor (PDGF-R) tyrosine kinase and 
began  high throughput screening.  The  compound  CGP57148, later  branded  as 
STI  571  ((signal  transduction  inhibitor  571),  imatinib  mesylate  (IM),  Glivec
®,  or 
Gleevec
®),  emerged  as  a  potent  inhibitor  of  PDGF-R,  ABL,  ARG  and  C-KIT 
(Druker et al. 1996; Heinrich et al. 2000; Okuda et al. 2001) (Figure 1-4).  
 
Figure 1-4 Structure of imatinib mesylate (IM) 
 
IM exerts  its effect on BCR-ABL  by  binding  to  only  the  highly conserved  NH2-
terminal anchor region of the ATP binding pocket of the enzyme, known as the 
“activation  loop”,  preventing  phosphorylation  of  substrates  and  inhibiting 
intracellular signals (Figure 1-5). This region controls the catalytic activity of the 
kinase  by  switching  between  the  active  and  inactive  states.  Crystallographic Jordanides Niove, 2008    Chapter 1 34 
studies show that IM binds to the ATP site only when the activation loop is closed, 
thus stabilizing the inactive state (Schindler et al. 2000). 
 
Figure 1-5 Mechanism of IM 
BCR-ABL  requires  ATP  binding  for  phosphorylation  of  substrates  and 
subsequent activation of downstream pathways that promote cell survival, 
proliferation  and  regulation.  IM  can  compete  with  ATP,  binding  to  the 
inactive  state  of  BCR-ABL,  preventing  the  phosphorylation  of  substrates 
that  would  activate  intracellular  signals.  [Subs.  -  substrate,  p- 
phosphorylation] 
 
The efficacy of this compound was validated in myeloid cell lines, demonstrating 
inhibition of cell proliferation and tumour formation (Druker et al. 1996). Colony 
forming cell (CFC) assays of peripheral blood (PB) or BM cells from CML patients 
showed a 92-98% decrease in the number of BCR-ABL colonies formed compared Jordanides Niove, 2008    Chapter 1 35 
to no inhibition of normal colony formation at 1µM IM. At 10µM, normal BM colony 
formation  was  inhibited  by  15-20%,  with  substantial  loss  at  very  high  doses 
(50µM),  suggesting  that  at  this  dosage  there  was  loss  of  selectivity  causing 
inhibition of other tyrosine kinases. Experimental data with thymidine assays that 
measure proliferation also correlated with CFC assays (Gambacorti-Passerini et 
al.  1997).  Murine  studies  demonstrated  inhibition  of  tumour  growth  in  mice 
inoculated  with  bcr-abl,  with  no  adverse  effects  in  the  control  mice,  confirming 
efficacy  in  vivo  (Druker  et  al.  1996)  and  complete  eradication  of  tumour  was 
achieved with continuous administration of IM (le Coutre et al. 1999). 
The high selectivity of this compound at suppressing BCR-ABL cell expansion in 
CML  patient  samples  and  eradicating  bcr-abl  tumours  in  mice  led  to  its 
introduction to clinical trials. Phase I dose escalating studies were initially carried 
out  in  CP  CML  patients  who  had  failed  IFNα.  Haematological  and  cytogenetic 
responses were observed in 98% and 53% respectively with side effects including 
nausea,  myalgia,  oedema  and  diarrhoea  (Druker  2001).  Phase  II  studies 
continued  to  show  efficacy  and  low  toxicity  (Atallah  et  al.  2002),  however  IM 
resistance in some patients was starting to develop (Ottmann and Hoelzer 2002). 
The  success  of  the  above  phase  I/II  trials  led  to  a  multicentre  phase  III, 
randomised  study  (IRIS,  International  Randomised  study  of  IFNα  plus  Ara-C 
versus STI571), comparing IM with IFNα + Ara-C in newly diagnosed CP CML 
patients. Within 18 months the superiority of IM over conventional IFNα treatment 
was evident. A MCR of 87.1% was observed in patients treated with IM, compared 
to 34.7% for those treated with IFNα + Ara-C. Furthermore, complete cytogenetic 
response (CCR) was observed in 76.2% of patients treated with IM versus 14.5% 
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the IM group. The efficacy and tolerance quickly resulted in the approval of IM as 
the first line of treatment for patients with newly diagnosed CML in CP (O'Brien et 
al. 2003). 
The study has now reached its sixth year with the most recent cumulative CCR 
and  MCR  rates  at  57%  and  67%  respectively,  and  an  overall  survival  rate  of 
patients  who have received IM as initial therapy of 76%. In addition, there has 
been no increase in rates of serious adverse effects with continued use of IM, 
demonstrating  that  it  is  an  effective  and  safe  therapy  for  CP  CML  patients 
(Hochhaus et al. 2007). 
1.3.4 Molecular resistance 
However, despite the efficacy of IM, molecular resistance has been noted. This is 
generally observed in CML patients at the advanced stage of disease, although it 
has also been seen in CP patients, resulting in IM being less successful (Talpaz et 
al. 2002).  Resistance can  be described  either as  primary,  defined  as failure to 
achieve CHR in 3 months or CCR in 12 months, or acquired, defined as loss of 
established IM response or progression to AP or BC. 
It has been speculated that IM resistance may be either BCR-ABL independent or 
BCR-ABL dependent. Worryingly, BCR-ABL independence would suggest that the 
cells are no longer reliant upon BCR-ABL to drive proliferation, but have acquired 
other  oncogenic  mutations  (Donato  et  al.  2004).  This  would  mean  that  kinase 
inhibitors such as IM, that specifically target BCR-ABL, would never be able to kill 
the  insensitive  stem  cell.  There  is  also  increasing  evidence  that  SRC  family 
kinases may reduce the BCR-ABL dependence of the leukaemic cell, as patients 
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activity,  while  the  BCR-ABL  transcripts  and  protein  are  reduced  (Donato  et  al. 
2003). This has led to the development of new agents that target the SRC kinase 
and inhibit other non-ATP binding sites. 
In contrast, CSC resistance may be dependent upon BCR-ABL. Firstly, it has been 
hypothesised that Ph
+ cells have various mechanisms to evade the pro-apoptotic 
effect of IM. These include the development of mutations within the IM binding 
domain (Gorre et al. 2001) with in excess of 40 mutations having been detected so 
far (Branford et al. 2002). These are found within the ATP binding site (P-loop), 
activation loop (A-loop) or the carboxy terminus. Some mutations only confer a 
moderate degree of resistance, however, the mutations that are found in the P-
loop are associated with a poorer outcome (Branford et al. 2002). This is probably 
due  to  the  mutations  altering  and  destabilising  the  conformation  of  the  ATP-
binding site and restricting the binding of IM (Shah et al. 2002). In addition, the 
single nucleotide substitution of C to T at position 315, resulting in an isoleucine 
residue  instead  of  a  threonine  remains  the  most  clinically  significant  due  to  its 
resistance  to  high  IM  concentrations  and  poor  prognosis  in  CML  patients. 
Threonine  is  vital  to  IM  inhibition  as  it  forms  critical  hydrogen  bonds  and  the 
replacement with isoleucine results in a steric clash, preventing IM binding (Gorre 
et al. 2001). 
1.3.5 New therapeutic developments 
In order to overcome these therapeutic shortfalls of IM in resistance, the quest for 
superior drugs has led to the assessment of many new antileukaemic agents that 
may be used alone or in combination to circumvent this (Table 1-1). These include 
selective  ABL  inhibitors,  dual  SRC/ABL  kinase  inhibitors  and  other  non-ATP Jordanides Niove, 2008    Chapter 1 38 
competitive inhibitors. Two agents with promising results to date are nilotinib and 
dasatinib. 
Target  Mechanism  Agents 
BCR-ABL activity  New TKIs - ABL kinase  
                 - ABL and SRC kinase 
Nilotinib, ON012380 
dasatinib, bosutinib 
PD166326 
 
Heat shock protein 90 inhibitors  17-AAG  BCR-ABL 
stability  Histone deacetylase inhibitors  Trichostatin A 
 
BCR-ABL 
localisation 
Nuclear trapping  Leptomycin B 
 
 
Aurora kinase inhibitors  MK-0457, PHA-739358 
Farnesyl transferase inhibitors 
(FTI) 
Lonafarnib, SCH66336, 
L-744,832 
Induction of apoptosis  TRAIL 
PI3-kinase inhibitors  Wortmannin, LY294002 
Proteasome inhibitors  Bortezomib, PS341 
Protein kinase C  Bryostatin 
Alternative 
targets 
Reactive oxygen species  Adaphostin 
 
Table 1-1. Summary of antileukaemic agents being evaluated in CML. 
Modified and adapted from (Heaney and Holyoake 2007) 
 
1.3.5.1  Nilotinib (AMN107, Tasigna
®) 
In order to eliminate IM resistance, Novartis designed a new inhibitor based on the 
crystal structure of the IM-ABL complex. The result was nilotinib (Figure 1-6), a 
high affinity aminopyrimidine-based ATP competitive inhibitor with approximately 
20x  more  potency  than  IM  in  killing  BCR-ABL  expressing  cell  lines  (K562). 
Nilotinib can also inhibit the activity of ARG, C-KIT, and PDGF receptor kinases. In 
addition, nilotinib has shown effectiveness against all BCR-ABL mutations except 
for T315I (Manley et al. 2002; Manley et al. 2005). The additional methyl group of Jordanides Niove, 2008    Chapter 1 39 
isoleucine  restricts  access  to  the  drug  and  hence  inhibits  binding.  In  addition, 
nilotinib, as with IM, can only bind to the inactive conformation of BCR-ABL. 
 
Figure 1-6 Structure of nilotinib  
 
In a phase I dose-escalation study, IM-resistant CML patients treated with nilotinib 
showed haematological and cytogenetic responses of 92% and 53% respectively 
for CP and 72% and 48% respectively for AP patients, with a favourable safety 
and tolerability profile. Common side effects included myelosuppression, skin rash 
and hyperbilirubinaemia. Yet, in contrast to IM, nilotinib was not associated with 
oedema. Ongoing phase II studies in patients  who have failed IM therapy  also 
show favourable responses (Kantarjian et al. 2006).  
1.3.5.2  Dasatinib (BMS-354825, Sprycel
®) 
In addition to the requirement for more powerful BCR-ABL inhibitors, there has 
been a need to develop agents that can bind to the BCR-ABL complex regardless 
of the conformation status, thus reducing the likelihood of resistance. In addition, 
the development of new generation inhibitors that can simultaneously bind to ABL 
and SRC family kinases has been explored, as the overexpression of SRCs may 
mediate  BCR-ABL  independent  IM  resistance  and  may  be  associated  with  the Jordanides Niove, 2008    Chapter 1 40 
pathogenesis of the disease. One such agent is dasatinib (Figure 1-7), developed 
by Bristol-Myers Squibb. Dasatinib is a highly potent active inhibitor of SRC and 
SRC family kinases which also has inhibition against BCR-ABL, C-KIT, PDGF and 
ephrin  receptor  tyrosine  kinases  (Lombardo  et  al.  2004;  Nam  et  al.  2005; 
Schittenhelm et al. 2006).  Unlike IM and nilotinib, dasatinib can form a complex 
with  ABL  both  in  the  active  and  inactive  conformation  (Lombardo  et  al.  2004). 
Dasatinib has a 325x greater potency than IM and, like nilotinib, can effectively 
bind to all the mutations except for T315I (O'Hare et al. 2005) (Shah et al. 2004). 
 
Figure 1-7 Structure of dasatinib 
 
A phase I dose escalation study in IM resistant CML patients showed 92.5% of CP 
patients and 70% of AP patients attained haematological response. The common 
side  effects  included  myelosuppression,  pericardial  effusion  and  oedema. 
Completed phase II trials also show positive data with a CHR in 90%, instigating 
the  accelerated  licence  approval  for  use  in  CML  patients  in  the  U.S.  and  U.K. 
(Talpaz et al. 2006; Guilhot et al. 2007).  Jordanides Niove, 2008    Chapter 1 41 
1.3.6 Disease persistence 
However, in addition to molecular resistance and despite effective CCR in CP with 
TKIs and  other new  agents,  the majority  of patients have  persistent detectable 
disease  by  sensitive  RT-PCR  assay  (Hughes  and  Branford  2003;  Muller  et  al. 
2003;  Branford  et  al.  2004).  Investigations  have  described  two  populations  of 
primitive  leukaemic  cells.  The  first  subset  undergo  cell  cycle  arrest  and 
accumulate  in  the  G0/G1  phase  in  the  presence  of  anti-proliferative  agents, 
including IM (Jorgensen et al. 2005b), which may be encouraged into cell cycle 
with sequential pulsed therapy. The second are a deeply quiescent Ph
+ stem cell 
population identified by their in vitro progenitor activity demonstrated by an LTC-IC 
assay  and  their  ability  to  engraft  immunodeficient  mice  (Holyoake  et  al.  1999). 
Further studies have demonstrated that these CML LSCs are insensitive to the 
pro-apoptotic  effect  of  IM,  even  at  concentrations  10x  higher  than  those 
achievable in vivo (Holyoake et al. 1999; Graham et al. 2002). Even continued IM 
therapy does not eradicate these cells (Bhatia et al. 2003). In addition, these cells 
are  resistant  to  nilotinib  (Jorgensen  et  al.  2007a)  and,  although  a  little  more 
responsive,  persist  in  the  presence  of  dasatinib  (Copland  et  al.  2006). 
Furthermore,  patients  relapse  rapidly  following  discontinuation  with  IM,  further 
confirming that these cells persist. It is likely, therefore, that it is these BCR-ABL 
positive cells within the patient that are responsible for the MRD detected in the 
majority of IM treated patients and may be the cause for relapse at a later date.  
1.3.7 Disease resistance by transport 
One explanation for the failure of the TKIs to effectively eradicate the stem cell 
population is that the drug never reaches a therapeutic intracellular concentration. Jordanides Niove, 2008    Chapter 1 42 
This  mechanism  of  drug  resistance,  termed  multidrug  resistance  (MDR),  is  a 
common phenomenon and has been attributed to the broad specificity drug efflux 
pumps  of  the  ATP  binding  cassette  (ABC)  family.  These  efflux  proteins  limit 
tumour kill by reducing the accumulation of cytotoxic agents to below therapeutic 
thresholds, either by limiting uptake, enhancing efflux or affecting membrane lipids 
(Yanovich and Taub 1983). Furthermore, they may alter the distribution within the 
cell and thus limit the exposure of the cytotoxic agents to the target (Kitazono et al. 
1999)  and  may  provide  resistance  by  protecting  the  tumour  cells  from multiple 
forms of caspase-dependent apoptosis (Smyth et al. 1998).  
In  some  cases,  resistance  may  also  be  associated  with  progressive  BCR-ABL 
gene amplification (Gorre et al. 2001), where multiple copies of the BCR-ABL gene 
can  be  detected  in  the  interphase  nuclei  in  patients  who  relapse  after  initially 
responding to IM. Characterisation by FISH (Fluorescence In Situ Hybridization) 
shows a unique inverted duplicate Ph chromosome with interstitial amplification of 
the  BCR-ABL  fusion  gene,  again  suggesting  that  there  may  be  insufficient  IM 
present in the leukaemic cell to inhibit the increased level of oncogenic protein. 
1.4 ABC transporters 
The membrane of a living cell is mainly composed of a lipid bilayer that prevents 
the free flow of molecules across the membrane barrier and has transporters that 
actively  pump  solutes.  Drug  transporters  have  been  classified  into  two  major 
families:  ABC  transporters  and  solute  carrier  transporters  (Choudhuri  and 
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ABC transporters were given their name in 1992 based on the most characteristic 
feature  of  this  superfamily,  namely  the  ATP  binding  cassette  (Higgins  1992). 
These plasma membrane glycoproteins are present in most cells and mediate the 
transfer  of  a  substrate  across  the  membrane  against  a  concentration  gradient, 
using energy derived from ATP hydrolysis. In normal physiology there is uptake of 
substrates,  including  nutrients  and  biologically  active  substances,  while  toxic 
compounds are actively effluxed from tissues, secretory organs and blood-brain 
barrier,  providing  an  important  protective  function  (Sarkadi  et  al.  2004).  These 
toxic compounds,  however,  also  include specific chemotherapeutic compounds, 
which affect therapeutic intervention by lowering the effective drug concentration 
inside the cell. 
Typically,  an  ABC  transporter  is  composed  of  four  parts;  two  hydrophobic 
transmembrane domains (TMD) and two ATP hydrolysing domains, bound by a 
flexible linker region (Figure 1-8). The membrane domains anchor the protein to 
the membrane and form pores that allow the substrate to cross the membrane and 
therefore  determine  the  substrate  specificity.  The  ATP  binding  domains,  also 
known as nucleotide binding domains (NBDs) are located in the cytoplasm and 
provide  the  energy  to  transport  the  substrate  across  the  membrane.  Some 
transporters  consist  of  only  one  membrane  integral  domain  and  one  NBD; 
however  these  “half  transporters”  must  form  homodimers  or  heterodimers  for 
active function.  Jordanides Niove, 2008    Chapter 1 44 
 
Figure 1-8 Schematic diagram of an ABC transporter 
An ABC transporter typically consists of two hydrophilic cytosolic nucleotide 
binding domains (NBD) and two transmembrane domains (TMD), each of 
which  spans  the  membrane  six  times.  The  binding  of  ATP  at  the  NBD 
provides energy for transport of  substrates  across  the  membrane. Some 
transporters e.g. ABCG2 are half-transporters and composed of only one 
NBD and one TMD. 
 
To  date  there  are  in  excess  of  50  members  belonging  to  the  ABC  family, 
categorised  into  seven  subfamilies.  These  are  characterised  by  a  high  level  of 
sequence  homology  and  extensive  conservation  of  the  ATP-binding  domains 
(Higgins 1995; Gottesman and Ambudkar 2001). Of these, 15 have been shown to 
have  involvement in the  extrusion  of chemotherapeutic  compounds, of which 3 
have the greatest influence in malignant cells and account for nearly  all of the 
MDR.  
1.4.1 MDR1 (Multidrug resistance 1) 
Initially discovered in 1976 (Juliano and Ling 1976) and most extensively studied, 
MDR1 (also known as p-glycoprotein or p-gp, ABCB1, gp170) was the first ABC 
transporter observed to modulate drug permeability in tumour cells. Located on 
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consisting  of  two  610aa  half-transporters  joined  by  a  60aa  flexible  linker.  This 
transporter  is  normally  expressed  in  the  plasma  membrane  of  the  HSC 
(Chaudhary  and  Roninson  1991),  colon,  small  intestine  and  kidney  (Tan  et  al. 
2000). It may also play a role in the blood-brain (Rao et al. 1999) and placental 
barriers  (Smit  et  al.  1999)  by  removing  toxic  substances  and  protecting  vital 
organs.  The substrates of MDR1 range in  size  and chemical structure,  yet the 
common denominator is their amphipathic nature, suggesting a mechanism in their 
drug translocation. The hydrophobic parts of the drug allow rapid insertion into the 
inner hemi-leaflet of the cell membrane, but the hydrophilic residues slow the entry 
into  the  inner-leaflet  such  that  the  pump  is  able  to  extrude  the  drug.  As  such, 
amphipathic  anticancer  agents  are  included  in  the  active  efflux  of  substrates, 
including  anthracyclines,  taxanes,  anthracenes,  epipodophyllotoxins  and  vinca 
alkaloids (Bates et al. 2001). 
MDR1 overexpression has been shown in numerous tumour cells, including breast 
cancer (Trock et al. 1997), ovarian cancer (van der Zee et al. 1995), head and 
neck  tumours  (Ng  et  al.  1998)  and  non-Hodgkins  lymphoma  (Yuen  and  Sikic 
1994). Furthermore, repeated courses of cytotoxic or radiation therapy may induce 
MDR1 overexpression, hence accounting for the increasing clinical resistance in 
these diseases (Ng et al. 1998). Indeed, the presence of MDR1 is so detrimental 
to patients that those with MDR1 positive tumours have poorer prognoses than 
those with MDR1 negative neoplasms. A meta-analysis of 31 studies of MDR in 
breast  cancer  observed  that  patients  expressing  MDR1  were  three  times  more 
likely  to  fail  chemotherapy  than  those  that  were  MDR1  negative  (Trock  et  al. 
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Some  studies  have  also  shown  that  MDR1  expression  is  associated  with  AML 
(Musto et al. 1991; Zhou et al. 1992). Zhou et al studied 126 adult AML samples 
and noted a significantly higher incidence of MDR1 expression in resistant patients 
(60%) in comparison to untreated or relapsing patients (27%). Furthermore, 68% 
of patients positive for MDR1 eventually developed resistance to chemotherapy, in 
comparison to 23% who did not have MDR1 expression.   
In addition, MDR1 has been associated with AML CD34
+ blasts. In elderly patients 
with AML, MDR1 was expressed in 71% of cases, 58% of which demonstrated 
functional drug efflux (Leith et al. 1997). In contrast, younger AML patients who 
achieved higher remission and longer overall survival rates only expressed MDR1 
in  35%  of cases (Leith et  al.  1999). This suggests that the  lower frequency  of 
MDR1  expression in the younger AML patients may in part explain the greater 
response to chemotherapy and in turn suggest that MDR modulators may benefit 
patients with this disease.  
However, although MDR is present in the CD34
+ cell population, when the cells 
were fractionated to determine the role of MDR1 in CD34
+38
-, the results were 
surprising. Although MDR1 protein was preferentially expressed in the CD34
+38
- 
population compared to the more mature CD34
+38
+ BM cells at levels comparable 
to those observed in normal BM, the MDR1 transport was markedly decreased in 
the  primitive cells  (Raaijmakers  et  al.  2006). This  would therefore  suggest that 
MDR1  modulation  would  not  circumvent  drug  extrusion  and  may  explain  the 
relatively  poor  results  in  attempting  to  reverse  drug  resistance  by  MDR1 
modulation in clinical trials (Lee  et al. 1999; Chauncey  et al. 2000; Baer  et al. 
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However, even in solid tumours such as renal cell cancer and colon cancer, MDR1 
modulation  therapy  does  not  show  significant  response  despite  relatively  high 
MDR1  expression  levels,  suggesting  that  there  may  be  other  mechanisms 
contributing to drug resistance. This view, combined with studies indicating that 
some cell lines with an absent MDR efflux pump still had a resistant phenotype, 
led  to  the  identification  of  the  second  transporter  as  having  a  potential  role  in 
clinical multidrug resistance. 
1.4.2 MRP1 (multidrug resistance-associated protein 1) 
MRP1 (also known as ABCC1) was identified by isolating the overexpressed gene 
in a doxorubicin resistant lung cancer cell line that did not over-express MDR1 
(Cole et al. 1992). The identified gene was located on chromosome 16 and coded 
for a 190kD glycoprotein (Krishnamachary and Center 1993; Evers et al. 1996). 
Subsequent analysis has shown that MRP1 is almost ubiquitously expressed in all 
major tissues and cell types (Burger et al. 1994), with high levels in lung, testis, 
kidney, placenta, skeletal and cardiac muscles. MRP1 is predominately located in 
the basolateral membrane of epithelial cell layers, suggesting a role as a cellular 
defence by preventing the accumulation of toxic compounds in the cells (Evers et 
al. 1996). 
MRP1  functions  mainly  as  a  transporter  of  amphipathic  organic  anions. 
Leukotriene  C4  (LTC4),  a  potent  inflammatory  mediator,  is  the  highest  affinity 
substrate for MRP1 protein and mrp-/- knockout mice show a reduced response to 
an  inflammatory  stimulus  (Wijnholds  et  al.  1997).  Like  MDR1,  MRP1  also 
transports hydrophobic substrates and indeed can confer resistance to many of 
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However  MRP1  cannot  transport  these  drugs  when  they  are  unmodified,  but 
requires  conjugation  or  co-transportation  of  the  substrate  with  the  anionic 
tripepetide glutathione (Rappa et al. 1997a). 
As MRP1 is present in virtually all human tissues and most human tumour cell 
lines and samples, it was assumed that MRP1 contributed to drug resistance. In 
cell  lines,  the  drugs  most  affected  by  the  presence  of  MRP1  are  etoposide, 
vincristine  and  anthracyclines,  yet  the  evidence  in  clinical  practice  is  unclear. 
Patients  with  relapsed  AML  have  higher  MRP1  expression  levels  compared  to 
those  at  diagnosis  (Schneider  et  al.  1995;  Zhou  et  al.  1995).  Furthermore, 
simultaneous  expression  of  MRP  with  MDR1  in  AML  has  shown  higher 
daunorubicin and etoposide resistance (Legrand et al. 1999). However, there is no 
correlation between MRP protein expression and clinical response (Filipits et al. 
1997),  suggesting  that  overcoming  resistance  may  require  modulation  of  both 
transporters, and possibly others in addition, to achieve a clinical response. 
1.4.3 ABCG2  
More recently, ABCG2 (also known as BCRP, MXR, ABCP) was identified in the 
highly  doxorubicin-resistant  breast  cancer  subline  MCF7/AdrVP  (Doyle  et  al. 
1998).  ABCG2  is  a  half  transporter  and  requires  dimerisation  for  efficient 
transmembrane substrate translocation (Allikmets et al. 1998; Ross et al. 1999). It 
is located on chromosome 4 and expressed on the plasma membrane of many 
primitive cell populations, including embryonic stem cells, placenta (Allikmets et al. 
1998), breast (Doyle et al. 1998), liver, muscle (Zhou et al. 2001), gastrointestinal 
tract  (Maliepaard  et  al.  2001)  and  pancreas  (Lechner  et  al.  2002).  In  addition, 
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recognised with flow cytometry by their appearance as a SP of cells, based on 
their ability to exclude Hst. Zhou et al (Zhou et al. 2001) observed SP cells from 
mouse and rhesus monkey expressed high levels of abcg2 mRNA. Moreover, the 
most  primitive  mouse  HSC  (CD34
-)  highly  expressed  abcg2  mRNA,  which 
markedly  decreased  with  stem  cell  differentiation  (CD34
+).  When  abcg2 
expression  was  enforced  in  BM,  the  SP  population  expanded  and  caused  a 
reduction in mature cells, suggesting that ABCG2 may be preventing the cellular 
accumulation  of  a  substrate  essential  for  stem  cell  differentiation.  However, 
knockout mice showed normal haematological parameters with no developmental 
or observable organ defects, indicating that ABCG2 is unlikely to mediate a non-
redundant role in stem cell regulatory mechanisms (Zhou et al. 2003). In addition, 
although a significant decrease of SP cells was observed in BM compared to the 
wild type mice, competitive BM transplants resulted in  no significant advantage 
and  ABCG2-mediated  Hst  transport  activity  can  be  eliminated  without  any 
functional defect in steady state haemopoiesis. This suggests that either ABCG2 
functionality  is  not  required  for  normal  stem  cell  function  in  mice  or  that  when 
ABCG2 is knocked out, the activity of this transporter may be substituted by other 
transporters (Zhou et al. 2002).  
The  only  natural  substrates  of  ABCG2  identified  so  far  are  porphyrins  and 
porphyrin-like  compounds  (Jonker  et  al.  2002).  Accumulation  of  porphyrin  is 
detrimental  to  cells  as  accumulation  ultimately  leads  to  cell  damaging  reactive 
oxygen  species  and  deficient  mitochondrial  function  (Antolin  et  al.  1994).  In 
hypoxic conditions, the survival of progenitor cells was markedly reduced in abcg2 
null  mice  compared  to  abcg2+/+,  a  condition  which  was  reversed  by  blocking 
heme  biosynthesis  (Krishnamurthy  et  al.  2004).  Also,  accumulation  of  dietary 
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mice, causing a porphyria-like syndrome of photosensitivity (Jonker et al. 2002). 
Similarly, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
(PhIP) and protoporphyrin XI are natural substrates (Abbott 2003), suggesting that 
ABCG2  has  a  physiological  role  in  protecting  primitive  cells  against  toxic 
substances in the hypoxic environment.   
As with the other transporters, ABCG2 overexpression has been shown to induce 
resistance  to  anticancer  drugs,  including  mitoxantrone,  topotecan,  doxorubicin, 
campothecins, flavopiridol and daunorubicin (Doyle et al. 1998; Maliepaard et al. 
1999; Ross et al. 1999; Kawabata et al. 2001; Komatani et al. 2001; Robey et al. 
2001b).  There  have  also  been  studies  describing  elevated  levels  of  ABCG2  in 
malignancies, especially in AML, although the data have been conflicting. Ross et 
al  (Ross  et  al.  2000)  showed  that  33%  of  blast  cells  had  a  5  fold  increase  of 
ABCG2 mRNA by RT-PCR with Sargent et al (Sargent et al. 2001) detecting a 
similar  protein  expression.  Furthermore,  ABCG2  expression  was  elevated  in 
patients  at time of relapse, in comparison to diagnosis both in adults (van den 
Heuvel-Eibrink et al. 2002) and paediatric AML patients (Steinbach et al. 2002). 
Furthermore,  high  expression  correlated  with  a  poorer  outcome  despite  some 
patients having favourable cytogenetic abnormalities. In other expression studies, 
there  has  been  no  association  of  ABCG2  expression  with  prognosis,  either  at 
diagnosis or at relapse (Sargent et al. 2001; van der Kolk et al. 2002; van der Pol 
et al. 2003). The discrepancy may partly be attributed to possible contamination 
from  normal  HSC.  A  recent  study  validated  ABCG2  expression  in  AML  and 
determined that 85% of newly diagnosed AML patients had higher level of mRNA 
expression than in BM or PB compared to normal controls, yet the level was below 
that shown to correlate with drug resistance (Abbott et al. 2002). However, flow 
cytometric  analysis  detected  that  the  increased  level  was  not  due  to  low Jordanides Niove, 2008    Chapter 1 51 
homogenous expression in every leukaemic cell, but to high expression in a small 
subpopulation which may correlate to the presence of a LSC with a very immature 
surface  immunophenotype.  This  suggested  therefore,  that  although  the  overall 
mRNA expression level detected in the whole population was below that shown to 
correlate  with  drug  resistance,  the  relatively  high  expression  in  the  small 
subpopulation might be above the threshold level required for drug resistance.  
1.4.4 Drug transporters and TKIs 
The  advent  of  IM  as  a  targeted  therapeutic  drug  dramatically  improved  the 
outcome  in  patients  suffering  from  CML.  Yet  molecular  resistance  leading  to 
persistence of the disease led to the role of drug transporters in mediating this 
response being the topic of an increasing amount of study (Figure 1-9). Recent 
reports have shown hOCT1 to actively mediate the transport of IM into the cells 
(Thomas et al. 2004; White et al. 2006). OCT1 (Organic Cation Transporter 1) is a 
member of the solute carrier transporters encoded by the SLC22 gene family. It is 
primarily expressed on the basolateral membrane of kidney, liver, and placenta 
and  has  been  shown  to  transport  cyclic  weak  bases  and  a  variety  of  drugs. 
Thomas et al demonstrated that uptake of IM was an active process by comparing 
the concentration of radiolabelled IM at 4
oC and 37
oC and confirming temperature 
dependence (Thomas et al. 2004). By a process of elimination using a series of 
inhibitors,  the  OCT  identified  to  be  involved  was  hOCT1  and  not  hOCT2  or 
hOCT3, suggesting that differential expression of this transporter may be a critical 
determinant  of  intracellular  IM  levels.  Further  expression  studies  demonstrated 
that hOCT1 mRNA in CML patients was not significantly different to normal BM 
donors. However, patients who remained at least 65% Ph
+ after 10 months IM 
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compared  to  those  who  achieved  a  CCR  within  12  months  (Crossman  et  al. 
2005a), confirming that hOCT1 mRNA expression may predict a more favourable 
molecular response to IM. In contrast, nilotinib was not shown to be a substrate for 
this transporter, despite being structurally related to IM (White et al. 2006). 
 
Figure 1-9 Intracellular drug concentration by transporters 
In  the  absence  of  drug  transporters  the  cellular  concentration  will  be 
equilibrated with the external medium. Influx transporters such as hOCT1 
will actively uptake IM but not nilotinib, against a concentration gradient. 
However,  if  the  TKIs  are  also  substrates  of  efflux  transporters, 
overexpression will reduce the accumulation in the cell. It is the balance of 
the influx and efflux transporters that may mediate resistance to TKI. 
 
In contrast, several reports have identified active efflux by MDR1 as a contributory 
factor to IM resistance. MDR1 was originally highlighted to interact with IM using a Jordanides Niove, 2008    Chapter 1 53 
calcein extrusion assay. Generally the uptake of calcein is slow in cells that have 
active transporters; however, agents that interact with the proteins inhibit the dye 
extrusion  and  accelerate  the  calcein  accumulation.  The  increased  uptake 
suggested an interaction with IM, although the assay could not delineate between 
an interaction as a competitive substrate or as a direct inhibitor (Hegedus et al. 
2002).  Other  studies  demonstrated  that  a  cell  line  overexpressing  MDR1  was 
resistant to IM, which was reversed in the presence of MDR1 inhibitors (Mahon et 
al. 2003; Mukai et al. 2003), suggesting that IM is a substrate for this transporter. 
This was further confirmed by a high-performance liquid chromatography-based 
(HPLC)  method  demonstrating  decreased  intracellular  IM  levels  in  cell  lines 
overexpressing MDR1 which was also associated with loss of IM effect on cellular 
proliferation and apoptosis (Illmer et al. 2004). Furthermore, knockdown of MDR1 
in  an  IM  resistant  cell  line  verified  sensitivity  to  IM  and  reduced  CrkL 
phosphorylation (Rumpold et al. 2005). 
However, there have also been reports refuting the role of MDR1 in IM resistance. 
Ferrao et al (Ferrao et al. 2003) demonstrated no significant growth advantage in 
the  retrovirally  transduced  MDR1  cell  line,  compared  to  the  wild  type  and 
concluded that MDR1 was not a substrate of IM, while overexpression of BCLXL 
conferred  partial  protection  instead.  Furthermore,  Zong  et  al  demonstrated  no 
difference to IM resistance in cell lines overexpressing MDR1. The lack of effect 
was further demonstrated in mice transplanted with mdr1a/1b null BM that had 
been transduced with a bcr-abl retroviral vector. Both the wild-type and mdr1a/ab 
null  mice  displayed  similar  responses  to  IM,  with  no  change  in  incidence  of 
disease (Zong et al. 2005). Similarly MDR1 expression in BM mononuclear cells 
(MNC)  from  CML  patients  did  not  correlate  with  response  to  IM  (Carter  et  al. Jordanides Niove, 2008    Chapter 1 54 
2001),  suggesting  that  MDR1  does  not  confer  resistance  to  IM  alone  and  that 
there may be other transporters contributing to the effect.  
Recently, ABCG2 expression has been put forward as a possible mechanism for 
promoting IM resistance, but with conflicting results. In cell lines, Houghton et al 
(Houghton et al. 2004) found IM to be a potent inhibitor of ABCG2 as IM increased 
topotecan accumulation in ABCG2 overexpressing cells. They found IM was not a 
substrate as there was no difference in accumulation of radiolabelled drug in the 
presence or absence of functional ABCG2. In contrast, Burger et al (Burger et al. 
2004) found IM to  be  a substrate as the accumulation  of  radiolabelled IM  was 
significantly lower in the overexpressing ABCG2 cell lines compared to the wild-
type.  Both  of  these  investigations,  however,  used  non-haemopoietic  cell  lines 
engineered to over-express ABCG2, neither of which represented clinical targets 
for IM. A recent study, however, in ABCG2 knockout mice demonstrated a 2.5 fold 
greater increase in brain penetration of intravenous IM with a greater increase in 
wild-type  mice  with  ABCG2  inhibitors,  suggesting  ABCG2  influences  the 
bioavailability and pharmacokinetics of IM (Breedveld et al. 2005). 
The  role  of  MRP1  with  IM  has  not  been  studied  extensively,  although  an 
interaction has been confirmed (Hegedus et al. 2002). Mukai et al (Mukai et al. 
2003) have determined that IM is not a substrate for MRP1 in the K562 cell line. 
However, Lange et al (Lange et al. 2003) demonstrated that low levels of MRP1 
are  predictive  of  IM  response  in  BC  CML,  thereby  suggesting  IM  may  be  a 
substrate of MRP1.    
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1.4.5 Aims 
The role of these transporters in conferring TKI resistance is still in contention. To 
date,  studies  demonstrate  that  the  three  main  active  efflux  transporters  confer 
resistance  to  many  cytotoxic  agents  and  studies  have  confirmed  expression  in 
AML cells. However, the role of drug transporters in primary cells from CML and, 
in  particular,  the  immature  population  that  might  be  responsible  for  disease 
resistance and persistence has not been demonstrated. Furthermore, MDR1 and 
ABCG2 have been shown to interact with current TKIs, although it has not been 
conclusively  confirmed  in  what  capacity.  Therefore,  this  thesis  will  explore  the 
expression  and  function  of  the  three  main  drug  transporters  associated  with 
malignancy and determine their effect on the efficacy of the current therapeutic 
TKI agents for CML.  
The experiments described in this thesis aim: 
1.  To determine the expression and function of ABCG2, MDR1 and MRP1 in 
CP CML CD34
+ cells 
2.  To determine whether IM, nilotinib or dasatinib are substrates or inhibitors 
of these drug transporters  
3.  To  determine  whether  inhibition  of  these  drug  transporters  alters  the 
intracellular concentration of TKIs  
4.  To  determine the effect of drug transporter inhibition on the response of 
CML cells to IM, nilotinib and dasatinib 
5.  To determine the expression of drug transporters during TKI therapy in vitro  Jordanides Niove, 2008    Chapter 1 56 
6.  To  identify other transporters in CP CML  CD34
+ cells that may have  an 
effect in the resistance to TKI  Jordanides, Niove 2008      57 
2  Materials and Methods       
2.1 Materials 
2.1.1 Tissue culture plastics 
Plastics  Supplier 
Cryotube  Fisher Scientific, Loughborough, UK 
Falcon tubes (FACS)  Fred Baker Scientific, Cheshire, UK 
Non-adherent tissue culture dishes 
(35mm) 
Scientific Lab supplies, Coatbridge, 
UK 
Non-adherent tissue culture flasks 
(75cm
3) 
Scientific Lab supplies, Coatbridge, 
UK 
Pipette tips  Greiner bio one, Gloucestershire, UK 
Plates (24-well)  Greiner bio one, Gloucestershire, UK 
Plates (48-well)  Greiner bio one, Gloucestershire, UK 
Plates (96-well flat bottomed)  Greiner bio one, Gloucestershire, UK 
Tissue culture flasks (25cm
3)  Greiner bio one, Gloucestershire, UK 
Tissue culture flasks (75cm
3)  Greiner bio one, Gloucestershire, UK 
Table 2-1 Table of plastics used for tissue culture and suppliers 
 
2.1.2 Tissue culture reagents 
Reagent  Supplier 
β-mercaptoethanol  Invitrogen, Paisley, UK 
Bovine serum albumin (BSA)  Sigma-Aldrich, Dorset, UK 
Bovine serum albumin, Insulin/ 
Transferrin (BIT)   
Stem Cell Technologies, British 
Columbia, Canada 
Colcemid  Invitrogen, Paisley, UK 
Dimethyl sulphoxide (DMSO)  Sigma-Aldrich, Dorset, UK 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
Sigma-Aldrich, Dorset, UK 
DNase I (Recombinant human 
DNAse) 
Stem Cell Technologies, British 
Columbia, Canada 
Dulbecco’s phosphate buffered saline 
(w/o Ca
2+ and Mg
2+) (PBS) 
Invitrogen, Paisley, UK 
Ethanol 100% molecular grade  Sigma-Aldrich, Dorset, UK 
Filter mats  Perkin Elmer, Buckinghamshire, UK 
Foetal Calf serum (FCS)  Invitrogen, Paisley, UK 
GM-CSF  RD Systems Inc., California, USA Jordanides Niove, 2008    Chapter 2 58 
Human serum albumin 4.5% (HSA 
4.5%) 
Scottish National Blood Transfusion 
Service, Edinburgh, UK 
Human serum albumin 20% (HSA 
20%) 
Scottish National Blood Transfusion 
Service, Edinburgh, UK 
Iscove’s modified Dulbecco’s medium 
(IMDM) 
Sigma-Aldrich, Dorset, UK 
L-glutamine 200mM (100x)  Invitrogen, Paisley, UK 
Low density lipoprotein (LDL)  Sigma-Aldrich, Dorset, UK 
Magnesium Chloride (1.25M)  Sigma-Aldrich, Dorset, UK 
Optiphase supermix liquid scintillation 
cocktail 
Perkin Elmer, Buckinghamshire, UK 
Penicillin (5000u)/ streptomycin 
(5mg/ml) solution 
Invitrogen, Paisley, UK 
Recombinant human erythropoietin 
(rHu-Epo) 
Pharmacy, Glasgow Royal Infirmary, 
UK 
Recombinant human Flt-3 ligand (rHu-
Flt-3L) 
Stem Cell Technologies, British 
Columbia, Canada 
Recombinant human G-CSF (rHu-G-
CSF) 
Chugai Pharma, London, UK 
Recombinant human IL-3 (rHu-IL-3)   Stem Cell Technologies, British 
Columbia, Canada 
Recombinant human IL-6 (rHu-IL-6)  Stem Cell Technologies, British 
Columbia, Canada 
Recombinant human SCF (rHu-SCF)  Stem Cell Technologies, British 
Columbia, Canada 
Recombinant human thrombopoietin 
(rHU-Tpo) 
RD Systems Inc., California, USA 
RPMI 1640 medium (RPMI)  Invitrogen, Paisley, UK 
Sodium Azide  Sigma-Aldrich, Dorset, UK 
Sterile water (dH20)  Baxter Healthcare, Northampton, UK 
Tri-sodium citrate  Sigma-Aldrich, Dorset, UK 
Trypan Blue solution (0.4%)  Sigma-Aldrich, Dorset, UK 
Wax scintillant  Perkin Elmer, Buckinghamshire, UK 
Table 2-2 Table of reagents used for tissue culture and suppliers 
 
2.1.3 Flow cytometry reagents 
FACS reagents  Supplier 
Annexin V antibody  Becton Dickinson, Oxford, UK 
Annexin V 10x Buffer  Becton Dickinson, Oxford, UK 
Anti-mouse IgG2a FITC   Becton Dickinson, Oxford, UK 
Anti-rabbit IgG FITC conjugate   Sigma-Aldrich, Dorset, UK 
Anti-rabbit IgG horseradish 
peroxidase-linked secondary antibody 
Cell signalling, New England Biolabs, 
Hitchin, UK 
Carboxy-fluorescein diacetate 
succinimidyl ester (CFSE) 
Molecular Probes, Eugene, OR Jordanides Niove, 2008    Chapter 2 59 
FACS flow solution  Becton Dickinson, Oxford, UK 
FACS clean solution  Becton Dickinson, Oxford, UK 
Fix and Perm
® A and B  Caltag Laboratories, Silverstone, UK 
Mouse anti-human BXP-21 antibody  Alexis Biochemicals, Nottingham, UK  
Mouse anti-human C219 antibody  Alexis Biochemicals, Nottingham, UK  
Mouse anti-human glycophorin A 
FITC 
Becton Dickinson, Oxford, UK 
Mouse anti-human-CD3 PE antibody  Becton Dickinson, Oxford, UK 
Mouse anti-human-CD11b FITC 
antibody 
Becton Dickinson, Oxford, UK 
Mouse anti-human-CD13 PE antibody  Becton Dickinson, Oxford, UK 
Mouse anti-human-CD14 PE antibody  Becton Dickinson, Oxford, UK 
Mouse anti-human-CD19 PE antibody  Becton Dickinson, Oxford, UK 
Mouse anti-human-CD34 FITC 
antibody 
Becton Dickinson, Oxford, UK 
Mouse anti-human-CD34 PE antibody  Becton Dickinson, Oxford, UK 
Mouse anti-human-CD45 FITC 
antibody 
Becton Dickinson, Oxford, UK 
Mouse anti-human-CD61 FITC 
antibody 
Becton Dickinson, Oxford, UK 
Mouse anti-human QCRL-3 antibody  Alexis Biochemicals, Nottingham, UK  
Mouse IgG1a FITC  Becton Dickinson, Oxford, UK 
Mouse IgG1a PE  Becton Dickinson, Oxford, UK 
Propidium Iodide (PI)  Sigma-Aldrich, Dorset, UK 
Rabbit anti-human p-CrkL antibody  Cell signalling, New England Biolabs, 
Hitchin, UK 
Viaprobe  Becton Dickinson, Oxford, UK 
Table 2-3 Table of FACS reagents used and suppliers 
 
2.1.4 Supply of TKIs 
Drugs  Supplier 
Dasatinib (BMS-354825, Sprycel
®)  Kind gift from Dr F. Lee  
Bristol-Myers Squibb, Princeton, NJ 
14C-dasatinib   Kind gift from Dr F. Lee  
Bristol-Myers Squibb, Princeton, NJ 
Imatinib Mesylate (IM, Gleevec
®, 
Glivec, STI571) 
Provided by Dr E. Buchdunger 
Novartis Pharma, Basel, Switzerland 
14C-IM   Provided by Dr E. Buchdunger 
Novartis Pharma, Basel, Switzerland 
Nilotinib (AMN107, Tasigna
®)  Provided by Dr E. Buchdunger 
Novartis Pharma, Basel, Switzerland 
14C-nilotinib    Provided by Dr E. Buchdunger 
Novartis Pharma, Basel, Switzerland 
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14C-dasatinib  (specific  activity  of  31.9 Ci/ml)  was  stored  at 
-20
oC  as  a  stock 
solution of 20.4mM in DMSO. 
14C-IM (specific activity of 84 Ci/mg) was stored at 
4
oC  as  a  stock  solution  of  100mM  in  dH20. 
14C-nilotinib  (specific  activity  of 
100 Ci/mg) was stored at 4
oC as a stock solution of 1.34mM in PBS. Dasatinib 
(MW 489) was stored in multiple aliquots at
 -20
oC at a stock solution of 10mg/ml in 
DMSO. IM (MW 590) was stored at 4
oC at a stock solution of 100mM in dH20. 
Nilotinib (MW 529.5) was stored at 
-20
oC as a stock solution of 10mM in DMSO.  
2.1.5 Specific substrates and inhibitors of drug transporters 
Substrate  Supplier 
3H-Mitoxantrone 
  Moravek Biochemicals, Brae, CA, USA 
BODIPY-Prazosin     Molecular probes, Eugene, Oregon, 
USA 
Fluo-3 AM  Axxora, Nottingham, U.K 
Rhodamine 123  Invitrogen, Paisley, UK 
Table 2-5 Table of substrates tested and suppliers 
 
3H-Mitoxantrone  (specific  activity  4Ci/mmol),  the  known  ABCG2  substrate,  was 
stored at 
-20
oC at a stock solution of 148.17 g/ml in PBS. BODIPY-Prazosin, the 
known  ABCG2  substrate,  was  stored  at 
-20
oC  at  a  stock  solution  of  250 M  in 
DMSO and used at a final concentration of 200nM. Fluo-3 AM, the known MRP1 
substrate,  was  stored  at 
-20
oC,  diluted  with  DMSO  and  used  at  a  final 
concentration of 5 g/ml in DMSO. Rhodamine 123, the known MDR1 substrate, 
was stored at 
-20
oC at a stock solution of 1mg/ml in 100% ethanol and used at a 
final concentration of 0.5 g/ml.  
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Inhibitors  Supplier 
Fumitremorgin C (FTC)  Axxora, Nottingham, U.K 
PSC 833  Gift from Novartis 
MK571   Axxora, Nottingham, U.K 
Table 2-6 Table of inhibitors tested and suppliers 
 
FTC, the specific ABCG2 inhibitor, was stored at 4
oC at a stock solution of 10mM 
in DMSO and used at a final concentration of 10 M. PSC 833, the MDR1 inhibitor, 
was stored at 
-20
oC at a stock solution of 10mM in DMSO and used at a final 
concentration of 5 M. MK571, the specific MRP1 inhibitor, was stored at 
-20
oC at 
a stock solution of 10mM in dH20 and used at a final concentration of 30 M in 
K562 and CML CD34
+ cells and 100 M in the transduced MRP cell line (K-MRP). 
2.1.6 Cell lines  
Cells  Disease  Supplier 
AML3  
(OCI-AML3) 
AML  Donated by Dr B. Sorrentino  
(St Jude Children’s Research 
Hospital, Memphis, USA) 
AML3.3 
(OCI-AML3 transfected 
to over-express 
ABCG2) 
AML  Donated by Dr B. Sorrentino  
(St Jude Children’s Research 
Hospital, Memphis, USA). 
AML6.2  
(OCI-AML3 transfected 
to over-express 
ABCG2) 
 
AML  Donated by Dr B. Sorrentino  
(St Jude Children’s Research 
Hospital, Memphis, USA) 
HL60  APML  Donated by Dr J. Mountford  
(Royal Infirmary, Glasgow, UK) 
ATCC
® no. CCL-240 
HL60-BCRP  
(HL60 transfected to 
over-express ABCG2) 
AML  Donated by Dr J. Mountford  
(Royal Infirmary, Glasgow, UK) 
K562-WT (K-WT)  CML BC  Donated by Dr L. Fairbairn  
(Paterson Institute for Cancer 
Research, Christie Hospital NHS 
Trust, Manchester, UK) 
ATCC
® no. CCL-243 
K562-MDR-GFP (K-
MDR: K562-WT 
CML BC  Donated by Dr L. Fairbairn  
(Paterson Institute for Cancer Jordanides Niove, 2008    Chapter 2 62 
transfected to over-
express MDR1 and 
GFP) 
Research, Christie Hospital NHS 
Trust, Manchester, UK) and 
generated as described (Southgate 
et al. 2006). 
K562-MRP-GFP 
(K-MRP: K562-WT 
transfected to over-
express MRP1 and 
GFP) 
CML BC  Donated by Dr L. Fairbairn  
(Paterson Institute for Cancer 
Research, Christie Hospital NHS 
Trust, Manchester, UK) and 
generated as described (Southgate 
et al. 2006). 
Table 2-7 Table of cell lines used and suppliers 
 
2.1.7 Tissue culture media 
2.1.7.1  RPMI/ 10% FCS/ 1% L-glutamine (RPMI medium) 
RPMI 1640  500ml 
FCS  50ml 
L-glutamine (200mM)  5ml 
 
2.1.7.2  Serum-free medium (SFM) 
IMDM    77.4ml       
BIT  20ml 
Penicillin (5000u)/ streptomycin 
(5mg/ml) solution  
1ml 
L-glutamine  1ml  
ß-mercapto-ethanol (200mM)  200 l (400µM) 
LDL (10mg/ml)  400µl (40µg/ml)  
Filter sterilised 
 
2.1.7.3  Serum-free  medium  supplemented  with  growth  factor  cocktail 
medium (5GF) 
  Volume  Final concentration 
SFM  10ml   
IL-3 (50 g/ml)  4 l   20ng/ml 
IL-6 (50 g/ml)  4 l   20ng/ml 
Flt-3L (50 g/ml)  20 l   100ng/ml 
G-CSF (20 g/ml)  10 l   20ng/ml Jordanides Niove, 2008    Chapter 2 63 
SCF (50 g/ml)  20 l   100ng/ml 
 
2.1.7.4  Differentiation media 
  Volume  Final concentration 
SFM  10ml   
G-CSF (20 g/ml)  2.5 l   5ng/ml 
IL-3 (50 g/ml)  0.2 l   1ng/ml 
Epo (1000U/ml)  10µl   1U/ml 
rHu-Tpo (5 g/ml)  1 l   5ng/ml 
GM-CSF (10 g/ml)  3 l  30ng/ml 
 
2.1.8 Buffers and solutions 
2.1.8.1  Annexin buffer 
Annexin 10x buffer  1ml 
IMDM  9ml 
  
2.1.8.2  Fix perm wash - PBS/ 1% BSA/ 0.1% Azide 
BSA  10g  
Sodium Azide  1g 
PBS  To 1L 
 
2.1.8.3  Freezing solution- for CML samples  
HSA 4.5%  8ml 
DMSO  2ml   
 
2.1.8.4  Freezing solution- for cell lines 
FCS  8ml 
DMSO  2ml 
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2.1.8.5   Lysis buffer -PBS/ 0.2M NaOH/ 1%v/v SDS 
NaOH  8g 
SDS  10g 
PBS  To 1L 
 
2.1.8.6  PBS/ 2% FCS (PBS/2%) 
PBS  98ml 
FCS  2ml 
 
2.1.8.7  PBS/ 20% FCS (PBS/20%) 
PBS  80ml 
FCS  20ml 
 
2.1.8.8   PBS buffer- PBS/ 2mM EDTA/ 0.5%v/v HSA  
EDTA  2mM  
HSA  2.5ml  
PBS  To 500ml 
 
2.1.8.9  Thawing  solution  for  cryopreserved  CD34
+  or  unmanipulated  cell 
aliquots from liquid nitrogen (DAMP)  
  Volume  Final concentration 
PBS  418.75ml   
Tri-sodium citrate (0.155M)  53ml  8.2mM 
HSA 20%  25ml  1% 
DNase I (~2500U/vial (1ml)  2ml  10U/ml 
MgCl2 (400x, 1.0M)  1.25ml  2.5mM 
 
2.1.8.10  Wash buffer 
DMEM  90ml 
FCS  10ml 
Table 2-8 Composition of buffers and solutions Jordanides Niove, 2008    Chapter 2 65 
2.1.9 Primers and probes for RT-PCR 
ABCG2: 
forward (ABCG2F): 5’-TGG CTG TCA TGG CTT CAG TA-3’ 
reverse (ABCG2R): 5’- GCC ACG TGA TTC TTC CAC AA-3’   
  probe (ABCG2P):  5’-AGC AGG GCA TCG ATC TCT CAC CCT G –3’ 
Actin:    
forward (ACTINF):  5’-CGT GAT GGT GGG CAT GGG TCA G-3’ 
reverse (ACTINR):  5’-CTT AAT GCT ACG CAC GAT TTC C-3’ 
2.2 Cell handling and selection 
2.2.1 Cell lines 
The cell lines were grown in suspension culture in RPMI media. The cells were 
maintained at 10ml in 25cm
3 tissue culture flasks and passaged every two days by 
removing  ¾  (7.5ml)  of  the  volume  and  replacing  with  warm  fresh  media  to 
maintain a density of between 1x10
5-1x10
6.  
2.2.2 Normal CD34
+ cells 
For qPCR analysis, RNA (1 g aliquots) derived from normal CD34
+ cells isolated 
from mobilized PB (mPB), was purchased from Cambrex Bioscience (Wokingham, 
United Kingdom) and Stem cell Technologies UK (Vancouver, Canada) and stored Jordanides Niove, 2008    Chapter 2 66 
at 
-80
oC. In addition CD34
+ cells were obtained from patients with non-stem cell 
haematological malignancies (e.g. non-Hodgkin’s lymphoma or multiple myeloma) 
and were classed as ‘non-CML’ cells and used as comparisons. These cells were 
isolated  and  selected  as  for  the  CML  CD34
+  counterparts  and  stored  in  liquid 
nitrogen. 
2.2.3 Selection of CD34
+ cells from CML samples 
All samples were collected with the approval from the Local Research and Ethics 
Committee and with written informed patient consent from patients at diagnosis of 
chronic phase CML. Each sample was determined to be Ph
+ by FISH and BCR-
ABL
+ by PCR. Cells were collected by leukapheresis prior to any drug treatment. 
Enrichment  for  CD34
+  cells  was  achieved  using  the  sterile  CliniMACS  system 
(Miltenyi Biotech, Surrey, UK), which positively selects for CD34
+ cells and was 
performed by the stem cell banking unit within the research group. Briefly, micro 
magnetic  MACS  beads  coupled  with  anti-CD34
+  monoclonal  antibody  (Miltenyi 
Biotec, Germany) were added to the sample, which in turn bound to the sample. 
The sample was then passed through a magnetic field where the target cells were 
retained in the column and the unlabelled cells flushed through and discarded. The 
bound cells were then eluted after removal from the magnetic field, collected and 
stored in cryotubes within the vapour phase of liquid nitrogen until required. 
2.2.4 Freezing cells 
Between 2x10
6-2x10
7 CD34
+ selected cells and 5x10
6-1x10
7 cell-line cells were 
resuspended in the appropriate freezing solution and aliquoted into cryotubes. The 
cryotubes  were  cooled  overnight  in  a  polystyrene  box  at 
-80
oC  to  provide  a Jordanides Niove, 2008    Chapter 2 67 
controlled temperature reduction and then transferred to the vapour phase of liquid 
nitrogen for storage.  
2.2.5 Recovering frozen cells 
CML cells were removed from liquid nitrogen and immediately thawed at 37
oC in a 
water bath until most of the ice crystals had melted. The cells were then recovered 
by  slowly  adding  10ml  of  thawing  solution  (DAMP)  drop-wise  over  a  20  mins 
period with constant agitation to prevent clumping of the cells. The cells were spun 
at  1,000rpm  for  10  mins,  the  supernatant  was  poured  away  and  the  pellet 
loosened by flicking. The pellet was then washed twice in DAMP and centrifuged, 
then resuspended in 5GF media for counting and cell viability. The CML cells were 
then plated in 35mm non-adherent tissue culture dishes at ~2x10
6/ml. 
Cell lines were thawed in a 37
oC water bath and recovered slowly as above but in 
PBS/2%. The cells were then washed twice more with PBS/2% and resuspended 
in 10ml of RPMI media, then plated in 25cm
3 tissue culture flasks. 
2.2.6 Cell counting and viability assessment 
All  cell  counts  were  performed  on  a  Hawksley  BS.748  improved  Neubauer 
counting chamber (Weber Scientific International, West Sussex, UK).  The cells 
were counted using trypan blue exclusion. Trypan Blue was diluted at 1:10 with 
PBS. Ten  l of the diluted solution was then added to 10 l of the cell suspension 
(1:1  dilution).  Approximately  15 l  of  the  mixture  was  transferred  to  a 
haemocytometer. Cells that have damaged membranes are porous and absorb 
the trypan blue dye, so appear with a distinctive blue colour under the microscope 
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unstained cells were counted and the remaining stained dead cells were deemed 
non-viable. 
2.3 Flow Cytometry 
Flow Cytometry is a quantitative technique that permits the visualisation of cells by 
multiple  parameters  using  fluorescent  emissions.  In  comparison  to 
spectrophotometry,  it  is  capable  of  measuring  fluorescence  per  cell,  hence 
allowing accurate analysis of single cells. All the flow cytometric analyses were 
carried out on a Becton Dickinson FACSCalibur. 
Following antibody staining (section 2.3.1), the cells were visualised with either a 
linear  or log scale,  as appropriate,  on  a  forward scatter (FSC) vs.  side scatter 
(SSC)  dot  plot.  FSC  detects  cell  size  whilst  SSC  determines  cytoplasmic 
granularity. The resulting dot plot view allowed the live cells to be distinguished 
from the smaller debris and dead cells (Figure 2-1A). When required, the smaller 
debris and other cell populations were excluded from further analysis by drawing a 
gate around the key live population using the flow cytometry software palette. The 
cells within this graphical boundary formed the basis for all further analysis.   
The cells were then visualised either in a log scale FL1 (FITC) vs. FL2 (PE) dot 
plot or a histogram (Figure 2-1B). Isotype  controls were used to determine the 
emission of non-specific binding and these cells were positioned in the first log 
decade of the parameter(s) by altering the voltage settings. Additionally, positive 
controls  were  required  to  compensate  for  spectral  overlap  between  the 
fluorochromes using the compensation settings. This was achieved by subtracting 
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fluorescence. This allocates the cells in the bottom right hand and top left hand 
corners of the FACS dot plot according to the fluorescent conjugate used (Figure 
2-1C).  Once  the  flow  cytometer  was  optimally  compensated,  the  test  samples 
were  run  and  the  percentages  of  the  discrete  population  calculated.  At  least 
10,000 of viable gated cells were collected in all experiments. 
 
Figure 2-1 Analysis of a flow cytometry plot 
A. A FSC vs. SSC dot plot showing the cellular composition of BM. B. The 
gated cells stained with isotype FITC and PE shown on FL1 vs. FL2 dot 
plot. Using the voltage settings the cells were positioned in the first decade 
of the parameters. C. Uncompensated PE staining (panels 1 and 2) and 
uncompensated  FITC  staining  (panels  3  and  4).  D.  Compensated  PE 
staining with all the cells positioned in the top left corner, within the first 
parameter of FL1 (panel 1), compensated FITC staining with all the cells in 
the bottom right hand corner within the first parameter of FL2 (panel 2), dual 
staining of FITC and PE (panel 3) 
A.  B. 
C. 
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2.3.1 Detection of surface receptors 
Prior  to  any  experiments,  all  samples  were  confirmed  as  ≥97%  CD34
+  and 
negative  for  glycophorin  A  or  lymphoid  markers  (Table  2-9).  Briefly,  the 
appropriate antibody conjugated to a fluorochrome was added to 1x10
5 cells at 
1:100 dilution for 20 mins at room temperature, then washed twice in PBS/2% and 
spun at 1000rpm for 10 mins, then resuspended in FACS flow solution.  
In addition live populations were gated using PI by staining at 1 g/ml for 5 mins 
prior to the washing stage of antibody staining to discriminate dead cells. Cells 
with  damaged  porous  membranes  absorb  PI,  which  then  binds  to  DNA  by 
intercalating  between  the  bases.  Hence,  unstained  cells  with  impermeable 
membranes were viable and subsequently gated for analysis in the FL3 channel, 
which detects PI. 
Antibody  Target cell(s)  Dilution 
CD3  T-lymphocytes  1:100 
CD11b  Monocytes, granulocytes  1:100 
CD19  B-lymphocytes  1:100 
CD13  Monocytes, granulocytes  1:100 
CD14  Monocytes  1:100 
CD34  Haemopoietic progenitor  1:100 
CD45  Leucocytes  1:100 
CD61  Megakaryocytes  1:100 
Glycophorin A  Erythroid cells  1:100 
Table 2-9 Table of surface antibodies used for identification of cell 
populations 
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2.3.2 Detection of intracellular receptors 
2.3.2.1  Detection of intracellular protein 
Using the Fix & Perm
® Cell Permeabilisation kit, the cells were permeabilised and 
stained  according  to  the  manufacturer’s  instructions.  Briefly  1x10
5  cells  were 
resuspended in 100ml of fixing reagent (reagent A) from the fix & perm kit and 
incubated  for  15  mins.  The  cells  were  then  washed  in  3ml  of  fix  perm  wash, 
centrifuged  at  1200rpm  for  3  mins,  blotted,  and  resuspended  in  100ml  of 
permeabilising reagent (reagent B) from the kit, with either 1µl (1 in 100 dilution) of 
the primary monoclonal antibody to MDR1 (C219), or MRP1 (QCRL-3), or 0.875ml 
(1 in 125 dilution) of the primary monoclonal antibody to ABCG2 (BXP-21), or the 
equivalent dilution of the isotype control for 1hr. The cells were washed in fix perm 
wash and spun at 1200rpm for 3 mins twice, then resuspended in 100ml of fix perm 
wash with the secondary antibody (anti-mouse IgG2a FITC conjugate, i.e. 0.875ml 
for ABCG2 or 1µl for MDR1 or MRP1) and incubated at room temperature in the 
dark  for  30  mins.  The  cells  were  again  washed  twice  with  fix  perm  wash  and 
analysed by flow cytometry. 
2.3.2.2  CrkL phophorylation by flow cytometry 
There  is  no  specific  antibody  that  is  able  to  detect  the  activity  of  BCR-ABL. 
However,  it  is  known  that  one  of  the  prominent  downstream  substrates 
constitutively  phosphorylated by the BCR-ABL oncoprotein is the 39kD adaptor 
protein CrkL. This protein is the major tyrosyl phoshophoprotein detected in CML 
neutrophils  and  it  has  been  shown  that  CrkL  phosphorylation  is  inhibited  in  a 
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with BCR-ABL phosphorylation. The specificity of CrkL phosphorylation to BCR-
ABL may therefore be used to indirectly assess the status of this oncoprotein. 
The  rabbit  anti-human  phospho-CrkL  (p-CrkL)  antibody  used  for  this  assay 
detected endogenous levels of CrkL only when it was phosphorylated at tyrosine 
207, the BCR-ABL phosphorylation site. Measuring the difference in the geometric 
mean  (GM)  of  p-CrkL  peaks  determined  the  effect  of  the  treatments  on  the 
inhibition of BCR-ABL. 
Samples  for  analysis  of  p-CrkL  levels  were  prepared  by  permeabilisation  and 
staining using the Fix & Perm
® Cell permeabilisation kit as above (section 2.3.2.1), 
but with minor modifications. Following resuspension with 100 l fixing reagent, the
 
cells were resuspended in 25ml of permeabilising reagent with 2.5ml of the p-CrkL 
antibody for 1hr. The cells were washed twice and resuspended in 100ml fix perm 
wash with 2 l of the secondary anti-rabbit IgG FITC conjugate and incubated at 
room  temperature  in  the  dark  for  30  mins.  In  addition  1x10
5  HL60  cells  were 
treated alongside the test population and used as BCR-ABL negative controls. 
2.3.3 Assessment of apoptosis and necrosis  
For analysis of cell death, cells were incubated with 5 l annexin V-FITC and 10 l 
Viaprobe  in  100 l  annexin  buffer for  15  mins  in  the  dark.  The  cells  were  then 
topped with 400 l annexin buffer and read by flow cytometry within the hour to 
identify necrotic (Viaprobe detected in FL-3) and apoptotic (Annexin V detected in 
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2.3.4 Substrate displacement assay 
The  activity of drug transporters  may  be  determined by measuring transport  of 
specific  fluorescent  compounds  against  concentration  gradients.  Using  flow 
cytometry,  the  GM  for  each  resulting  histogram  can  be  used  as  a  measure  of 
fluorescence to calculate the efflux values. Cells with an inactive efflux transporter 
will  retain  the  fluorescent  compound  resulting  in  a  higher  fluorescent  GM 
compared to cells with an active efflux transporter. Conversely, cells with an active 
transporter  will  have  decreased  dye  retention.  The  addition  of  a  competing 
substrate or an inhibitor in these cells would then reduce the efflux of the known 
substrate  resulting  in  an  increase  in  fluorescence  and  hence  confirming  active 
efflux. Similarly, if the addition of a test compound, i.e. drug, also increased the 
fluorescence, then it can be assumed that the compound is interacting with the 
protein either as a competitive substrate or inhibitor (Figure 2-2).  
To measure the function  of transporters, the assay was based on a previously 
published  efflux  assay  (Robey  et  al.  2001a),  but  with  minor  modifications. 
Approximately 1x10
6 cells were resuspended in wash buffer ± inhibitor or ± drug 
and incubated in a water bath at 37
oC for 15 mins. This provided the opportunity 
for the action of the drug and inhibitors on the transporters to take effect. The 
fluorescent compound was then added and incubated for a further 30 mins at 37
oC 
for ABCG2 or 1hr for MDR1 and MRP1 (a final concentration of 200nM BODIPY-
prazosin, 0.5 g/ml Rhodamine or 5µg/ml Fluo-3 AM for ABCG2, MDR1 or MRP1 
respectively).  This  loading  step  allowed  the  cells  to  take  up  the  fluorescent 
compound and establish uptake and efflux in the cells if present.   Jordanides Niove, 2008    Chapter 2 74 
 
Figure 2-2 Substrate displacement assay 
Schematic  diagram  demonstrating  the  substrate  displacement  assay.  A. 
Cells  with  an  inactive  transporter  retain  the  fluorescent  substrate  (dark 
green), cells with an active transporter efflux the substrate and have low 
fluorescence (light green). The addition of a competing substrate or inhibitor 
at increasing concentrations reduces the efflux and increasingly retains the 
dye  (progressively  darker  green).  B.  Replacing  the  known  competitive 
substrate  or inhibitor  with the test compound (i.e. TKI)  will  determine no 
interaction (i.e. not an inhibitor or a competitive substrate), as shown by plot 
overlaying the active efflux transporter or an interaction with the transporter 
(i.e.  an  inhibitor  or  a  competitive  substrate),  as  shown  by  the  increased 
fluorescence. 
 
The cells were then washed in ice-cold wash buffer to stop the loading, spun for 
10 mins at 1000rpm, resuspended in 1ml wash buffer +/- drug +/- inhibitor and 
incubated for 60 mins for ABCG2 or 90 mins for MDR1 and MRP1 at 37
oC. This 
step allowed the active transporters to efflux the compound and the drug and/or 
A. 
B. Jordanides Niove, 2008    Chapter 2 75 
inhibitors  to  maintain  their  action  on  the  transporters.  The  action  of  the 
transporters was then stopped by washing in ice-cold medium and centrifuging at 
1000rpm for 10 mins. The cells were then placed on ice in the dark and analysed 
immediately by flow cytometry. All the dyes can be detected in the FL1 channel. 
Debris was eliminated by gating around the viable cell population on FSC vs. SSC 
dot plot and at least 10,000 viable events were collected.  
2.4 Cellular techniques 
2.4.1 Tracking of CD34
+ cells 
2.4.1.1  Carboxy-fluorescein diacetate succinimidyl ester (CFSE) staining 
CFSE is an intracellular fluorescein-based dye that permits the tracking of stem 
cell  divisions.  This  is  due  to  the  intensity  of  the  fluorescent  stain  within  a  cell 
partitioning  equally  between  the  daughter  cells  with  each  cell  division,  thereby 
allowing  the  identification  of  every  cell  division  by  tracking  the  decreasing 
brightness. Figure 2-3A shows the intensity of CFSE halving with each cell division 
and Figure 2-3B the subsequent FACS histogram identifying the ‘fingers’, which 
each represent a cell division.  
Following  successful  thawing  and  recovery  of  cells  (section  2.2.5)  and 
resuspension in PBS/2%, a stock solution of 5mM CFSE (in DMSO) was diluted at 
1 in 10 dilution with PBS/2% and added to 5ml of cells at a final concentration of 
1 M. The cells were then incubated in a water bath at 37
oC for exactly 10 mins (as 
the  staining  is  time  dependent).  The  cells  were  immediately  diluted  with  10x 
volume of ice-cold PBS/20% in order to stop the staining reaction and the cells 
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washed in fresh PBS/2%, then resuspended in 5GF at a concentration of 2x10
6/ml 
and incubated overnight in 35mm non-adherent tissue culture dishes (at 37
oC in 
5% CO2) to allow the excess dye to leach out of the cells. 
 
 
Figure 2-3 Tracking a cell with CFSE stain 
A. A schematic diagram of the brightness of the CFSE stain in a cell halving 
in  the  daughter  cells  with  each  division.  B.  A  histogram  of  a  FACS  plot 
showing the classic ‘fingers’ pattern with the undivided cells showing the 
highest fluorescence and the intensity halving with each division. A single 
peak  can  be  gated  to  determine  the  percentage  of  cells  in  the  total 
population  that  have  undergone  the  equivalent  number  of  divisions. 
[U.D=undivided] 
 
2.4.1.2  Cell division tracking with CFSE 
After  CFSE  staining  and  overnight  incubation,  500 l  of  cells  at  2x10
5/ml  were 
aliquoted into a 48-well plate (1x10
5 per well). The conditions included TKI alone, 
TKI +/- drug transporter inhibitors, drug transporter inhibitors alone, an untreated 
control, an unstained control (i.e. no CFSE staining) and 100ng/ml colcemid
®. The 
plate was then incubated for 72hrs (at 37
oC in 5% CO2).  
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Following 72 hrs incubation, each well was resuspended in PBS/2%, counted and 
then stained with the CD34-PE antibody and PI for analysis by flow cytometry. The 
cells  treated  with  colcemid
®  were  used  to identify the  position of the undivided 
population on the FACS plot and the untreated cells to differentiate the position of 
each division. The region gates were then positioned such that the fluorescence 
intensity was halved with each cell division. The cells unstained for CFSE were 
used to alter the voltage settings and optimally compensate for spectral overlap. 
2.4.1.3  Calculation of cell recovery 
Following 72 hrs treatment, the effect of TKIs on cell survival and proliferation was 
determined. The viable cell population was initially gated in FSC vs. SSC dot plots 
and PI staining eliminated any dead cells. By selecting the cell population (R10) 
(Figure 2-1A) that are also PI negative (R9) (Figure 2-4B) and plotting these on a 
third dot plot, the upper right quadrant (R1) represents the percentage of viable 
cells that are CD34
+ (Figure 2-4C). 
A histogram plotting these viable cells (i.e. those in R1 and R9 and R10) identified 
the  quiescent  population  and  subsequent  division  peaks.  The  undivided  region 
was guided by the colcemid
® control and the subsequent regions spanning the 
peaks were positioned by halving the GM according to the halving of the CFSE 
fluorescence  intensity.  The  percentage  of  viable  cells  that  were  undivided  and 
CD34
+  (R2)  could  then  be  measured.  Similarly,  cells  that  had  undergone  one 
division, two divisions etc could also be measured (R3, R4, R5 etc) (Figure 2-4D).  Jordanides Niove, 2008    Chapter 2 78 
 
Figure 2-4 Gates and regions used for calculation of cell recovery 
A. A FSC vs. SSC FACS dot plot gating on the live population (R10). B. A 
FSC  vs.  FL3  FACS  dot  plot  presenting  only  the  cells  in  R10.  The  gate 
eliminated any additional apoptotic or necrotic cells that were positive for PI 
staining (R9). C. A FL1 vs. FL2 FACS dot plot presenting only the cells that 
were in R10 and R9. D. A histogram presenting only the cells that were in 
R10 and R9 and R1. The separate peaks represent cells divisions. Each 
peak may  be separated  by  a separate region. Region 2 (R2) represents 
cells that are undivided, R3 represent cells that have undergone 1 division, 
R4 represent cells that have undergone 2 divisions etc.  
 
The  percentages  of  cells,  after  72  hrs  treatment,  recovered  from  the  starting 
population in each division, were calculated as below. 
 
A.  B.  C. 
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The  percentage  of  total  viable  CD34
+  cells  recovered  in  each  division  was 
calculated by dividing the absolute number of CD34
+ cells in a division region by 
the total number of starting cells and then multiplying by 100. 
In addition, the above calculations were repeated for the total number of viable 
cells (i.e. CD34
+ and CD34
-). This was achieved by expanding the gate in Figure 
2-4C (R1) to encompass the upper right and lower right quadrant.  
 
2.4.2 Long term cell proliferation 
Following successful recovery from frozen and overnight incubation (section 2.2.5) 
500 l of 2x10
5/ml cells were plated in a 48 well plate and incubated +/-10 M FTC 
in 5GF media. On day 4 and day 7, the wells were split by removing half the media 
from the surface ensuring the cells in the dish that have settled on the well bed 
were not disturbed and replenished with equal amounts of fresh 5GF media +/- 
10 M FTC. The cells were counted and analysed for CD34
+ expression by surface 
staining on days 4, 7 and 10. 
2.4.3 Long term cell differentiation 
Following successful recovery from frozen and overnight incubation (section 2.2.5) 
1ml of 2x10
5/ml cells were added to a 24 well plate and incubated +/-10 M FTC in 
5GF media for 3 days. The cells were then harvested with PBS/2% and spun for 
10 mins at 1000rpm, then resuspended in 4mls of differentiation media and the 
resuspended cells were split into 2 wells. On day 7, the wells were again split at 
1:1 by removing 1ml media from the surface ensuring the cells that have settled on 
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The cells were then analysed by flow cytometry on day 10 with antibodies against 
surface markers that would be present on differentiated cells.  
2.5 Biochemical techniques 
2.5.1 Determination of cellular drug levels. 
To directly determine the activity of TKIs with regard to drug transporters, specific 
substrates and TKIs may be labelled with radiolabelled isotypes and the cellular 
concentration measured by scintillation counting. An accumulation of radiolabelled 
drugs,  in  the  presence  of  specific  inhibitors,  in  comparison  to  the  absence  of 
inhibitors,  would suggest  that the  drug might be  a  substrate  of the  protein. No 
difference in the presence or absence of specific inhibitors however would suggest 
that the drug is not a substrate for the transporter (Figure 2-5A). 
Similarly, adding known substrates with radiolabelled isotypes in the presence of 
TKIs would determine if these drugs are inhibitors of these drug transporters. An 
increase in the level of specific radiolabelled substrates in the presence of a TKI 
would suggest it is an inhibitor of the transporter (Figure 2-5B). 
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Figure 2-5 Radiolabelled assays to determine interaction of TKI 
A.  Radiolabelled  assay  to  determine  if  TKI  is  a  substrate  of  an  efflux 
transporter  using  parental (WT)  and transduced  (+ve  cell line)  cell  lines. 
The cellular concentration of TKI increases relative to the increasing TKI 
concentration in the parental cell line (black). Similarly the overexpressing 
cell line with the specific inhibitor will demonstrate similar CPM (green) with 
increasing  TKI  concentration.  A  similar  degree  of  CPM  in  the 
overexpressing  cell  line  in  the  absence  of  the  specific  inhibitor  will 
determine that the TKI is not a substrate (panel 1, dashed blue). In contrast 
a  reduced  accumulation  of  TKI  in  the  overexpressing  cell  line  in  the 
absence  of  a  specific  inhibitor  will  determine  that  the  TKI  is  a  substrate 
(panel 2, dashed blue). B. Radiolabelled assay to determine if TKI is an 
inhibitor of an efflux transporter using parental (WT) and transduced (+ve 
cell line) cell lines. The cellular concentration of substrate increases relative 
to the increasing substrate concentration in the parental cell line (black). 
The overexpressing cell line will have a much reduced accumulation of the 
substrate (green), which will be returned to a concentration similar to the 
parental cell line  in the presence  of the specific inhibitor  (red).  A similar 
degree  of  CPM  in  the  overexpressing  cell  line  with  the  specific  inhibitor 
when it is replaced with the TKI will determine that the TKI is an inhibitor 
(panel  1,  dashed  blue).  In  contrast  no  increase  in  accumulation  in  the 
overexpressing cell line in the presence of TKI will determine that the TKI is 
not an inhibitor (panel 2, dashed blue). 
A. 
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2.5.1.1  Standard curve of radiolabelled drug 
To determine the efficiency of the scintillation counter in detecting the isotopes, a 
standard  curve  measuring  the  counts  per  minute  (CPM)  against  increasing 
concentrations of radiolabelled drug were prepared. In the scintillation vials, 500µl 
of  radiolabelled  drug  were  added  in  increasing  concentrations  with  3ml  of 
scintillant fluid, mixed well, and counted on a Microbeta TriLux scintillation counter 
(Perkin  Elmer,  Wellesley,  MA,  USA).  The  results  were  plotted  on  Sigma  plot 
software  and  analysed  using  GraphPad  Prism  software  to  provide  a  standard 
curve, which in turn allowed the interpolation of unknown amounts of drug in cell 
pellets.  
2.5.1.2  Radiolabelled inhibitor assay 
The cells (5x10
5 cell lines or 1x10
5 CML CD34
+) were resuspended in 500ml wash 
buffer and initially incubated at 37
oC for 15 mins +/- inhibitor to allow the action of 
the inhibitor to take effect. Following incubation, 500ml of 
14C-IM, 
14C-nilotinib or 
14C-dasatinib was added at the desired concentration +/- inhibitor and the cells 
were incubated for a further 1hr to allow loading and effluxing of drug from the 
cells.  The  cells  were  then  washed  three  times  in  ice-cold  PBS/2%  to  stop  the 
activity  of  the  protein  and  spun  at  2000rpm  for  3  mins.  The  pellet  was  then 
resuspended in 100 l dH20, vortexed briefly and 200 l lysis buffer was added and 
incubated for 1hr at 37
oC to solubilise the cells and release the drug. The lysed 
cells were then placed in 4ml scintillation vials with 3ml of scintillant Beta phase 
Optimix, mixed well, and the CPM measured by the Microbeta TriLux scintillation 
counter.  Each  determination  was  carried  out  in  triplicate  within  a  single 
experiment. Jordanides Niove, 2008    Chapter 2 83 
2.5.1.3  Radiolabelled substrate assay 
As above, the cells (5x10
5 cell lines or 1x10
5 CML CD34
+) were resuspended in 
500ml wash buffer and incubated at 37
oC for 15 mins +/- inhibitor +/- drug to allow 
the action of the inhibitor and drug to take effect. Following incubation 500ml of 
3H-
mitoxantrone  was  added  at  the  desired  concentration  +/-drug  +/-  inhibitor.  The 
cells were incubated for a further 1hr to allow loading and effluxing of the specific 
radiolabelled  substrate.  The  cells  were  then  washed  three  times  in  ice-cold 
PBS/2% to stop the activity of the protein and spun at 2000rpm for 3 mins. The 
pellet was then resuspended in 100 l dH20, vortexed briefly and 200 l lysis buffer 
was added and incubated for 1hr to solubilise the cells and release the substrate 
from the cells. The lysed cells were then placed in 4ml scintillation vials with 3ml of 
scintillant Beta phase Optimix and the CPM measured by the Microbeta TriLux 
scintillation counter. Each assay was carried out in triplicate. 
2.6 Molecular techniques 
2.6.1 Cell pellets for storage 
Following successful thawing or after drug treatment, cells that were required for 
subsequent RNA extraction were washed twice in PBS and spun at 8,000rpm for 2 
mins. The pellet was then briefly air-dried and snap-frozen in liquid nitrogen for 20 
secs. The resulting pellet was stored at 
-80
oC until further use. 
2.6.2 RNA synthesis  
Total RNA was isolated from pellets using the RNeasy Mini Kit (Qiagen, Crawley, 
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was  quantitated  using  a  nanodrop  spectrophotometer  Nd-1000  (Labtech 
International, East Sussex, UK). An absorbance at 260nm quantified nucleic acid 
and the ratio of 260/280 determined purity (pure RNA ratio is 2.0).  
 
Figure 2-6 Agilent images 
An electropherogram plot of a good quality (A) or degraded (B) RNA and 
ladder  (C).  The  same  data  represented  as  a  gel  image  (D).  Lane  1 
represents the ladder and lanes 2-6 represent samples. Samples 2 and 3 
show  degradation,  samples  4  and  5  show  good  quality  RNA,  sample  1 
demonstrates a little degradation. 
 
The  integrity  of  the  RNA  was  observed  on  a  DNA600  LabChipÔ  kit  using  the 
Agilent  2100  Bioanalyser  (Agilent  Technologies,  Wokingham,  United  Kingdom). 
This  system  allowed  rapid  separation  of  fragments  according  to  their  size  by 
molecular sieving through the microchannels of the well. These fragments were 
detected by fluorescence at the detection point and the data was displayed either 
as  a  gel  like  image  or  an  electropherogram  plot  (Figure  2-6)  .The  chip  was 
prepared for sample loading by spinning a gel dye mix through a spin filter and 
A.  B. 
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injected into the loading well of the chip. One  l of denatured sample was loaded 
(each chip can analyse 12 samples in each run) along with an upper and lower 
marker,  and  a  ladder  marker.  Each run  was completed in 30  mins. Two clean 
bands on the gel indicated good quality RNA.  Multiple bands indicated the RNA 
had degraded.  
2.6.3 cDNA synthesis 
RNA that was  deemed of good quality was synthesised to cDNA either by the 
Superscript II reverse transcriptase kit and random hexamers (Invitrogen, Paisley, 
U.K) or by the High Capacity cDNA Archive kit (Applied Biosystems, Warrington, 
U.K) according to the manufacturer’s instructions.    
2.6.4 Conventional RT-PCR for analysis of ABCG2 expression 
Diane Gilmour, a colleague from Glasgow Royal Infirmary, Glasgow, carried out all 
the conventional PCR. 
PCR  primers  (Sigma-Genosys,  Haverhill,  United  Kingdom)  for  the  analysis  of 
ABCG2  expression  were  as  described  previously  (section  2.1.9).  The  PCR 
conditions used were the following: 94°C for 3 mins, followed by 40 cycles of 94°C 
for 45 secs, 55°C for 30 secs, 72°C for 90 secs, final extension of 72°C for 10 
mins, yielding an amplified product of 202 base pairs (bp).  
Correction for loading of RNA and PCR efficiency was achieved by β-actin, an 
endogenous control gene. The PCR reaction conditions were the following: 94°C 
for 2 mins, followed by 35 cycles of 94°C for 1 mins, 58°C for 45 sec, 72 °C for 1 
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2.6.5 Quantitative RT-PCR for analysis of ABCG2 expression 
Diane Gilmour carried out the real-time PCR for the analysis of ABCG2 expression 
using single primers and probes. 
The mRNA levels of ABCG2 and the endogenous reference gene glyceraldehyde-
3-phosphate  dehydrogenase  (GAPDH)  were  measured  using  the  ABI  PRISM 
7900HT  sequence  detector  (Applied  Biosystems  (ABI),  Warrington,  U.K).  The 
ABCG2 PCR products were detected using a probe containing a FAM reporter and 
TAMRA  quencher.  For  the  GAPDH  reaction  VIC  replaced  FAM.  The  GAPDH 
mRNA levels were measured using the pre-developed Taqman Assay reagents for 
human GAPDH (Applied Biosystems, Warrington, U.K).  
Two ml of the first strand reaction was used as template and added to 300nM of 
forward and reverse ABCG2 primers and 200nM of probe, made to a total volume 
of 50ml with qPCR Mastermix Plus (Eurogentec, Southampton, UK). Each reaction 
was carried out in triplicate. Samples were run on the ABI PRISM 7900 with the 
following reaction conditions: 50°C for 2 mins, 95°C for 10 mins followed by 40 
cycles of 95°C for 15 sec and 60°C for 1 mins. The relative expression levels of 
ABCG2 were calculated using the validated 2
-DDCT method to calculate the relative 
expression. 
2.6.6 Quantitative  RT-PCR  by  Taqman  Low  Density  Array 
technology 
The expressions of transporter genes were measured using Taqman
 Low Density 
Array  (TLDA)  cards  (Applied  Biosystems,  Warrington,  U.K)  (Figure  2-7).  TLDA Jordanides Niove, 2008    Chapter 2 87 
cards are micro fluidic cards that allow 384 reactions to run simultaneously. Each 
well contains custom-made lyophilised primers and probes and are all supplied by 
8 ports in total, with each port delivering mastermix and cDNA to 48 wells in a total 
reaction volume of 2µl. The plate may be designed to detect from a minimum of 12 
genes in quadruplicate, to 384 genes (including 3 endogenous controls) singly.  
 
Figure 2-7 TLDA card 
 
The  cDNA  required  for  the  Taqman  was  synthesised  from  100ng  of  RNA  and 
prepared to a total volume of 50µl. This was then added in equal volume to the 
Taqman universal master mix (Applied Biosystems, Warrington, U.K) and  100µl 
pipetted into each loading port. The plate was then spun twice at 1200rpm for 
1min, sealed and placed into the ABI PRISM 7900HT real-time PCR system. 
The genes of interest for this project were chosen, ordered and preloaded from a 
database  of  ~47,000  optimised  human,  mouse  and  rat  assays 
(http://www.appliedbiosystems.com). The customised TLDA card ordered had 24 
genes in duplicate and included all the available drug transporters, genes for stem 
cells and an array of endogenous controls. The list is in table 2-1. Jordanides Niove, 2008    Chapter 2 88 
Gene  Alternative name(s)  Assay ID  NCBI gene ref. 
18S    18S  N/A 
ABL1    Hs00245443_m1  NM_005157 
ABCB1  MDR1, P-gp  Hs00184491_m1  NM_000927 
ACTB  β-actin  Hs99999903_m1  NM_001101 
ABCC1  ABCC, MRP1  Hs00219905_m1  NM_004996 
ABCC4  MOAT-B, MRP4  Hs00195260_m1  NM_005845 
ABCG2  ABCP, BCRP, MXR  Hs00184979_m1  NM_004827 
AKT1  PKB, RAC-α  Hs00178289_m1  NM_001014431 
BCR    Hs00244731_m1  NM_004327 
CASP3    Hs00234385_m1  NM_004346 
CD34    Hs00156373_m1  NM_001025109 
CD38    Hs00233552_m1  NM_001775 
GAPDH    Hs99999905_m1  NM_002046 
HIF1A  HIF-1α  Hs00153153_m1  NM_181054 
PROM1  CD133  Hs00195682_m1  NM_006017 
SLC22A1  OCT1  Hs00427554_m1  NM_003057 
SLC22A2  OCT2  Hs00161893_m1  X98333 
SLC22A3  OCT3  Hs00222691_m1  NM_021977 
SLC22A4  OCTN1  Hs00268200_m1  NM_003059 
SLC22A5  OCTN2  Hs00161895_m1  NM_003060 
SLC22A6  OAT1  Hs00191220_m1  NM_153276 
SLC22A7  OAT2  Hs00198527_m1  NM_153320 
SLC22A8  OAT3  Hs00188599_m1  NM_004254 
SLC22A9  OAT4  Hs00375768_m1  NM_080866 
Table  2-10  A  table  of  genes  included  on  the  TLDA  card  with  their 
alternative names, assay ID and NCBI gene reference 
 
2.7 Statistics 
The  results  are  shown  as  the  mean  +/-  standard  error  (s.e)  values  unless 
otherwise  stated.  Differences  between  treatments  in  samples  were  assessed 
using paired student’s t-test while differences between groups that were not linked 
were  assessed  using  normal  student’s  t-test.  A  level  of  p<0.05  was  deemed 
significant.Jordanides, Niove 2007     89 
3  Results 1- ABCG2 in CML CD34
+ cells 
There is a population of persisting stem cells in CML that is likely to be responsible 
for the MRD detected in the majority of IM treated patients (Bhatia et al. 2003) and 
it has been shown that increasing the IM concentration against  CML CD34
+ cells 
does not eliminate the primitive quiescent cells in vitro (Graham et al. 2002). It has 
been  hypothesised  that  this  may  be  due  to  sub  optimal  intracellular  drug 
concentrations, because of the activity of drug resistance proteins, including ABC 
proteins (Hegedus et al. 2002). 
ABCG2 mRNA expression has been observed in normal HSCs and in particular in 
cells in the G0/G1 phase of cell cycle. As described in section 1.1, HSCs can be 
recognised using flow cytometry by their appearance as a small side population 
(SP)  of  cells,  evident  by  their  ability  to  exclude  Hst.  This  was  found  to  be 
attributable to ABCG2 activity (Zhou et al. 2001), thus identifying ABCG2 as an 
important molecular marker for the SP phenotype and the most primitive stem cell 
associated transporter. 
ABCG2 expression has also been shown in AML, although evidence relating to the 
level and correlation with disease relapse has been conflicting. Elevated levels of 
ABCG2 have been shown to be attributable to a small subpopulation rather than 
the  homogeneous  expression  of  the  whole  population,  suggesting  ABCG2 
expression is predominantly restricted to LSCs (Abbott et al. 2002). 
However, although ABCG2 is expressed in AML and normal HSCs, it has not been 
previously shown if ABCG2 is expressed on primitive CML CD34
+ cells. To date 
there has only been an indication of an unidentified transporter other than MDR1 Jordanides Niove, 2008    Chapter 3 90 
or  MRP1  mediating  resistance  in  CML  MNCs  (Carter  et  al.  2001).  Hence,  the 
following studies were designed to:  
1.  determine the expression of ABCG2 in CML CD34
+ cells 
2.  confirm the function of ABCG2 in CML CD34
+ cells 
3.  identify whether the current TKIs are substrates or inhibitors of ABCG2 
4.  ascertain the effect of ABCG2 in the treatment of CML HSCs with TKIs 
3.1 Expression of ABCG2 mRNA  
The expression of ABCG2 was first investigated in CML CD34
+ cells using semi-
quantitative RT-PCR.  Distinct  bands  in  all the  CML samples tested  (n=8)  were 
shown in Figure 3-1A panel 1, with bands of the same size as that seen in the 
positive  controls  AML3.3  and  AML6.2  (two  transduced  AML  cells  expressing 
ABCG2  at  low  and  high  levels  respectively)  and  placenta,  a  naturally  high 
expressing tissue. In panel 2, the signals from CML CD34
+ cells were shown to be 
stronger compared to normal mPB CD34
+ cells, suggesting that CML CD34
+ may 
have higher levels of ABCG2. To confirm, the  experiment was replicated using 
sensitive  Taqman
®  technology,  with  single  probes  and  primers,  designed 
specifically to isolate and amplify the ABCG2 gene. Human placenta was again 
used as a positive control and GAPDH as the endogenous reference gene. As 
shown  in  Figure  3-1B,  a  signal  was  detected  at  an  earlier  cycle  in  the  CML 
samples  in  comparison  to  normal  PB  indicating  a  higher  level  of  mRNA 
expression.  
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Figure 3-1 Expression of ABCG2 mRNA in CML CD34
+ cells 
Expression of ABCG2 mRNA in normal and CML CD34
+ cells. A. Semi- 
quantitative  PCR  assay  of  cDNA  synthesised  from  mRNA  from  two 
transduced  cell  lines,  AML3.3  and  AML6.2;  CD34
+  cells  from  4  normal 
controls  and  from  8  CML  CD34
+  cells.  NTC-  no  template  control.  All 
samples were positive for b-actin control. Samples 1-4 in left panel were 
included in the set of 1-8 in right panel. B. Taqman amplification plot of 
placenta (n=2 in duplicate), CML and normal samples (n=4 in duplicate). C. 
Mean  CT of all CML and normal samples tested by taqman technology. All 
samples were tested in duplicate. 
 
A. 
B. 
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The  advantage  of  the  qPCR  over  the  semi-quantitative  PCR  is  the  ability  to 
relatively quantify the gene in one sample and compare it to another sample. This 
is independent of the initial amount of starting material as the amount of gene in 
the sample is quantified relative to the amount of endogenous gene present. This 
provides  a  relative  value  that  may  then  be  used  to  compare  samples  and 
accurately  determine  differing  expression.  This  comparative  crossing  threshold 
method is achieved by subtracting the endogenous control Ct (cycle number at 
which the curve  intersects the threshold) from the target gene  Ct (in  this case 
ABCG2) to give a  Ct (Figure 3-1C). To obtain a comparison between samples, 
the  Ct of the calibrator sample (in this case a normal mPB CD34
+ sample) is 
calculated  and  then  subtracted  from  the   Ct  value  of  the  target  sample  (CML 
CD34
+) to give   Ct. The resulting number is then used as the power figure in the 
equation 2
-   Ct to give expression levels of normalised ABCG2 in CML CD34
+ in 
comparison to the normal samples (Figure 3-2). 
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 Ct =   Ct [gene] - Ct [endogenous control] 
 
   CT=   Ct [target sample] -  Ct [calibrator sample] 
 
2
-  Ct =  Expression level of target sample in relation to calibrator 
sample 
RQ
-(-2.7) =   6.5 fold greater in target (CML) compared to calibrator (normal) 
 
Figure 3-2 A representative example of the calculation for relative 
quantification 
 
Using the equation above, data from 7 CML and 4 normal samples resulted in 
mean  Ct values of 15.2±0.8 and 12.5±0.5 respectively (p<0.01) and a   Ct of 
2.76.  Using  the  equation  2
-  Ct  this  assay  determined  that  CML  CD34
+  cells 
expressed 6.8 fold more ABCG2 than their normal counterparts (Figure 3-3). Jordanides Niove, 2008    Chapter 3 94 
 
Figure 3-3 Expression of ABCG2 mRNA expression in CML CD34
+ cells 
relative to normal CD34
+ cells 
Relative  quantification  (2
-  CT)  of  ABCG2  expression  in  CML  CD34
+  cells 
(dark grey fill; n=8 in dupicate) compared to normal CD34
+ cells (black fill; 
n=4 in duplicate). 
 
3.2 Expression of ABCG2 protein 
CML samples were also tested for protein expression using the specific antibody 
BXP-21.  This  antibody  has  been  generated  against  an  N-terminal  intracellular 
epitope (Maliepaard et al. 2001) and hence requires permeabilisation of the cell 
membrane  in  order  to  access  the  epitope.  The  BXP-21  antibody  was  initially 
optimised by comparing the staining in the HL60 cell line transduced with ABCG2 
(HL60-BCRP), a cell line in which approximately 60% of the cells express ABCG2, 
against  a  wild  type  control  (HL60-WT)  that  does  not  express  ABCG2.  Serial 
dilutions of the antibody established that a 1:125 dilution of the antibody followed 
by the same dilution of the secondary antibody produced the most distinct peaks 
(Figure 3-4). Jordanides Niove, 2008    Chapter 3 95 
 
Figure 3-4 Optimisation and validation of the ABCG2 antibody  BXP-21 
Increasing  dilutions  of  the  ABCG2  antibody  BXP-21  in  HL60  cell  line 
transduced  to  over-express  ABCG2  in  60%  of  the  cells  (HL60-BCRP). 
Panel 1 represents cells stained with the FITC isotype. Panels 2-6 illustrate 
increasing dilutions of the BXP-21 antibody and resulting percentages. A 
dilution of 1:125 produced the optimal segregation in the two populations. 
 
Following optimisation, the assay was carried out in parental AML3 (ABCG2-ve) 
(Figure  3-5A)  and  transduced  AML6.2  (ABCG2+ve)  (Figure  3-5B)  cells.  A 
significant increase in fluorescence was shown in the transduced cells (AML6.2- 
isotype  geometric mean (GM)=4.3 vs.  AML6.2-BXP21 GM=12.7) demonstrating 
protein expression.  Jordanides Niove, 2008    Chapter 3 96 
 
Figure 3-5 Expression of ABCG2 protein in cell lines and CML CD34
+ 
cells 
A  representative  example  of  ABCG2  protein  expression  in  AML3  (A), 
AML6.2 (B) and CML CD34
+ cells (C) with the isotype (black fill) and the 
ABCG2  test  antibody  BXP21  (white  fill).  n=4  for  cell  lines,  n=7  for  CML 
CD34
+  cells.  Each  sample  was  run  in  duplicate  and  all  replicates  were 
consistent. 
 
The protein expression of ABCG2 was then measured in 7 CML samples (Figure 
3-5C).  The  staining  was  positive  in  all  the  samples  and  staining  resulted  in 
significantly  higher  mean  fluorescence  than  the  isotype  control  counterpart 
(isotype GM=3.8±0.2, BXP 21 GM=7.8±0.8, p<0.002). Furthermore, in 5 of the 7 
samples >25% of the cells (range 25.3-79.0%) were positive for ABCG2 staining 
A. 
B. 
C. 
AML3 
AML6.2 
CML 
CD34
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indicating that the increase in fluorescence and subsequent higher GM was not 
due to a small subpopulation of cells but to an expression of the ABCG2 protein by 
more than a quarter of the cells. 
3.3 Function of ABCG2 protein  
It has been previously described that in some cases the level of ABCG2 mRNA 
and/or protein expression may not always correlate with function (Suvannasankha 
et al. 2004). Hence the CML CD34
+ cells were tested in a substrate displacement 
assay  to  confirm  that  the  ABCG2  protein  was  also  functional  by  tracking  a 
fluorescent ABCG2 substrate in the presence or absence of a known inhibitor.  
BODIPY-Prazosin  is  a  fluorescent  conjugate  of  the  specific  ABCG2  substrate, 
Prazosin (Robey et al. 2001a) that can be detected by flow cytometry and FTC is a 
specific chemosensitising agent isolated from Aspergillus fumigatus (J. Antibiotics 
49:527 (1996), that is a specific inhibitor of ABCG2. The combination of specific 
substrate and inhibitor was used to demonstrate inhibition of functional efflux. This 
assay  was first optimised  and  validated in  cell lines before  being conducted in 
primary CML samples. 
The substrate displacement assay was optimised in the parental and transduced 
cell lines. It was initially established that an incubation period of 15 mins with FTC 
prior to the addition of BODIPY-Prazosin was required, to allow effective protein 
inhibition.  To  determine  the  optimal  concentration  of  BODIPY-Prazosin,  serial 
dilutions were then added in the transduced AML6.2 cell line. A concentration of 
200nM BODIPY-Prazosin resulted in maximal efflux, which in turn was maximally 
inhibited  by  10 M  FTC  to  a  similar  degree  to  that  of  AML3  (Figure  3-6).  The 
significant increase in fluorescence confirmed that ABCG2 was functional in these Jordanides Niove, 2008    Chapter 3 98 
cell lines and that this assay could be used to examine the function of ABCG2 in 
CML CD34
+ cells. 
 
Figure 3-6 Function of ABCG2 protein in cell lines and CD34
+ cells  
ABCG2 function by efflux of a known substrate in a cell line model (A), CML 
CD34
+ cell (B) and non-CML CD34
+ cells (C). A. Unstained cells (black fill), 
AML6.2 and BODIPY/Prazosin (light grey fill), AML3 and BODIPY/Prazosin 
(dark grey fill) and AML6.2 and BODIPY/Prazosin with 10 M FTC (black 
line). B. and C. Unstained cells (black fill), with BODIPY/Prazosin (light grey 
fill), with BODIPY/Prazosin and 10 M FTC (dark grey fill).  
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Six CML patients were tested for function of ABCG2 (Figure 3-6B demonstrates a 
representative example). In order to reduce inter-experimental variation, cells with 
10 M FTC were considered to be maximally loaded with BODIPY-Prazosin and 
classed  as  the  control  condition.  The  mean  data  from  the  6  CML  samples 
indicated a significant efflux from the cells in the absence of FTC (54.4±19.3% 
retention  in  comparison  to  the  control,  p=0.04),  indicating  functional  ABCG2 
protein. In contrast, no difference in fluorescence was detected in the non-CML 
samples (n=3), demonstrating no functional ABCG2 in these cells (Figure 3-6C). 
3.4 Interaction of IM with ABCG2 protein 
The  substrate  displacement  assay  was  repeated  as  above  but  this  time  the 
inhibitor  FTC  was  replaced  by  the  TKI  IM.  This  drug  was  added  at  increasing 
concentrations in the parental and transduced cell lines AML3 and AML6.2 to test 
its effect on the ABCG2 protein. The addition of IM resulted in a dose dependent 
decrease  in  efflux  of  BODIPY-Prazosin.  Furthermore,  at  >0.5 M  IM,  a  similar 
decrease in reduction was seen to that with 10 M FTC, suggesting that ABCG2 
mediated efflux was inhibited by IM at a clinically achievable dose (Figure 3-7A). 
The substrate displacement assay was then repeated in CML CD34
+ cells. The 
efflux  of  BODIPY-Prazosin  in  CD34
+  cells  was  inhibited  by  the  addition  of 
therapeutic  IM  concentrations  (Figure  3-7C)  with  5 M  IM  resulting  in  retention 
values  of  223.5±66.4%,  p=0.03,  in  comparison  to  the  CD34
+  cells  with  the 
substrate alone (54.4±19.3%, Figure 3-7D). Although appearing to result in more 
retention, the effect observed with IM was statistically similar to that shown with 
FTC and no significant additive effect resulted from the combination of both drugs. Jordanides Niove, 2008    Chapter 3 100 
In  contrast,  the  addition  of  IM  to  non-CML  CD34
+  cells  showed  no  significant 
retention (Figure 3-7B). 
 
Figure 3-7 Efflux inhibition of an ABCG2 substrate by IM 
Interaction of IM with the protein ABCG2 in cell line AML 6.2 (A), non-CML 
cell  (B)  and  CML  cells  (C).  Unstained  cells  (black  fill),  with  BODIPY-
Prazosin (light grey fill), with BODIPY-Prazosin and 10 M FTC (dark grey 
fill),  with  BODIPY-Prazosin  and  0.1µM  (green  line),  0.5µM  (pink  line)  or 
5µM IM (black line), AML6.2 and 10µM FTC (blue line) D. Percentage of 
efflux by ABCG2. Cells with BODIPY-Prazosin and 10 M FTC (dark grey-
fill)  were  considered  to  have  maximal  retention,  BODIPY-Prazosin  alone 
(light  grey-fill)  and  BODIPY-Prazosin  with  5 M  IM  (white  fill);  n=6  in 
duplicate, ns=not significant. 
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The interaction of IM with ABCG2 in CML cells suggested that IM may be either 
acting as an inhibitor by blocking the transporter and hence retaining the substrate 
within  the  cell  or,  alternatively,  behaving  as  a  competitive  substrate  and  being 
preferentially effluxed out of the cell by ABCG2.  
3.5 Assessment of IM as a substrate of ABCG2  
The substrate displacement assay above demonstrated an interaction of IM with 
ABCG2,  however,  it  cannot  delineate  between  reduction  of  efflux  by  inhibitory 
activity  or  as  a  competitive  substrate.  Other  groups  have  also  investigated  the 
effect of IM, but with conflicting results. Houghton et al (Houghton et al. 2004) 
have shown IM to be a potent inhibitor, but not a substrate of ABCG2, where as 
Burger  et  al  (Burger  et  al.  2004)  have  observed  IM  to  be  a  substrate  for  this 
transporter. The investigations however, were performed in cell lines engineered 
to over-express ABCG2 that were Ph
- and therefore not responsive to IM.  
In  order  to  determine  the  mechanism  of  IM  binding  to  ABCG2,  the  cellular 
concentration  of  radiolabelled  IM  was  determined  in  AML3  (ABCG2-ve)  and 
AML6.2  (ABCG2+ve).  A  reduction  of  IM  accumulation  in  the  cell  line  with 
functional ABCG2 protein would suggest that IM is a substrate, while no difference 
would determine that IM is not a substrate. There was no significant reduction of 
14C-IM in AML6.2 in comparison to AML3 indicating that the presence of ABCG2 in 
the transduced cell line did not reduce the drug concentration and suggests that 
IM was not a substrate of ABCG2. The IM in the cell was not altered even with the 
addition of the specific ABCG2 inhibitor FTC; further confirming that IM was not 
effluxed by ABCG2 (Figure 3-8A). Jordanides Niove, 2008    Chapter 3 102 
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Figure 3-8 Radiolabelled IM in cell lines and CML CD34
+ cells 
Cellular concentration of 
14C-IM in cell lines (A) and CML CD34
+ (B) cells in 
the presence and absence of FTC. A. ABCG2-ve cell line AML3 (red lines, 
circles)  and  ABCG2+ve  cell  line  AML6.2  (blue  lines,  triangles)  in  the 
presence  (black  symbols)  or  absence  (white  symbols)  of  FTC.  B.  CML 
CD34
+ cells in the presence (black symbols) and absence (white symbols) 
of FTC. All data are mean of duplicate analyses of n=3. 
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The protocol was then repeated in 3 CML CD34
+ cells with 5mM 
14C-IM and again 
demonstrated that ABCG2 inhibition by 10mM FTC had no effect on the cellular 
concentration  of  IM  in  these  cells  (Figure  3-8B),  confirming  that  IM  was  not  a 
substrate of ABCG2. 
3.6 Assessment of IM as an inhibitor of ABCG2  
In order to establish whether ABCG2 was an inhibitor of ABCG2, a radiolabelled 
assay  was  designed  using  a  specific  ABCG2  substrate.  Radiolabelled 
3H-
mitoxantrone  was  added  to  the  two  cell  lines  AML3  (ABCG2-ve)  and  AML6.2 
(ABCG2+ve) and the level of 
3H-mitoxantrone was assessed in the presence and 
absence  of  the  specific  ABCG2  inhibitor,  FTC.  In  AML3  cells, 
3H-mitoxantrone 
accumulated in the cell in a dose dependent manner and as expected the cellular 
concentration  was  significantly  reduced  in  the  ABCG2+ve  cell  line  (AML3  vs. 
AML6.2 p<0.001 at 50ng/ml and 100ng/ml). As expected, the addition of 10mM 
FTC, in the ABCG2+ve cell line, restored the concentration of the radiolabelled 
substrate within the cell to that of the ABCG2-ve cells (AML3 vs. AML6.2 + FTC 
p=n/s, AML6.2 vs. AML6.2 + FTC p<0.001 at 50ng/ml and 100ng/ml). When the 
assay was repeated with 5mM IM instead of the specific inhibitor FTC there was a 
similar degree of ABCG2 inhibition, with a similar accumulation of 
3H-mitoxantrone 
(AML3  vs.  AML6.2  +  IM  p=n/s,  AML6.2  vs.  AML6.2  +  IM  p<0.01  at  50ng/ml, 
p<0.001 at 100ng/ml) (Figure 3-9A) suggesting that IM was an inhibitor of ABCG2.  
Assessment of CML CD34
+ cells in this protocol produced a similar pattern. The 
addition of 10µM FTC significantly increased the concentration of mitoxantrone at 
100ng/ml (CML vs. CML + FTC  p=0.003).  Replacing  the inhibitor  with  5µM IM 
demonstrated similar retention of the mitoxantrone (CML vs. CML + IM p=0.004 at Jordanides Niove, 2008    Chapter 3 104 
50ng/ml, p=0.01 at 100ng/ml). This increased accumulation of mitoxantrone by the 
addition of IM confirmed that IM was an inhibitor of ABCG2 (Figure 3-9B). 
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Figure 3-9 Radiolabelled mitoxantrone in cell lines and CML CD34
+ 
cells 
Cellular concentration of 
3H-mitoxantrone in cell lines (A) and CD34
+ (B) 
cells in the presence  and absence of FTC or IM.  A. ABCG2-ve cell line 
AML3 (black symbols) and ABCG2+ve cell line AML6.2 (white symbols) in 
the presence of 10 M FTC (red lines), 5 M IM (blue lines) or alone (black 
lines). B. CML CD34
+ cells with mitoxantrone alone (black line), + 10 M 
FTC  (red  line),  +  5 M  IM  (blue  line).  All  data  are  mean  of  duplicate 
analyses of n>3. *=p<0.05 
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3.7 Cellular concentration of IM 
By plotting increasing concentrations of radiolabelled IM in scintillant against their 
corresponding CPM, a standard curve can be generated. The curve can then be 
extrapolated to predict the cellular IM concentration by generating the equation: 
 ng= -44.21+0.01629*CPM (as calculated by graphpad prism software) 
In CML CD34
+ cells, 11899 counts were observed in 5x10
5 cells with 5 M 
14C-IM. 
This equated to a cellular concentration of IM equivalent to 150ng per 5x10
5 cells 
and  represented  an  uptake  of  5.1%  of  the  available 
14C-IM  in  the  incubation 
medium.   
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Figure 3-10 Standard curve of radiolabelled IM 
Increasing concentrations of 
14C-IM in scintillant plotted against counts per 
minute (CPM)  Jordanides Niove, 2008    Chapter 3 106 
3.8 Assessment of nilotinib interaction with ABCG2  
In addition to the conflicting data in the literature regarding the interaction of IM 
with ABCG2, there had been no studies to date determining the interaction of the 
new  generation  drugs  nilotinib  or  dasatinib  with  ABCG2.  Therefore,  the  assay 
using  radiolabelled  drug  was  repeated  with 
14C-nilotinib.  As  with 
14C-IM,  no 
significant difference in the cellular level was demonstrated between the two cell 
lines, AML3 and AML6.2. Furthermore, the addition of the specific inhibitor FTC 
did  not  alter  the  cellular  concentration  (Figure  3-11A).  This  showed  that  the 
presence of ABCG2 protein did not reduce the drug concentration, suggesting that 
nilotinib was not a substrate of ABCG2.  
Replacing the cell lines with primary CML cells replicated the cell line results with 
no difference in cellular nilotinib concentration, confirming that, like IM, nilotinib 
was not a substrate of ABCG2 (Figure 3-11B).  Jordanides Niove, 2008    Chapter 3 107 
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Figure 3-11 Radiolabelled nilotinib in cell lines and CML CD34
+ cells 
Cellular concentration of 
14C-nilotinib in cell lines (A) and CML CD34
+ (B) 
cells in the presence and absence of FTC. A.  ABCG2-ve cell line AML3 
(red lines, circles) and ABCG2+ve cell line AML6.2 (blue lines, triangles) in 
the presence (black symbols) and absence (white symbols) of FTC. B. CML 
CD34
+ cells in the presence (black symbols) and absence (white symbols) 
of FTC. All data are mean of duplicate analyses of n=3. 
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To test whether nilotinib is an inhibitor of ABCG2 the assay with 
3H-mitoxantrone 
was  performed.  As  previously  demonstrated,  the  cellular  concentration  in  the 
ABCG2+ve  cell  line  was  significantly  reduced  (AML3  vs.  AML6.2  p<0.05  at 
50ng/ml and 100ng/ml). Furthermore, the addition of 10 M FTC not only restored 
the  cellular  accumulation  but  also  significantly  increased  the  retention  of 
mitoxantrone  in relation to the ABCG2-ve cell  line  (AML6.2 vs. AML6.2 + FTC 
p<0.001 at 50ng/ml and 100ng/ml), although this was not significantly different to 
AML3 (AML3 vs. AML6.2 + FTC  p=ns). Replacing FTC  with  5 M  nilotinib  also 
resulted in a significant mitoxantrone accumulation (AML6.2 vs. AML6.2 + nilotinib 
p<0.05 at 50ng/ml, p<0.001 at 100ng/ml) suggesting that nilotinib was acting as an 
inhibitor (Figure 3-12A). 
Replacing the cell lines with primary CML cells replicated the pattern generated by 
the cell lines with significant accumulation by the addition of nilotinib compared to 
CML alone (p=0.04 at 100ng/ml). This confirmed, that, like IM, nilotinib was not a 
substrate of, but an inhibitor for ABCG2 (Figure 3-12B). Jordanides Niove, 2008    Chapter 3 109 
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Figure 3-12 Radiolabelled mitoxantrone in cell lines and CML CD34
+ 
cells 
Cellular concentration of 
3H-mitoxantrone in cell lines (A) and CD34
+ (B) 
cells in the presence and absence of FTC or nilotinib. A.  ABCG2-ve cell 
line AML3 (black symbols) and ABCG2+ve cell line AML6.2 (white symbols) 
in the presence of 10 M FTC (red lines), 5 M nilotinib (blue lines) or alone 
(black lines). B. CML CD34
+ cells with mitoxantrone alone (black line), + 
10 M  FTC  (red  line),  +  5 M  nilotinib  (blue  line).  All  data  are  mean  of 
duplicate analyses of n=3. *=p<0.05 
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3.9 Cellular concentration of nilotinib 
Increasing  concentrations  of  radiolabelled  nilotinib  were  plotted  against  their 
corresponding  CPM,  to  generate  a  standard  curve.  The  curve  was  then 
extrapolated to predict the cellular nilotinib by the equation: 
 ng= 15.56+0.005711*CPM (as calculated by graphpad prism software) 
In  CML CD34
+  cells,  5629 counts  were  observed  in  5x10
5 cells  with  5 M 
14C-
nilotinib, equating to a cellular concentration of 48ng per 5x10
5 cells, representing 
an uptake of 1.8% of the available 
14C-nilotinib in the incubation medium.   
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Figure 3-13 Standard curve of radiolabelled nilotinib 
Increasing concentrations of 
14C-nilotinib in scintillant alone plotted against 
counts per minute (CPM) 
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3.10 Assessment of dasatinib interaction with ABCG2 
The  assay  using  radiolabelled  drug  was  repeated  with 
14C-dasatinib.  However, 
unlike  nilotinib  and  IM,  when  the  ABCG2+ve  cell  line  was  incubated  with 
14C-
dasatinib, the level accumulated in the cells was significantly lower (p<0.001 at 
150nM, 300nM and 600nM) in comparison to the ABCG2-ve cell line. Furthermore, 
the  addition  of  10mM  FTC  to  the  ABCG2+ve  cell  line  restored  the  level  of 
radiolabelled drug in the cell to a similar level to the ABCG2-ve cell line (AML6.2 
vs. AML6.2+ FTC p<0.001 at 150nM, 300nM and 600nM, AML6.2 + FTC vs. AML3 
p=ns) (Figure 3-14). This suggested that dasatinib was effluxed from the cell via 
ABCG2, suggesting that it was a substrate, and the blocking of this transporter by 
the specific inhibitor restored the cellular drug level to that of the cell line with no 
ABCG2 (AML3-ve). 
The experiment was also attempted in CML CD34
+. However, the specific activity 
of  the  radiolabelled  drug  was  too  low  to  produce  statistically  significant  CPM 
values in this assay. In addition, combination of the small number of cells available 
at each concentration for this assay (only 1x10
5 per data point for CD34
+ CML 
cells in comparison to 5x10
5 per vial for cell lines) and the low concentration of 
drug required (nM for dasatinib in comparison to  M for IM and nilotinib) meant 
that the CPM accrued were not enough to distinguish from the background level 
and determine efflux activity.  
The above assay in cell lines suggested that dasatinib was a substrate of ABCG2. 
However, to confirm this speculation the assay was repeated with 
3H-mitoxantrone 
in the presence and absence of 150nM dasatinib to determine whether it is an 
inhibitor.  Jordanides Niove, 2008    Chapter 3 112 
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Figure 3-14 Radiolabelled dasatinib in cell lines 
Cellular  concentration  of 
14C-dasatinib  in  cell  lines  in  the  presence  and 
absence  of  FTC.  ABCG2-ve  cell  line  AML3  (red  lines,  circles)  and 
ABCG2+ve cell line AML6.2 (blue lines, triangles) in the presence (black 
symbols)  and  absence  (white  symbols)  of  FTC.  All  data  are  mean  of 
duplicate analyses of n=3. *p<0.05  
 
As expected, the concentration of 
3H-mitoxantrone was significantly reduced in the 
ABCG2+ve cells and only restored to the level similar to ABCG2-ve cells when the 
transporter  was  inhibited  by  the  addition  of  10mM  FTC.  Replacing  the  specific 
inhibitor with 150nM dasatinib did not however, have the same effect and indeed 
3H-mitoxantrone in the ABCG2+ve cell line remained significantly reduced and at a 
similar level to the cell line alone (Figure 3-15). This was significantly different to 
the addition of 5mM nilotinib or 5mM IM and suggested that dasatinib does not act 
as an inhibitor of ABCG2.  
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Figure 3-15 Radiolabelled Mitoxantrone in cell lines and CML CD34
+ 
cells 
Cellular concentration of 
3H-mitoxantrone in cell lines (A) and CD34
+ (B) 
cells in the presence and absence of FTC or dasatinib. A.  ABCG2-ve cell 
line AML3 (black symbols) and ABCG2+ve cell line AML6.2 (white symbols) 
in  the  presence  of  10 M  FTC  (red  line),  150nM  dasatinib  (blue  line)  or 
alone (black line). B. CML CD34
+ cells with mitoxantrone alone (black line), 
+ 10 MFTC (red line), + 150nM dasatinib (blue line). All data are mean of 
duplicate analyses of n=3, ns=not significant 
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When the experiment was repeated in 3 CML CD34
+ cells, there was again no 
significant  accumulation  of 
3H-mitoxantrone  in  the  presence  of  dasatinib, 
confirming that in CML CD34
+ cells, dasatinib was not an inhibitor at therapeutic 
concentrations. 
3.11 Effect  of  ABCG2  inhibition  on  CML  CD34
+  cells 
following 72hrs culture 
To ascertain the effect of the aberrant ABCG2 expression in CML, CD34
+ cells 
were cultured with TKIs, in the presence and absence of the specific inhibitor FTC, 
to determine if the inhibition of the transporter further enhanced the overall kill with 
dasatinib  specifically  (apparent  substrate  for  ABCG2),  but  also  with  IM  and 
nilotinib (not expected if both drugs act as pure inhibitors of ABCG2).  
Consistent with previous reports (Graham et al. 2002; Jorgensen et al. 2005a), 
treatment of CD34
+ cells with 5 M IM for 72hrs resulted in a reduction in the total 
number  of  cells  in  comparison  to  the  5GF  alone  (14.0±3.7  x10
5 in  5GF  alone, 
4.7±1.3 x10
5 with IM, p=0.04) (Figure 3-16A). Blocking the ABCG2 transporter by 
the  addition  of  10 M  FTC  had  no  effect  on  the  total  number  of  viable  cells 
compared to the 5GF alone (13.6±3.3 x10
5 with FTC, p=ns), indicating that FTC 
alone  was  not  toxic  to  the  cells.  This  was  of  importance  to  confirm  since  any 
additional  differences  in  the  presence  of  IM  would  be  due  to  a  synergistic  or 
additive effect rather than a toxic effect.  
When the cells were cultured in the combination  of IM and FTC, an enhanced 
reduction  was  observed  in  the  total  number  of  cells  in  comparison  to  the  5GF 
alone. However, this did not reach statistical significance when compared to IM Jordanides Niove, 2008    Chapter 3 115 
alone (3.9±1.1 x10
5 with IM + FTC, p=ns) (Figure 3-16A). This suggested that the 
inhibition of ABCG2 in the absence of IM did not have an effect on CML cells and 
did not significantly enhance the reduction of total cells in combination with IM.   
Similarly, treatment of CD34
+ cells with nilotinib for 72hrs resulted in a reduction of 
total  number  of  cells  (16.4±2.8x10
5  in  5GF  alone,  5.6±0.7x10
5  with  nilotinib, 
p=0.03). The combination of nilotinib and FTC demonstrated no further reduction 
in the total number of cells in comparison to the nilotinib alone (6±0.6x10
5 with 
nilotinib and FTC, p=ns), suggesting that, as expected, the co-treatment of IM or 
nilotinib with the ABCG2 inhibitor did not significantly enhance the reduction of 
total cells (Figure 3-16B). 
The treatment of CD34
+ cells with dasatinib for 72hrs resulted in a reduction of 
total  number  of  cells  (16.4±2.8x10
5  in  5GF  alone,  7.3±1.6x10
5  with  dasatinib, 
p=0.006). Unexpectedly, the combination of dasatinib with FTC did not significantly 
reduce the number of total cells in comparison to dasatinib alone (5.2±0.9x10
5 with 
dasatinib and FTC, p=ns), indicating that blocking the transporter with FTC does 
not significantly enhance the reduction of total cells by dasatinib, despite this TKI 
being a substrate for this transporter (Figure 3-16C). 
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Figure 3-16 Inhibition of ABCG2 in total viable cells 
Total number of cells remaining following 3 days in culture in the presence 
of FTC and IM n=6 (A), nilotinib n=4 (B), or dasatinib n=4 (C); CD34
+ cells 
treated  with  5GF  alone  (ND-black  fill),  +10 M  FTC  (dark  grey  fill),  +TKI 
(light grey fill) or combination of 10 M FTC and TKI (white fill). CD34
+ cells 
were seeded at 1x10
5 cells at d0 (dotted line) All data are mean of duplicate 
analysis, *=p<0.05, ns=not significant.  
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3.12 Assessment of q34
+ cells following 72hrs culture 
Following  72hrs  of  culture,  the  population  of  cells  remaining  quiescent  was 
assessed for enhanced reduction in the presence of FTC and in combination with 
TKIs. These experiments were performed using CFSE to track cell division, with 
the  quiescent  population  identified  on  a  FACS  plot  by  their  maximal  bright 
fluorescence that was comparable to the cells treated with colcemid (see section 
2.4.1).  The  recovered  q34
+  cells  were  then  calculated  as  a  percentage  of  the 
starting cell number. The different conditions were plotted relative to the no drug 
control to identify the effect of treatment on the quiescent population. 
There was no significant reduction in the presence of FTC alone (Figure 3-17). 
Similarly the addition of IM, nilotinib or dasatinib did not significantly reduce the 
q34
+ population, but accumulated the cells arrested in the G0/G1 phase, although 
this was not significant. These findings correlate with published reports that have 
also reported accumulation of q34
+ in the presence of TKIs (Graham et al. 2002; 
Copland  et  al.  2006;  Jorgensen  et  al.  2007b).  The  combination  of  the  ABCG2 
inhibitor with any of the TKIs also showed no significant reductions. These results 
therefore suggest that blocking the ABCG2 protein did not enhance the ability of 
the TKIs to target the most primitive quiescent CML stem cells. 
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Figure 3-17 Inhibition of ABCG2 on quiescent CD34
+ CML cells 
Percentage of q34
+ following 72hrs of culture as a percentage of input cells 
with IM; n=6 (A), nilotinib; n=4 (B) or dasatinib, n=4 (C). No drug control 
(ND, black fill), + FTC (dark grey fill), + TKI alone (light grey fill), + TKI + 
FTC (white bar). All data are mean of duplicate analysis, ns=not significant.  
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3.13 Assessment of CrkL phosphorylation 
To further define the effects of ABCG2 inhibition on the efficiency of TKI to inhibit 
BCR-ABL  activity,  the  phosphorylation  of  the  downstream  BCR-ABL  substrate 
CrkL  was  examined  at  16  and  72hrs.  As  previously  reported  (Hamilton  et  al. 
2006), at 16hrs, the addition of the TKIs significantly reduced the percentage of p-
CrkL  compared  to  the  untreated  control  (IM-  52.5±11.3%,  nilotinib-  46±5.2%, 
dasatinib-  45.4±5.5%, untreated control  100%,  p<0.05,  Figure  3-18A). At 72hrs 
(Figure  3-18B),  the  p-CrkL  remained  significantly  reduced  with  nilotinib 
(62.2±12.2%,  p=0.03)  and dasatinib (65.1±9.2%, p=0.01),  but  was not inhibited 
with IM at this time point. These data confirm that these TKIs inhibit the activity of 
BCR-ABL. This was in contrast to FTC, which, as expected, did not significantly 
reduce p-CrkL  at  either 16hrs (87.8±6.4%, p=ns) or  72hrs (98.3±13.4%,  p=ns), 
demonstrating that FTC alone does not inhibit BCR-ABL activity. 
When co-treating CML CD34
+ cells with TKIs in combination with FTC, there was 
no further reduction in p-CrkL compared to TKIs alone, at 16hrs (IM 52.5±11.3%, 
vs. IM+ FTC 66±22.7%, nilotinib 46±5.2% vs. nilotinib + FTC 67±23.4%, dasatinib 
45.4±5.5% vs. dasatinib + FTC 48.8±4.7%, p=ns for all combinations) or at 72 hrs 
(p=ns for all combinations), confirming that blocking ABCG2 does not enhance the 
potency of the TKIs (Figure 3-18). 
 
 
 
 Jordanides Niove, 2008    Chapter 3 120 
 
ND   IM Nil Das
%
 
G
M
 
p
-
C
r
k
L
 
(
1
6
h
r
s
)
0
20
40
60
80
100
120
140
CML - 72hrs
CML + FTC - 72hrs
ND   IM Nil Das
%
 
G
M
 
p
-
C
r
k
L
 
(
7
2
h
r
s
)
0
20
40
60
80
100
120
140
CML - 72hrs
CML + FTC - 72hrs
 
Figure 3-18 BCR-ABL inhibition as a measure of percentage p-CrkL in 
CML CD34
+ cells 
Percentage of GM p-CrkL remaining relative to no drug control (ND) and in 
the presence (grey fill) or absence (black fill) of FTC at 16hrs (A) or 72hrs 
(B) n=5 for IM, n=6 for nilotinib and dasatinib, *p<0.05 
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3.14 Assessment of apoptosis 
In  order  to  determine  the  effect  of  blocking  ABCG2  transporter  by  FTC,  CML 
CD34
+ cells were stained with annexin and viaprobe to determine early and late 
apoptosis  respectively.  A  significant  increase  in  apoptosis  was  observed  in  the 
presence of nilotinib compared to the untreated control (37.7±3% vs. 19.0±4.6%, 
p=0.01). In contrast, the treatment with FTC alone did not significantly increase 
apoptosis (23.3±4.4%), demonstrating that FTC was not toxic to the cells. 
%
 
a
p
o
p
t
o
t
i
c
 
c
e
l
l
s
0
10
20
30
40
50
 
Figure 3-19 Apoptosis in the presence and absence of FTC 
Percentage of cells undergoing apoptosis following treatment with TKIs in 
the presence (dark grey fill) or absence (black fill) of FTC; *p<0.05; n=3, 
ND-no drug, F-FTC. 
 
The  co-treatment  of  TKIs  with  FTC  did  not  result  in  any  further  increase  in 
apoptosis demonstrating that inhibition of ABCG2 does not further enhance the 
apoptotic effect of TKIs. 
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3.15 Effect of ABCG2 inhibition on CD34
+ CML cells 
A closer inspection as to the effect of FTC on the cells following a 72hr culture 
period revealed differences in the phenotype of the cells. Whilst FTC alone did not 
reduce the absolute number of cells compared to the 5GF control, nor alter the 
number  of  qCD34
+  cells,  treatment  resulted  in  a  significant  decrease  in  the 
proportion of CD34
+ cells remaining compared to 5GF alone (4.45±0.8x10
5 in 5GF 
alone, 2.5±0.5 x10
5 with FTC, p=0.01) and this reduction was of a similar degree 
to that seen with IM alone (1.7±0.3 x10
5 with IM, FTC vs. IM, p=ns, Figure 3-20).  
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Figure 3-20 Inhibition of ABCG2 in viable CD34
+ cells 
Total number of viable CD34
+ cells remaining following 72hrs in culture in 
5GF alone (black fill), + 10 M FTC (dark grey fill), + 5 M IM (light grey fill) 
or 5 M IM + 10 M FTC (white fill). CD34
+ cells were seeded at 1x10
5 cells 
at d0 (dotted  line) n=6 in duplicate; *=p<0.05; ns=not significant, [ND-no 
drug] 
 
The  combination  of  IM  and  FTC  further  reduced  the  CD34
+  cells  compared  to 
treatment with either IM or FTC alone (1.2±0.3 x10
5, p=0.04 either drug alone). 
Furthermore, the combination was the only treatment under which the CD34
+ cells 
did not significantly increase from the initial cells seeded at d0 of 1x10
5. Therefore, 
*  
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combining the inhibition of ABCG2 with IM treatment may enhance the ability of IM 
to reduce the CML CD34
+ cells. 
3.16 Effect  of  ABCG2  inhibition  on  proliferation  and 
differentiation of CD34
+ cells 
The reduction  of CD34
+ cells  by inhibition  of ABCG2 suggested that functional 
ABCG2  might  have  an  effect  on  survival  or  differentiation.  To  validate  this,  a 
number of experiments were carried out to identify how FTC may target the CD34
+ 
cells. CML CD34
+ cells (n=4)  were cultured in  a  combination  of growth factors 
designed to support differentiation rather than proliferation over a long time period 
and assayed for a range of surface markers to determine if ABCG2 inhibition led to 
altered differentiation. The presence of FTC did not alter the total cell number after 
10 days (Figure 3-21).  
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Figure 3-21 Effect of ABCG2 inhibition on long-term proliferation 
Total cell counts following long-term culture in differentiation media in the 
presence  (white  symbols)  or  absence  (black  symbols)  of  FTC;  n=4  in 
duplicate. Jordanides Niove, 2008    Chapter 3 124 
Furthermore,  there  was  no  significant  difference  by  paired  t-test  analysis  in  a 
range  of  surface  markers  that  are  characteristic  of  differentiating  cells  in  the 
presence or absence of FTC (Figure 3-22), suggesting that the reduction of CD34
+ 
cells  by  the  inhibition  of  ABCG2  was  not  due  to  alteration  of  the  number  of 
maturing cells in the CML cultures. 
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Figure 3-22 Effect of ABCG2 inhibition on the maturation of CML cells  
The  percentage  of  cells  expressing  mature  surface  markers  following 
culture in differentiation media including G-CSF, GM-CSF, rHu-Epo, rHu-
Tpo, low IL-3 for 7 days, in the presence (grey fill) or absence (black fill) of 
10 M FTC; n=4 in duplicate.  
 
3.17 Effect  of  ABCG2  inhibition  on  CD34
+  cells  by 
apoptosis 
In section 2-14 (see Figure 3-19), the apoptotic effect of FTC was observed at 
72hrs with no significant difference compared to 5GF alone. The experiment was 
repeated but with additional time points to determine whether apoptosis occurred Jordanides Niove, 2008    Chapter 3 125 
at an earlier stage compared to the control arm, which may explain the difference 
in CD34
+ count.    
CD34
+ CML cells (n=3) were cultured in control 5GF media ± FTC and assayed 
with annexin V and viaprobe and analysed periodically. Analysis revealed there 
was no significant difference between the 5GF alone and cells treated with the 
inhibitor  FTC  throughout  the  72hr  period  (Figure  3-23),  suggesting  that  early 
induction of apoptosis did not account for the reduction of CD34
+ cells. 
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Figure 3-23 Assessment of early apoptosis by ABCG2 inhibition 
The percentage of cells undergoing apoptosis in the presence (grey) or 
absence (black) of FTC. All data are mean of n=3 in duplicate. 
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3.18 Effect  of  ABCG2  inhibition  on  proliferating  CD34
+ 
cells 
The effect of FTC in CD34
+ cells was examined further in the 72hr cultures using 
the stain CFSE. This allows the cells to be tracked at each division as the CFSE 
intensity  within  a  cell  is  halved  during  each  division,  hence  identifying  the 
proliferating and non-proliferating cells.  
For this analysis the cells were grouped into 2 categories, ‘non-proliferating’ and 
‘proliferating’. The non-proliferating category included the cells that had not divided 
at  all  (CFSEmax)  and  those  that  had  undergone  one  cycle  of  replication.  The 
rationale  for  adding  the  cells  that  had  completed  one  cycle  of  replication  was 
based on the view that when the drug was added and experiment initiated, the 
cells may all be in different stages of cycle. Some cells may therefore complete the 
division despite the addition of the drug at this stage. Hence, the first opportunity 
for a dividing cell to “see” the drug and arrest would be after division 1. 
As demonstrated in Figure 3-24A, there was no effect of FTC on the total cells 
remaining  after  culture  in  either  the  proliferating  or  the  non-proliferating 
compartment. The data  was then  reanalysed to include  only  the  cells  that  had 
CD34
+  expression  and  plotted  at  each  division.  The  percentage  of  non-
proliferating  CD34
+  cells  (the  undivided  cells  and  those  that  had  undergone  1 
division) were not significantly different in the presence of FTC compared to 5GF 
alone  (Figure  3-24B),  which  matched  the  cell  data  shown  in  Figure  3-24A. 
However, the expansion of CD34
+ cells within the proliferating set of cells was 
significantly reduced in the presence of FTC in comparison to growth factor alone Jordanides Niove, 2008    Chapter 3 127 
(5GF alone vs. FTC, p=0.03), suggesting a reduction in the expression of CD34 by 
cells that are proliferating.  
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Figure 3-24 Effect of ABCG2 inhibition on cell division in CML cells 
following 72hrs culture 
Cells were labelled with CFSE to allow tracking of their proliferative history. 
The  number  of  total  cells  (A)  or  CD34
+  cells  (B)  that  remain  undivided 
(U.D), have divided once (Div 1), twice (Div 2) etc. were calculated using 
the % of cells detected in each division, the cell number and % CD34
+ cells 
within  each  division  (see  calculation  in  2.4.1.3).  Cells  treated  with  5GF 
alone (black fill) compared with cells treated with 10mM FTC alone (grey fill). 
The divisions are grouped as ‘non-proliferating’ (CFSE max and 1 division) 
and  ‘proliferating’  (2  or  more  divisions).  All  data  are  mean  of  duplicate 
analyses of n=4 samples; * p<0.05, ns=not significant. 
Non-proliferating 
ns 
Non-proliferating 
ns 
Proliferating * p=0.03 
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3.19 Summary 
These experiments demonstrate that ABCG2 was not only present in CML CD34
+ 
cells, but also that ABCG2 expression was 6.8 fold higher in the leukaemic cells in 
comparison to normal HSCs. In addition, the protein was expressed showing that 
mRNA was translated.  Furthermore, the ABCG2 protein  was functional in CML 
CD34
+  cells  as  evidenced  by  the  retention  of  the  fluorescent  substrate  in  the 
presence of FTC.  
Replacing FTC with increasing concentrations of IM also reduced the efflux of the 
substrate,  with  a  similar  reduction  to  FTC  observed  at  5 M  IM,  indicating  an 
interaction with ABCG2. Further analysis with radiolabelled IM and mitoxantrone 
demonstrated that IM was an inhibitor and not a substrate of ABCG2, suggesting 
that the intracellular concentration will not be affected by the aberrant expression 
of ABCG2. The experiments were repeated for the new generation drugs nilotinib 
and dasatinib. Similarly to IM, nilotinib was also shown to be an inhibitor and not a 
substrate of ABCG2. Interestingly, the accumulation of nilotinib in the CML CD34
+ 
cells were lower than that observed with IM and this may be explained by the lack 
of  OCT1  effect  for  uptake  of  nilotinib.  Hence  in  a  short  tem  assay,  IM  will 
accumulate to higher levels than nilotinib.  
In contrast, inhibiting ABCG2 with FTC increased the intracellular concentration of 
dasatinib. Furthermore, efflux of radiolabelled mitoxantrone was not affected in the 
presence of dasatinib, confirming that dasatinib is a substrate and not an inhibitor 
of ABCG2. These data suggested that inhibition of the ABCG2 transporter may 
increase the intracellular concentration of dasatinib and might enhance the effect 
of dasatinib in reducing the total cells. Jordanides Niove, 2008    Chapter 3 129 
Following 72hrs culture of CML CD34
+ with TKIs and FTC, there was no further 
reduction  of  total  cells  in  comparison  to  TKIs  alone.  This  was  supported  by 
analysis of CrkL phosphorylation, which showed no significant difference in the 
presence or absence of FTC, either at 16 or 72hrs, indicating no additional BCR-
ABL  inhibition.  Apoptosis  analysis  confirmed  no  difference  when  inhibiting  the 
ABCG2 transporter. These results were expected for both IM and nilotinib as they 
were  demonstrated  to  interact  as  inhibitors  of  ABCG2.  The  inhibition  by  FTC 
therefore,  would  not  increase  the  cellular  concentration  and  hence  not  further 
enhance the effect of IM and nilotinib on the leukaemic cells. However, dasatinib 
was observed to be a substrate for ABCG2. Hence it could be postulated that the 
inhibition of ABCG2 by FTC would increase the accumulation of dasatinib within 
the  CML  CD34
+  cells  (as  occurred  in  the  cell  line),  predicting  an  enhanced 
dasatinib  effect.  Unexpectedly,  no  difference  was  observed  suggesting  two 
possible scenarios. It may be that the drug has reached its maximal effect, such 
that increasing the intracellular concentration will not further inhibit BCR-ABL or 
enhance cell kill. Alternatively, it may also suggest that the maximal intracellular 
concentration required for full inhibition is prevented by active efflux of dasatinib by 
other transporters that are functional on CML CD34
+ cells. 
In  conclusion, these  data suggest that although ABCG2 is over-expressed  and 
functional in CML CD34
+ cells, inhibition of this protein does not reduce the total 
number of cells with any of the tested TKIs, does not increase apoptosis and does 
further inhibit BCR-ABL, inferring that the aberrant ABCG2 expression does not 
mediate resistance in CML CD34
+ cells. 
In addition, although ABCG2 did not mediate CML stem cell resistance to TKIs, 
inhibition  by  FTC  apparently  reduced  the  number  of  CD34
+  cells  remaining Jordanides Niove, 2008    Chapter 3 130 
following 72hrs of culture. Further analysis showed this reduction was not due to 
increased differentiation or apoptosis or reduced proliferation overall, but due to a 
reduction in proliferating cells that expressed the CD34
+ phenotype. This suggests 
that inhibition of ABCG2 may have a role in the behaviour of CML CD34
+ cells by 
down-regulating the expression of CD34
+.  
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4  Results 2- MDR1 in CML CD34
+ cells 
The  data  described  in  chapter  3  demonstrated  that  although  ABCG2  is  over-
expressed and functional in CML CD34
+ cells, inhibition of this transporter does 
not reduce the total number  of cells in  combination  with any  of  the  three TKIs 
tested,  or increase  apoptosis  or further inhibit  BCR-ABL  activity,  demonstrating 
that the aberrant ABCG2 expression does not mediate resistance in CML CD34
+ 
cells. However, it is well known that ABC transporters are promiscuous and share 
many substrates. Furthermore, recent literature has demonstrated MDR1 to be of 
importance  with  elevated  expression  in  many  tumours  and  active  extrusion  of 
chemotherapeutic agents (van der Zee et al. 1995; Trock et al. 1997).  
Several reports have identified active efflux of IM by MDR1 as a contributory factor 
to  multidrug  resistance.  Increased  resistance,  combined  with  reduced  IM 
accumulation  in  cell  lines  (Mahon  et  al.  2000)  and  CML  cells  overexpressing 
MDR1 (Thomas et al. 2004) suggests that IM is a substrate for this transporter. In 
contrast, other studies report no increased sensitivity to IM in mice transplanted 
with mdr1 null BM retrovirally transduced with bcr-abl (Zong et al. 2005).  
At the beginning of the project, only MNC from CML patients had been tested for 
MDR1  expression  and  no correlation between  MDR1 expression  and response 
was observed with therapeutic doses of IM (Carter et al. 2001). However CML is a 
stem  cell  disease,  hence  to  determine  the  role  of  MDR1,  it  was  necessary  to 
analyse the CD34
+ population. The following studies were designed to examine 
the expression of MDR1 in CML HSCs and to identify any interaction of the current 
TKIs with MDR1.  Jordanides Niove, 2008    Chapter 4 132 
4.1 Expression of MDR1 mRNA  
In order to optimise experiments that would determine expression, function and 
the role of MDR1 in the presence of TKIs in CML CD34
+, a valid cell line model 
was required. The K562 WT cell line was chosen as a model for transduction as it 
has no MDR1 expression. This cell line, generated and donated by Dr L.Fairbairn, 
was  transduced  to  express  the  MDR1  gene,  producing  the  K-MDR  cell  line 
(MDR1+ve).  
The expression of MDR1 in cell lines and CML CD34
+ cells was investigated using 
real  time  qPCR.  The  Taqman  Low  Density  Array  (TLDA)  cards  consisted  of  a 
range  of  targets  including  the  3  clinically  relevant  efflux  transporters  (ABCG2, 
MDR1,  MRP1),  the  clinically  relevant  influx  transporter  (SLC22a1/OCT1),  an 
additional 8 OCT transporters (SLC22a2-9), and a range of endogenous controls 
(18S, GAPDH, β-actin). The two cell lines K-WT and K-MDR were analysed on the 
TLDA card. As seen in Figure 4-1A, K-WT had no expression of MDR1, whilst the 
K-562  cell  line  transduced  with  MDR1  (K-MDR)  had  a  Ct  value  of  19.9±0.98, 
confirming effective transduction. 
The  expression  of  MDR1  was  also  investigated  in  CML  CD34
+  and  normal 
counterparts. Figure 4-1B shows the CML samples consistently expressed MDR1 
mRNA, although the  signal  was detected  at  a  later cycle  than normal samples 
indicating a lower level of mRNA expression. Using GAPDH as the endogenous 
control,  7  CML  CD34
+  and  11  normal  CD34
+  samples  gave   Ct  values  of 
8.33±0.47 and 5.44±0.24 respectively (p=0.0003) and a   Ct of 2.89. Using the 
equation  2
-  CT  to  determine  relative  quantification,  this  assay  determined  that Jordanides Niove, 2008    Chapter 4 133 
CML CD34
+ cells expressed 7.41 fold less MDR1 than their normal counterparts 
(Figure 4-1C). 
 
Figure 4-1 Expression of MDR1 mRNA in cell lines and CML CD34
+ 
cells  
Expression of MDR1 mRNA. A. Taqman amplification plot of the cell line K-
WT and the transduced cell line K-MDR. B. Taqman amplification plot of 
CML and normal CD34
+ cells (n=2 in duplicate). C. Relative quantification 
(2
-  CT) of MDR1  expression in CML CD34
+ cells (dark grey fill;  n=11 in 
duplicate) compared to normal CD34
+ cells (black fill; n=7 in duplicate). 
B. 
A. 
C. Jordanides Niove, 2008    Chapter 4 134 
4.2 Expression of MDR1 protein 
The MDR1 protein was detected using the specific antibody C219. This antibody 
recognises an internal, highly conserved amino acid sequence found on MDR1 
and MDR3 isoforms (Georges et al. 1990). Serial dilutions of the antibody in the 
two cell lines established that a 100x dilution of the antibody followed by the same 
dilution of the secondary antibody produced the most distinct peaks. The assay 
demonstrated protein expression in the transduced cells (K-MDR isotype GM=3.27 
vs. K-MDR-C219 GM=4.89). 
 
Figure 4-2 Expression of MDR1 protein in cell lines and CML CD34
+ 
cells 
A representative example of MDR1 protein expression in K-WT (A), K-MDR 
(B) and CML CD34
+ cells (C) with the isotype (black fill) and the MDR1 test 
antibody C219 (white fill); n=3 in duplicate, all replicates were consistent. 
A. 
B. 
C. 
K-WT 
K-MDR 
CML 
CD34
+ Jordanides Niove, 2008    Chapter 4 135 
The  protein  expression  was  then  measured  in  3  CML  samples.  However,  the 
staining was undetectable in all 3 samples with no difference to controls (isotype 
GM, 2.96±0.7, C219 GM 2.98±0.4, p=ns). 
4.3 Function of MDR1 protein 
The  protein  assay  suggested  that  CML  CD34
+  cells  had  no  detectable  MDR1 
protein. However, the apparent absence of expression may be attributable to the 
sensitivity of the assay. Intracellular staining is often less sensitive than assays 
such as Western blotting for protein detection, hence the level in CML CD34
+ cells 
may be below the threshold of detection. Indeed, even though the transduced cell 
line K-MDR had high mRNA expression, there was only a small increase in the 
GM in the transduced cell line, suggesting that the assay may be less sensitive. 
For complete analysis of MDR1 in CML, the CD34
+ samples were tested for MDR1 
function, which by association will also confirm protein expression.  
The substrate displacement assay was carried out with the fluorescent substrate 
rhodamine 123 and the specific inhibitor PSC 833, a cyclosporin A analog. Initially, 
the assay was validated in the parental and transduced cell lines. In the K-WT cell 
line the addition of rhodamine 123 resulted in maximal retention, which was not 
further increased in the presence of PSC 833 (Figure 4-3A).  
The cell line K-MDR was then tested (Figure 4-3B). The background fluorescence 
observed in the K-MDR cell line isotype control (black fill) was due to the green 
fluorescent protein (GFP) present in the vector, which had been added to confirm 
effective transduction. Two peaks were identified in the isotype  control, a large 
peak on the right and a smaller peak within the first decade. The smaller peak Jordanides Niove, 2008    Chapter 4 136 
accounting for ~20% of the population represent the cells that were not effectively 
transduced with MDR1, as they do not possess the background GFP.   
It was established that the cell line K-MDR effluxed 50ng/ml of rhodamine 123 
resulting in two distinct peaks. The larger peak with the lower fluorescence (left 
peak of light grey fill) represented the cells expressing MDR1. The smaller peak 
with the higher fluorescence, accounting for ~20% of the population, represented 
the cells that do not express MDR1, and were assumed to be the same small 
population as those demonstrated in the isotype control. The efflux of rhodamine 
123  in  MDR1  expressing  cells  was  maximally  inhibited  by  5 M  PSC  833, 
confirming that MDR1 was functional in the cell line K-MDR.  
This  assay  was  then  repeated  in  3  CML  patients  (Figure  4-3C).  As  with  the 
analysis  of  ABCG2,  cells  with  the  transporter  inhibitor  5 M  PSC  833  were 
considered to be maximally loaded with rhodamine 123 and classed as the control 
condition. The mean data from 3 CML samples indicated some efflux from the 
cells  in  the  absence  of  PSC  833,  suggesting  a  low  level  of  functional  MDR1 
protein,  although  the  difference  observed  was  not  significantly  different  (Figure 
4-3D). Jordanides Niove, 2008    Chapter 4 137 
 
R+P R
%
 
m
a
x
i
m
u
m
 
r
h
o
d
a
m
i
n
e
 
r
e
t
e
n
t
i
o
n
0
20
40
60
80
100
120
 
Figure 4-3 Function of MDR1 protein in cell lines and CD34
+ cells  
MDR1 function by efflux of a known substrate in K-WT (A), K-MDR (B) and 
CML CD34
+ cells (C). Unstained cells (black fill), cells with rhodamine 123 
(light grey fill), cells with rhodamine 123 and 5 M PSC 833 (dark grey fill). 
D. Percentage of efflux by MDR1 in CML CD34
+ cells. Rhodamine 123 and 
5 M PSC 833 (dark grey-fill) was considered to have maximal retention, 
rhodamine  123  alone  (light  grey-fill).  R-rhodamine,  P-PSC  833,  ns=not 
significant.  
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4.4 Interaction  of  IM  with  MDR1  by  a  substrate 
displacement assay 
The substrate displacement assay was repeated by replacing the specific inhibitor 
with IM. This drug was added at increasing concentrations in the two cell lines to 
test its effect on the MDR1 transporter. The addition of IM resulted in a small dose 
dependent  decrease  in  efflux  of  rhodamine  123  in  K-MDR  (Figure  4-4A).  This 
interaction  suggested  that  IM  was  acting  as  a  possible  weak  inhibitor  or 
competitive substrate for this transporter.  
 
 
Figure 4-4 Efflux inhibition of a MDR1 substrate by IM  
Interaction of IM with the protein MDR1. A- Cell line K-MDR with rhodamine 
123  (blue  fill),  with  rhodamine  and  0.5µM  (green  line),  1µM  (pink  line), 
2.5µM (light blue line) or 5µM IM (dark blue line); n=3 in duplicate. B- CML 
CD34
+ cells with rhodamine 123 (light grey fill), with rhodamine and 5 M 
PSC 833 (dark grey fill), with rhodamine and 5µM IM (black line); n=3 in 
duplicate. 
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However,  when  this  assay  was  repeated  in  CML  samples,  only  1  of  3  tested 
demonstrated an increase in fluorescence in the presence of IM, suggesting that 
IM  was  a  very  weak  inhibitor/substrate  that  did  not  significantly  affect  the 
transporter (Figure 4-4B).    
4.5 Assessment of IM as a substrate of MDR1  
The substrate displacement assay above demonstrated some reduction of efflux 
by IM with MDR1 in cell lines and a small reduction in 1 of 3 CML samples. The 
reduction of efflux in the cell lines may be by inhibitory activity or as a competitive 
substrate.  In  order  to  test  whether  IM  is  a  substrate  for  MDR1,  increasing 
concentrations of radiolabelled IM were used to track the cellular retention in K-WT 
(MDR1-ve) and K-MDR (MDR1+ve). There was no significant accumulation of 
14C-
IM in K-WT in comparison to K-MDR, indicating that the presence of MDR1 did not 
reduce the drug concentration within the cell and that IM was not a substrate of 
MDR1. Furthermore, 
14C-IM did not accumulate in K-MDR cells in the presence of 
the known inhibitor PSC 833, further confirming that IM was not effluxed by MDR1 
(Figure 4-5A). 
The  experiment  was  also  repeated  in  3  CML  samples.  Similarly,  there  was  no 
significant increase in IM accumulation in the presence of PSC 833. These results 
suggest, either that IM was not a substrate for this transporter or that the MDR1 
was insufficiently  expressed in these cells for the effect to be apparent (Figure 
4-5B).  Jordanides Niove, 2008    Chapter 4 140 
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Figure 4-5 Radiolabelled IM in cell lines and CML CD34
+ cells 
Cellular concentration of 
14C-IM in cell lines (A) and CML CD34
+ (B) cells in 
the  presence  and  absence  of  PSC  833.  A.  K-WT  (MDR1-ve)  (red  lines, 
circles)  and  K-MDR  (MDR1+ve)  cell  line  (blue  lines,  triangles)  in  the 
presence  (black  symbols)  and  absence  (white  symbols)  of  PSC  833.  B. 
CML  CD34
+  cells  in  the  presence  (black  symbols)  and  absence  (white 
symbols) of PSC 833. All data are mean of duplicate analyses of n=3. 
A. 
B. Jordanides Niove, 2008    Chapter 4 141 
4.6 Interaction  of  nilotinib  with  MDR1  by  a  substrate 
displacement assay 
The substrate displacement  assay with rhodamine  123 was repeated, this time 
with  nilotinib  as  a  potential  inhibitor.  This  drug  was  again  added  at  increasing 
concentrations in the two cell lines to test its effect on the MDR1 protein. As with 
IM,  the  addition  of  nilotinib  resulted  in  a  dose  dependent  decrease  in  efflux  of 
rhodamine  123.  However,  the  decrease  in  efflux  was  to  a  higher  degree  with 
nilotinib, with 5 M resulting in a reduction of efflux similar to that seen with 5 M 
PSC 833, suggesting that MDR1 mediated efflux was inhibited by nilotinib at a 
clinically achievable dose (Figure 4-6A). This interaction suggested that nilotinib 
was acting as an inhibitor or as a strong competitive substrate for this transporter.  
The assay was repeated using CML CD34
+ cells (Figure 4-6B). The low level of 
rhodamine  123  efflux  was  inhibited  by  therapeutic  nilotinib  concentrations,  with 
5 M  nilotinib  resulting  in  retention  values  of  70.6±9.8%,  in  comparison  to  the 
CD34
+ cells with the  substrate alone (56.2±11.5%), however this did not reach 
statistical  significance  (Figure  4-6C).  This  may  be  due  to  the  low  protein 
expression  observed  in  CML  CD34
+  cells,  resulting  in  insufficient  efflux  to 
reproducibly see the inhibition.  
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Figure 4-6 Efflux inhibition of a MDR1 substrate by nilotinib  
Interaction  of  nilotinib  with  the  protein  MDR1.  A.  Cell  line  K-MDR  with 
rhodamine 123 (blue fill), with rhodamine and 0.5µM (green line), 1µM (pink 
line), 2.5µM (light blue line) or 5µM nilotinib (dark blue line); n=3. B. CML 
CD34
+ cells with rhodamine 123 (light grey fill), with rhodamine and 5 M 
PSC 833 (dark grey fill), with rhodamine and 5µM nilotinib (black line); n=3. 
C. Percentage of efflux by rhodamine 123. Rhodamine 123 and 5 M PSC 
833 (dark grey-fill) was considered to have maximal retention, rhodamine 
123 alone (light grey-fill) and rhodamine 123 with 5 M nilotinib (white fill); 
n=3 in duplicate. R-rhodamine, P-PSC 833, ns=not significant.  
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4.7 Assessment of nilotinib as a substrate of MDR1  
The  substrate  displacement  assay  above  again  cannot  delineate  between 
reduction  of  efflux  by  inhibitory  activity  or  competitive  substrate.  In  order  to 
establish  the  interaction  of  nilotinib  with  MDR1,  increasing  concentrations  of 
radiolabelled  nilotinib  were  used  to  track  the  cellular  concentration  in  K-WT 
(MDR1-ve) and K-MDR (MDR1+ve).   There was no significant  accumulation  of 
14C-IM in K-WT in comparison to K-MDR, indicating that the presence of MDR1 did 
not reduce the drug concentration within the cell and hence suggesting that 
14C- 
nilotinib was not a substrate of MDR1. Similarly, the addition of PSC 833 did not 
alter the cellular accumulation; further confirming that nilotinib was not effluxed by 
MDR1 (Figure 4-7A).  
The  intracellular  accumulation  was  also  observed  in  3  CML  CD34
+  samples 
(Figure  4-7B).  There  was  no  significant  accumulation  of 
14C-nilotinib  in  the 
presence of the inhibitor PSC 833. The results of this experiment combined with 
the substrate displacement assay suggested that nilotinib was a potent inhibitor, 
and not a substrate of, MDR1. Jordanides Niove, 2008    Chapter 4 144 
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Figure 4-7 Assessment of radiolabelled nilotinib accumulation in the 
presence of MDR1 protein 
Cellular concentration of 
14C-nilotinib in cell lines (A) and CML CD34
+ (B) 
cells in the presence and absence of PSC 833. A. K-WT (MDR1-ve) (red 
lines, circles) and K-MDR (MDR1+ve) cell lines (blue lines, triangles) in the 
presence  (black  symbols)  and  absence  (white  symbols)  of  PSC  833.  B. 
CML  CD34
+  cells  in  the  presence  (black  symbols)  and  absence  (white 
symbols) of PSC 833. All data are mean of duplicate analyses of n=3. 
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4.8 Interaction of dasatinib with K-MDR 
Finally,  the  substrate  displacement  assay  was  repeated  in  the  presence  of 
dasatinib. As before, this drug was added at increasing concentrations in the two 
cell lines to test its effect on the MDR1 protein. The addition of dasatinib however, 
resulted in no significant difference between the two cell lines, even at therapeutic 
concentrations,  suggesting  that  dasatinib  is  not  an  inhibitor  for  this  transporter 
(Figure 4-8A). 
Similarly,  no  significant  difference  was  observed  in  3  CML  CD34
+  samples, 
confirming that dasatinib  was not  an inhibitor of  MDR1 in  primary  cells (Figure 
4-8B). 
 
Figure 4-8 Efflux inhibition of a MDR1 substrate by dasatinib 
Interaction  of  dasatinib  with  the  protein  MDR1.  A.  Cell  line  K-MDR  with 
rhodamine 123 (blue fill), with rhodamine and 50nM (green line) and 150nM 
(pink line) dasatinib; n=3. B. CML CD34
+ cells with rhodamine 123 (light 
grey fill), with rhodamine and 5 M PSC 833 (dark grey fill), with rhodamine 
and 150nM dasatiniib (black line no fill); n=3.  
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4.9 Assessment of dasatinib as a substrate of MDR1  
The substrate displacement assay above demonstrated no interaction of dasatinib 
with  MDR1,  demonstrating  that  dasatinib  is  not  an  inhibitor.  However,  to 
conclusively  determine  whether  dasatinib  was  a  substrate,  increasing 
concentrations  of  radiolabelled  dasatinib  were  added  to  measure  the  cellular 
retention  in  K-WT  (MDR1-ve)  and  K-MDR  (MDR1+ve),  in  the  presence  and 
absence of PSC 833. Although not significant, there was less accumulation of 
14C-
dasatinib in the K-MDR transduced cell line compared to the wild type (Figure 4-9). 
However, the concentration of 
14C-dasatinib was not restored by the addition of the 
specific  MDR1  inhibitor,  nor  was  the  accumulation  significantly  increased.  This 
suggested therefore that dasatinib was not a substrate of MDR1.  
However, the significant difference in the two cell lines suggested that there might 
be another transporter that is capable of effluxing this TKI from these cells. Indeed, 
the  results  from  chapter  3  have  confirmed  that  dasatinib  was  a  substrate  for 
ABCG2 and hence the reduced accumulation in K-MDR might be due to the action 
of this transporter. Furthermore, expression analysis of these cell lines (detailed in 
chapter 5) demonstrated that although only transfected with MDR1, K-MDR cells 
had significantly elevated levels of ABCG2 (16.4 fold) compared to K-WT. Hence, 
it  can  be  postulated  that  ABCG2  attributed  to  the  difference  in  the  dasatinib 
accumulation in the two cell lines.    
As previously, this assay could not be performed using CML samples due to the 
low specific activity of dasatinib and the low cell numbers available for each assay 
(as detailed in 3.10). Jordanides Niove, 2008    Chapter 4 147 
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Figure 4-9 Radiolabelled dasatinib in cell lines  
Cellular concentration of 
14C-dasatinib in cell lines cells in the presence and 
absence  of  PSC  833.  K-WT  (MDR1-ve)  (red  lines,  circles)  and  K-MDR 
(MDR1+ve) cell line (blue lines, triangles) in the presence (black symbols) 
and absence (white symbols) of PSC 833, n=3 in duplicate  
 
4.10 Effect  of  MDR1  inhibition  on  CML  CD34
+  cells 
following 72hrs culture 
The previous experiments determined that IM was a weak and nilotinib a strong 
inhibitor of the MDR1 transporter, while dasatinib was neither a substrate nor an 
inhibitor  for  this  protein.  As  with  the  ABCG2  transporter,  the  three  TKIs  were 
tested in combination with the inhibitor PSC 833 to determine and confirm any 
effect of transporter inhibition on CML CD34
+ cells in culture. 
As shown in chapter 3, treatment of CD34
+ cells with 5 M IM, 5 M nilotinib, or 
150nM dasatinib for 72hrs resulted in a reduction in the total number of cells in Jordanides Niove, 2008    Chapter 4 148 
comparison to the 5GF alone (p<0.05) 
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Figure 4-10). Blocking the MDR1 transporter by the addition of 5 M PSC 833 also 
resulted in a reduction in the total number of cells in comparison to 5GF alone 
(17.7±2.19x10
5 in 5GF alone, 8±1.2x10
5 with PSC 833, p=0.002), indicating that 
PSC 833 alone had an effect on the cells. Jordanides Niove, 2008    Chapter 4 149 
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Figure 4-10 Inhibition of MDR1 in total viable cells 
Total number of cells following 3 days in culture, in the presence of TKIs 
alone (dark-grey fill) or combined with PSC 833 (light grey fill). In addition, 
total number of cells in 5GF alone (black fill), or PSC 833 alone (white fill) 
are plotted. CD34
+ cells were seeded at 1x10
5 cells at d0 (dotted line); n=4 
for IM, n=6 for nilotinib, n=7 for dasatinib. All data are mean of duplicate 
analysis, *=p<0.05, ns=not significant, [ND-no drug] 
 
The combination of nilotinib or dasatinib and PSC 833 further reduced the total 
number  of  cells  in  comparison  to  the  drug  alone  (6.17±0.9x10
5  with  nilotinib, 
3.37±1.3x10
5  with  nilotinib  and  PSC  833,  p=0.01,  8±1.3x10
5  with  dasatinib, 
2.77±0.5x10
5 with dasatinib and PSC 833, p=0.001). Although these data would 
appear to imply that there is an additive effect with the combination, the reduction 
of cells in the presence of PSC 833 alone suggests that it this may not be due to 
an  increase  in  TKI  effect,  but  based  upon  a  separate  PSC  833  action  that  is 
unconnected to the action of TKI. 
* 
* 
* 
* 
* 
* 
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4.11 Assessment of q34
+ cells following 72hrs culture  
Following 72hrs culture, the population of cells remaining quiescent was assessed 
for further reduction in the presence of PSC 833 ± TKI. There was no significant 
reduction in the presence of PSC 833 alone. Similarly the combination with TKIs 
also did not further reduce the q34
+ population (IM 11.7±8.3 vs. IM + PSC 3.6±0.9, 
nilotinib 8±4.4 vs. nilotinib + PSC 6.5±2, dasatinib 5.2±1.7 vs. dasatinib + PSC 
5.1±1.5,  p=ns  for  all  combinations).  These  results  therefore  demonstrated  that 
blocking the MDR1 transporter did not enhance the reduction of q34 cells in the 
presence of TKIs. 
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Figure 4-11 Inhibition of MDR1 on quiescent CD34
+ CML cells 
Percentage of q34 following 72hrs of culture as a percentage of input in the 
presence  of TKIs or  5GF alone  (black  bars) or combined  with  PSC  833 
(grey bars), n=4 for IM, n=6 for nilotinib, n=7 for dasatinib, [ND-no drug] 
 
ND             IM             Nil             Das Jordanides Niove, 2008    Chapter 4 151 
4.12 Effect  of  PSC  833  on  cell  division  in  CML  cells 
following 72hrs culture 
To dissect the effect of PSC 833 alone on cells following 72hrs culture, the stain 
CFSE was used to track cell division. The data was then analysed either as the 
whole  population  (top  right  and  bottom  right  quadrant  as  detailed  in  section 
2.4.1.3, Figure 4-12B) or as the population that are still CD34
+ (Figure 4-12C).  
As  demonstrated  in  Figure  4-12B,  although  there  was  no  significant  difference 
between  the  non-proliferating  and  proliferating  populations,  there  was  a  trend 
towards  a  higher  number  of  cells  in  the  early  divisions  compared  to  the  later 
divisions, just reaching statistical significance at division 4 (p=0.05). This would 
suggest  that  PSC  833  was  acting  as  an  anti-proliferative  agent,  and  hence 
accounting for the significant reduction in total cells (Figure 4-12A).  
Additionally, the total number of CD34
+ cells at each division was also analysed 
(Figure  4-12C).  There  was  no  significant  difference  at  any  division,  nor  when 
comparing the non-proliferating with the proliferating population. However, there 
again was a trend towards higher number of cells in the early divisions compared 
to  the  later  divisions,  supporting  the  observation  of  PSC  833  acts  as  an  anti-
proliferative agent.  
 Jordanides Niove, 2008    Chapter 4 152 
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Figure 4-12 Effect of PSC 833 on cell division in CML cells following 
72hrs culture 
Cells were labelled with CFSE to allow tracking of their proliferative history. 
A.  A  representative  FACS  histogram  plot  demonstrating  the  anti-
proliferative effect of PSC 833 (black line) compared to untreated control 
(grey fill). B and C. The percentage of total cells and CD34
+ cells in each 
division  following  72hrs  culture  respectively.  The  cell  numbers  are 
expressed as a percentage of the starting cell number. Cells treated with 
5GF alone (black fill) compared with cells treated with 5mM PSC 833 alone 
(grey fill). The divisions are grouped as ‘non-proliferating’ (CFSE max and 1 
division)  and  ‘proliferating’  (2  or  more  divisions).  All  data  are  mean  of 
duplicate  analyses  of  n=4  samples,  *  p=0.05,  ns=not  significant.  U.D- 
undivided, Div 1- division 1, etc. 
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4.13 Assessment of CrkL phosphorylation 
To define the effects of MDR1 inhibition in the presence of TKIs, the downstream 
substrate  CrkL  was  examined  at  16  and  72hrs  for  BCR-ABL  activity.  As 
demonstrated  in  the  previous  chapters,  the  addition  of  the  TKIs  significantly 
reduced p-CrkL at 16 hrs (p<0.05), with significant reduction retained with nilotinib 
and  dasatinib  at  72hrs  (p<0.05).  The  treatment  with  PSC  833  alone  also 
demonstrated significant CrkL phosphorylation compared to the untreated control 
at  16hrs  (PSC  833-  50.6±6.4% vs.  ND-  100%; p=0.01),  which  was  restored to 
control levels at 72hrs.  
However, the co-treatment of PSC 833 with either TKI did not further reduce p-
CrkL at 16rs or 72hrs (p=ns for all combinations), suggesting that blocking MDR1 
does not further enhance the potency of the TKIs.  It can therefore be suggested 
that the inhibition of MDR1 does not further increase the ability of TKIs to reduce 
p-CrkL and does not increase their potency. 
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Figure 4-13 BCR-ABL inhibition as a measure of percentage p-CrkL in 
CML CD34
+ cells 
Percentage of GM p-CrkL remaining relative to no drug control (ND) in the 
presence (grey fill) or absence (black fill) of PSC 833 at 16hrs (A) or 72hrs 
(B) n=5, *=p<0.05. 
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4.14 Assessment of apoptosis  
In order to determine the effect of blocking the MDR1 transporter by PSC 833, 
CML CD34
+ cells were stained with annexin and viaprobe to determine early and 
late apoptosis. As shown in chapter 3, apoptosis was increased in the presence of 
nilotinib (p=0.01). However, this was not enhanced when co-treated with PSC 833 
(TKI vs. TKI + PSC 833, n/s for all combinations), suggesting that inhibition of 
MDR1 does not further induce the apoptotic effect of the TKIs. 
In addition, increased apoptosis was also observed in the presence of PSC 833 
alone compared to growth factor alone (ND-18.95±4.6% vs. PSC 833 30.37±5.1%, 
p=0.03). These data suggest that MDR1 inhibition does not further enhance the 
apoptotic  effect  of  the  TKIs,  but  that  PSC  833  alone  increased  apoptosis  in  a 
manner unrelated to TKIs.  
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Figure 4-14 Apoptosis in the presence and absence of PSC 833 
Percentage of apoptosis in the presence (dark grey) or absence (black) of 
PSC 833; * p<0.05; n=3, ND-no drug, P-PSC 833 
*
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4.15 Summary 
The previous experiments demonstrated that although MDR1 was expressed in 
CML  CD34
+  cells,  it  was  significantly  lower  (7.41  fold)  than  the  expression  in 
normal counterparts. Although there was some protein function, it was weak, and 
the protein was immeasurable by intracellular staining. Intracellular staining as an 
assay has reduced sensitivity compared to other protein detection assays such as 
Western blotting and the low expression might have been due to the level being 
below the threshold range of the assay. Confirmation of protein expression might 
have been demonstrated with the more sensitive Western blot assay. However, 
the substrate displacement assay was able to confirm both protein expression and 
protein function at low levels, demonstrating that this assay was more sensitive.  
Replacing the specific  MDR1 inhibitor  with  TKIs demonstrated interactions  with 
this transporter. The effect was more obvious in the cell line model as high MDR1 
expression  allowed  the  interaction  with  increasing  concentrations  to  be  easily 
assessed. Increasing concentrations of IM in the MDR1 overexpressing cell line 
demonstrated a small reduction of efflux, suggesting that it might be acting either 
as a substrate or weak inhibitor. However, the effect was only seen in 1 of the 3 
CML patient samples tested, suggesting that the level of MDR1 present in CML 
CD34
+ was either insufficient to see any effect of IM or that the IM interaction was 
so  weak  that  it  did  not  affect  efflux  via  MDR1.  In  contrast,  nilotinib  showed  a 
stronger  interaction  with  MDR1  in  the  MDR1  cell  line  model.  At  therapeutic 
concentrations  (>1 M),  nilotinib  increased  rhodamine  123  retention  to  a  similar 
degree as PSC 833 in cell lines. However, as above, the degree of efflux seen in 
the CML samples was small and was not significantly altered by nilotinib.  Jordanides Niove, 2008    Chapter 4 157 
Although  the  MDR1  protein  was  minimal  in  CML  CD34
+  cells,  the  significant 
increase  in  fluorescence  in  cell  lines  demonstrated  that  these  TKIs  have  an 
interaction  with  MDR1.  Assays  with  radiolabelled  IM  and  nilotinib  in  cell  lines 
demonstrated no significant difference in the presence of the inhibitor PSC 833, 
suggesting that IM and nilotinib were not substrates of this transporter. Therefore 
the interaction observed in the substrate displacement assay suggested that these 
drugs were inhibitors of MDR1. Repeating the assay in CML CD34
+ cells further 
confirmed that IM or nilotinib were not substrates for this transporter. 
In contrast, the addition of dasatinib did not increase rhodamine 123 fluorescence 
in the cell lines or CML, even at the maximal therapeutic concentration, suggesting 
that dasatinib was not an inhibitor for this transporter. Further assessment with 
radiolabelled dasatinib also demonstrated no reduction in retention in the MDR1 
positive cells, demonstrating that dasatinib was not a substrate for this transporter 
either. Interestingly, the intracellular concentration of dasatinib in the transduced 
cell line was lower than the wild-type, suggesting that there might be increased 
expression  of  another  transporter  in  this  cell  line.  Drug  transporters  are 
promiscuous in that they actively efflux many shared compounds and are often co-
expressed and co-regulated. Further analysis of the expression of the wild type (K-
WT)  and  the  transduced  cell  line  (K-MDR)  (and  detailed  in  chapter  6)  showed 
elevated  expression  of  ABCG2  in  K-MDR.  The  data  presented  in  chapter  3 
demonstrated  that  dasatinib  was  a  substrate  for  ABCG2,  hence  the  reduced 
cellular  concentration  in  the  transduced  cell  line  might  be  attributable  to  the 
increased endogenous expression of ABCG2. However, the cell line model in this 
assay was only used to test the difference in cellular concentration of dasatinib in 
the  presence  or  absence  of  PSC  833.  As  there  was  no  difference  in  retention Jordanides Niove, 2008    Chapter 4 158 
when MDR1 was blocked in the two cell lines, then it was conclusively determined 
that dasatinib was not a substrate for MDR1. 
As  with  ABCG2,  for  completion,  the  effect  of  blocking  this  transporter  in  the 
presence of TKIs was tested. The treatment with PSC 833 significantly reduced 
the total number of cells remaining after culture. However, this was not selective 
for the CD34
+ population nor targeted the quiescent population. Instead PSC 833 
alone reduced the number of cells remaining both by exerting an anti-proliferative 
effect  and  by  inducing  apoptosis,  as  demonstrated  by  the  trend  of  increased 
number of cells at the earlier divisions both in the total and CD34
+ population. The 
co-treatment  with  TKI  and  PSC  833  did  result  in  significantly  lower  total  cell 
numbers compared to TKIs alone, however this can be attributed to the additional 
anti-proliferative  and  apoptotic  effects  seen  with  PSC  833  alone.  Furthermore, 
there  was  no  further  reduction  in  p-CrkL  and  more  importantly,  there  was  no 
reduction in the q34
+ population.   
Interestingly, there was a significant reduction in p-CrkL with PSC 833 alone at 
16hrs compared to the untreated control. This reduction by PSC 833 might either 
be  a  consequence  of  the  increased  concentration  of  an  endogenous  substrate 
caused  by  blocking  MDR1,  or  the  direct  inhibition  of  p-CrkL  by  PSC  833.  The 
underlying mechanism for this surprising result though, has not been resolved. 
Furthermore, there was no further increase in apoptosis with the combination of 
PSC 833 and TKIs compared to TKIs alone, although PSC 833 alone significantly 
increased  both  apoptosis.  Therefore,  it  can  be  concluded  that  the  additive 
reduction of cell number and reduced p-CrkL was not due to potentiation of TKI 
activity or concentration. Jordanides Niove, 2008     Chapter 5 159 
5  Results 3- MRP1 in CML CD34
+ cells 
The  previous  two  chapters  have  concentrated  on  the  clinically  relevant  ABC 
transporters ABCG2 and MDR1. For completion, the third transporter implicated in 
MDR in other forms of leukaemia was also studied. There have been fewer reports 
describing the role of MRP1 in mediating drug resistance, however it has been 
demonstrated that it can transport many of the same chemotherapeutic agents as 
MDR1 (Rappa et al. 1997b). MRP1 is also expressed in virtually all human tissues 
and  most  tumour  cell  lines,  suggesting  that  MRP1  may  contribute  to  drug 
resistance  (Burger  et  al.  1994).  Indeed,  AML  cells  from  patients  who  have 
relapsed  compared  to  those  with  responsive  disease  have  higher  expression 
levels of MRP1 (Zhou et al. 1995) and increased resistance to chemotherapeutic 
agents correlates with simultaneous MDR1 and MRP1 expression (Legrand et al. 
1999). 
The analyses of ABCG2 and MDR1 have shown different interaction profiles for 
the current TKIs. Dasatinib is a substrate for ABCG2, but does not interact with 
MDR1. In contrast, IM and nilotinib are both inhibitors for ABCG2 and MDR1. The 
following experiments were therefore designed to identify any interaction of the 
current TKIs in relation to MRP1 and to examine the expression and function of 
MRP1 in CML CD34
+ cells. 
5.1 Expression of MRP1 mRNA  
As for the other transporters, the expression of MRP1 was investigated in CML 
CD34
+ cells and compared to normal counterparts using real time PCR. As shown 
in  Figure  5-1,  CML  samples  expressed  MRP1  mRNA  at  similar  amplitude  in Jordanides Niove, 2008     Chapter 5 160 
comparison to normal PB CD34
+ cells. Using GAPDH as the endogenous control, 
11  CML  CD34
+ and  7 normal CD34
+ samples gave  Ct  values of 4.8±0.4 and 
4.7±0.4  respectively  and  a    Ct  of  0.11.  Using  the  equation  2
-  CT  this  assay 
determined that CML CD34
+ cells expressed equal amounts of MRP1 to normal 
PB CD34
+ cells (1.08 fold) (Figure 5-1C). 
 
Figure 5-1 Expression of MRP1 mRNA in cell lines and CML CD34
+ cells  
Expression of MRP1 mRNA. A. Taqman amplification plot of the cell line K-
WT and the transduced cell line K-MRP. B. Taqman amplification plot of CML 
and  normal  CD34
+  samples.  C.  Relative  quantification  (2
-  CT)  of  MRP1 
expression in CML CD34
+ cells (dark  grey fill; n=11) compared  to normal 
CD34
+ cells (black fill; n=7). 
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In order to optimise experiments that would determine expression, function and 
the  interaction  of  MRP1  with  TKIs  in  CML  CD34
+,  a  valid  cell  line  model  that 
expressed MRP1 was required. The K562 WT cell line, generated and donated by 
Dr L.Fairbairn, was transduced to express the MRP1 gene, producing the K-MRP 
cell line. These two cell lines were then analysed on the TLDA card. However, as 
seen in Figure 5-1A, there was endogenous expression of MRP1 in the wild-type 
control cell line, with a similar expression to the expression level in CML samples 
(K-WT  Ct 4.7±0.2 n=3; CML  Ct 4.8±0.4 n=11), although this expression was 
greatly increased in the transduced K-MRP cell line (K-MRP  Ct -0.03, n=2).  
5.2 Expression of MRP1 protein 
The MRP1 protein was detected using the specific antibody QCRL3. This antibody 
detects an intracellular epitope of the 190kD transmembrane phosphoglycoprotein 
and  does  not  cross  react  with  human  MDR1  (Hipfner  et  al.  1994).  As  for  the 
antibody staining for MDR1, serial dilutions of the antibody established that a 100x 
dilution of the antibody, followed by the same dilution of the secondary antibody, 
produced the most distinct peaks. Following optimisation, the assay was carried 
out  in  parental  K-WT  (MRP1+ve,  Figure  5-2A)  and  transduced  K-MRP  cells 
(MRP1++ve, Figure 5-2B). K-WT cells demonstrated an increase in fluorescence 
compared to the isotype (K-WT isotype GM=3.2±0.3 vs. test GM=5.3±0.6, p=0.01), 
while the transduced cells demonstrated an even higher increase in fluorescence 
(K-MRP isotype GM=3.7±0.6 vs. K-MRP1 GM=12.1±1.1 p=0.02), demonstrating 
protein expression in both cells lines.  
The antibody staining for MRP1 was repeated in 3 CML samples (Figure 5-2C). 
The  assay  demonstrated  positive  staining  in  all  the  samples,  resulting  in Jordanides Niove, 2008     Chapter 5 162 
significantly  higher  mean  fluorescence  than  the  isotype  control  (isotype  GM, 
3.0±0.7, QCRL3 GM 5.0±1.0, p=0.02).  
 
Figure 5-2 Expression of MRP1 protein in cell lines and CML CD34
+ 
cells 
A representative example of MRP1 protein expression in K-WT (A), K-MRP 
(B) and CML CD34
+ cells (C) with the isotype (black fill) and the MRP1 test 
antibody QCRL3 (white fill); n=3 in duplicate, all replicates were consistent.  
 
Comparing the change in GM ( GM) in the K-WT cell line to the  GM in the CML 
sample  demonstrated  that  the  two  samples  had  similar  protein  levels  (K-WT 
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 GM=2.1,  CML   GM=2).  This  correlated  with  similar  mRNA  expression  levels 
demonstrated by the TLDA card in section 5.2. 
5.3 Function of MRP1 protein 
To  confirm  the  function  of  MRP  in  the  transduced  cell  line,  the  substrate 
displacement assay was repeated with the fluorescent MRP1 substrate Fluo-3 AM, 
in a similar manner to the use of BODIPY-Prazosin for the function of ABCG2 and 
rhodamine 123 for the function of MDR1. The specific inhibitor of MRP1 used for 
these experiments was the competitive antagonist of the leukotriene D4 (LTD4) 
receptor, MK571 (Gekeler et al. 1995).  
Using the K-WT cell line, it was established that the cell line actively effluxed Fluo-
3 AM, and that this efflux was inhibited by the addition of 30 M MK571 (Figure 
5-3A). The use of K-MRP cells in this assay was complicated by the presence of 
GFP as a marker, as both GFP and fluo-3 AM are detected in the FL1 channel 
(Figure 5-3C). The presence of GFP meant that when fluo-3 AM was added to the 
K-MRP  cells,  no  further  increase  in  fluorescence  was  observed.  This  may  be 
either because there was maximal efflux or the fluorescence emitted by GFP was 
so bright it masked the signal.  Jordanides Niove, 2008     Chapter 5 164 
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Figure 5-3 Function of MRP1 protein in cell lines and CD34
+ cells 
MRP1 function by efflux of a known substrate in K-WT (A and B), K-MDR 
(C and D) and CML CD34
+ cells (E). Unstained cells (black fill), cells with 
fluo-3 AM (light grey fill), cells with fluo-3 AM and 30 M MK571 (dark grey 
fill), cells with fluo-3 AM and 100 M MK571 (black line). F. Percentage of 
efflux by MRP1 in CML CD34
+ cells. Fluo-3 AM and 30 M MK571 (dark 
grey fill), was considered to have maximal retention, fluo-3 AM alone (light 
grey-fill) 
*=p<0.001. F-Fluo3-AM 
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To test this, the function of MRP1 in the transduced cell line was measured in the 
presence of fluo-3 AM and the inhibitor. At 30 M MK571, a small inhibition in efflux 
was  observed,  however,  increasing  the  concentration  of  the  inhibitor  to  100 M 
caused  a  high  degree  of  inhibition  confirming  that  these  cells  have  functional 
MRP1 (Figure 5-3D). The requirement for increased doses of MK571 reflected the 
high level of MRP1 in this cell line. In contrast, the WT cell line showed no further 
inhibition in the  presence  of the higher  MK571  concentration (Figure  5-3B). As 
CML samples had similar expression levels of MRP1 to K-WT, 30 M MK571 was 
used for inhibition of CML CD34
+ cells.  
The assay was then repeated in 2 CML samples (Figure 5-3E). The fluorescence 
observed in cells with 30 M MK571 was considered to be maximally loaded and 
classed as the control condition. In the absence of MK571, there was a significant 
decrease  in  fluorescence  demonstrating  almost  complete  efflux  by  functional 
MRP1 protein (4.89±0.2% retention in comparison to the control, p=0.01 (Figure 
5-3F). 
5.4 Interaction  of  IM  with  MRP1  by  a  substrate 
displacement assay 
Due  to the  GFP potentially  concealing the  functional  efflux of fluo-3 AM  in the 
transduced cells and the need for increased inhibitor concentration to inhibit the 
protein, it was decided that all further substrate displacement assays assessing 
the interaction of TKIs would be carried out in the wild-type cell line. Unfortunately, 
there was no cell line available as a negative control due to high MRP1 expression 
observed  in  every  cell  line  tested  in  the  laboratory  and  no  MRP1-ve  cell  line Jordanides Niove, 2008     Chapter 5 166 
identified in the current literature. Therefore, the parental cell line K-WT and 30 M 
were used as a control for all substrate displacement assays. 
To  determine  whether  IM  interacts  with  MRP1,  increasing  concentrations  were 
added to the substrate displacement assay using the K-WT cell line (Figure 5-4A). 
The addition of IM resulted in no inhibition of efflux, even at 5 M IM, suggesting 
that IM did not interact with this drug transporter as either a competitive substrate 
or inhibitor. 
Similarly, when this assay was repeated with CML CD34
+ cells, IM did not reduce 
the level of fluo-3 AM efflux, confirming that IM does not interact with MRP1 in 
primary cells either (Figure 5-4B). 
 
Figure 5-4 Efflux inhibition of a MRP1 substrate by IM 
Interaction  of  IM  with  the  protein  MRP1  in  the  cell  line  K-WT;  n=3  in 
duplicate (A) and CML CD34
+ cells; n=2 in duplicate (B). Unstained cells 
(black fill), with fluo-3 AM (light grey fill), with fluo-3 AM and 30 M MK571 
(dark grey fill), with fluo-3 AM and [IM] (black line no fill)  
B. 
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CML 
CD34
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5.5 Assessment of IM as a substrate of MRP1  
The substrate displacement assay above demonstrated no interaction of IM with 
MRP1, suggesting that it was not an inhibitor or a strongly competitive substrate. 
However, in order to determine whether IM was a substrate of MRP1, increasing 
concentrations of 
14C-IM were added to assess the cellular concentration in K-WT 
(MRP1+ve) and K-MRP (MRP1++ve) cells. There was no significant accumulation 
of 
14C-IM in either cell line in the presence of the inhibitor MK571, compared to the 
cell line in the absence of the specific inhibitor, suggesting that IM was therefore 
not a substrate of MRP1 (Figure 5-4A).  
The assay was also repeated using CD34
+ cells from 5 CML patients. There was 
no difference in the cellular accumulation of IM in the presence or absence of the 
inhibitor,  again  supporting  the  conclusion  that  IM  was  not  a  substrate  for  this 
transporter in cell lines or primary CD34
+ cells (Figure 5-4B). 
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Figure 5-5 Radiolabelled IM in cell lines and CML CD34
+ cells 
Cellular concentration of 
14C-IM in cell lines (A) and CML CD34
+ (B) cells in 
the presence and absence of 30mM MK571. A.  K-WT (MRP1+ve) (blue 
lines, circles) and K-MRP (MRP1++ve) cell line (red lines, triangles) in the 
presence (black symbols)  or absence  (white  symbols)  of MK571, n=3 in 
duplicate. B. CML CD34
+ cells in the presence (black symbols) or absence 
(white symbols) of MK571; n=5 in duplicate. 
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5.6 Interaction  of  nilotinib  with  MRP1  by  a  substrate 
displacement assay 
To test whether other TKIs interact with MRP1, the substrate displacement assay 
was repeated, this time with the tyrosine kinase inhibitor nilotinib. This drug was 
again  added  at  increasing  concentrations  in  K-WT  loaded  with  fluo-3  AM,  to 
determine the effect on the MRP1 protein. The addition of nilotinib resulted in a 
dose dependent decrease in efflux of fluo-3 AM, although complete reduction of 
the  protein  comparable  to  30 M  MK571  was  not  reached  with  5 M  nilotinib 
(Figure 5-6A). 
The assay was again repeated in CML CD34
+ cells. The efflux of fluo-3 AM was 
inhibited  with  increasing  nilotinib  concentrations  (Figure  5-6B),  however  the 
retention values observed with 5 M nilotinib (15.31±6%) although slightly higher, 
were not significantly different to the substrate alone (4.89±0.2%, p=ns) and were 
significantly lower than 30 M MK571 (100% control, p=0.03) (Figure 5-6C). This 
incomplete reduction in fluo-3 AM efflux suggests that nilotinib might be either a 
weak inhibitor or a competitive substrate in CML CD34
+ cells. Jordanides Niove, 2008     Chapter 5 170 
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Figure 5-6 Efflux inhibition of a MRP1 substrate by nilotinib  
Interaction of Nilotinib with the protein MRP1 in cell line K-WT (A) and CML 
CD34
+ cells (B). Unstained cells (black fill), with fluo-3 AM (light grey fill), 
with fluo-3 AM and 30 M MK571 (dark grey fill), with fluo-3 AM and nilotinib 
(black line no fill); n=3. C. Percentage of efflux by fluo-3 AM. Fluo-3 AM and 
30 M  MK571  (dark  grey-fill)  was  considered  to  have  maximal  retention, 
fluo-3 AM alone (light grey-fill) and fluo-3 AM with 5 M nilotinib (white fill); 
n=3 *=p<0.05. F-Fluo3-AM 
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5.7 Assessment of nilotinib as a substrate of MRP1  
The  substrate  displacement  assay  demonstrated  an  interaction  of  nilotinib  with 
MRP1,  however,  it  cannot  delineate  between  a  competitive  substrate  and  an 
inhibitor.  To  clarify  the  interaction,  increasing  concentrations  of  radiolabelled 
nilotinib were added and the cellular CPM measured in the presence and absence 
of MK571.  
There was no reduced accumulation of 
14C-nilotinib in the cell line transduced to 
over-express  MRP1  (K-MRP)  compared  to  the  wild  type  that  had  some  MRP1 
protein  (K-WT).  Similarly,  there  was  no  significantly  increased  accumulation  of 
radiolabelled nilotinib in K-WT or K-MRP in the presence of MK571 compared to 
the cell lines alone, demonstrating nilotinib was not a substrate for MRP1.  
The assay was repeated in 3 CML CD34
+ samples. As with the cell lines, there 
was no significant difference of 
14C-nilotinib in the presence or absence of MK571, 
suggesting the interaction observed in the substrate displacement assay was most 
likely  due  to  nilotinib  acting  as  a  weak  inhibitor  but  certainly  not  a  competitive 
substrate. 
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Figure 5-7 Assessment of radiolabelled nilotinib accumulation in the 
presence of MRP1 protein 
Cellular concentration of 
14C-nilotinib in cell lines (A) and CML CD34
+ (B) 
cells in the presence and absence of MK571. A.  K-WT (MRP1+ve) (red 
lines  with  circles)  and  K-MRP  (MRP1++ve)  cell  line  (blue  lines  with 
triangles) in the presence (black symbols) and absence (white symbols) of 
MK571. B. CML CD34
+ cells in the presence (black symbols) and absence 
(white symbols) of MK571. All data are mean of duplicate analyses of n=3. 
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5.8 Interaction  of  dasatinib  with  MRP1  protein  by  a 
substrate displacement assay 
The substrate displacement assay was repeated by replacing the specific inhibitor 
with  the  tyrosine  kinase  inhibitor  dasatinib.  As  demonstrated  earlier,  there  is 
significant  reduction  of  efflux  in  the  presence  of  MK571  demonstrating  active 
protein. However, replacing the inhibitor with dasatinib did not result in an increase 
in fluo-3 AM retention in the K-WT cell line, suggesting that dasatinib was not an 
inhibitor for this drug transporter (Figure 5-8A).  
 
Figure 5-8 Efflux inhibition of a MDR1 substrate by dasatinib 
To investigate the interaction with MRP1, IM was added into this assay in 
place of the known inhibitor, MK571 in K-WT cells (A) and CML CD34
+ cells 
(B). A. K-WT cells unstained (black fill), with fluo-3 AM (light grey fill), with 
fluo-3 AM and 30 M MK571 (dark grey fill), with fluo-3 AM and dasatinib 
(black line no fill). B. CML CD34
+ cells unstained (black fill), with fluo-3 AM 
(light grey fill), with fluo-3 AM and 30 M MK571 (dark grey fill), with fluo-3 
AM and 150nM dasatinib (black line no fill). All data are mean of n=3 in 
duplicate. 
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The assay was repeated in 3 CML samples. There was no significant retention of 
fluo-3  AM  in  the  presence  of  dasatinib,  even  at  the  maximum  clinical  dose  of 
150nM, demonstrating that dasatinib was not an inhibitor of MRP1 (Figure 5-8A). 
5.9 Assessment of dasatinib as a substrate of MRP1  
The substrate displacement assay described above demonstrated no interaction of 
dasatinib  with  MRP1,  and  showed  that  dasatinib  was  not  an  inhibitor  of  this 
transporter.  To  determine  whether  dasatinib  was  a  substrate  of  MRP1, 
14C-
dasatinib  was  added  to  the  cells  in  increasing  concentrations.  The  addition  of 
30 M MK571 did not significantly increase the accumulation of dasatinib in the K-
MRP cell line (p=ns). However, there was a significant increase in 
14C-dasatinib 
accumulation in the K-WT cell line with 30 M MK571 compared to the cell line 
alone at 150nM (p=0.05), 300nM (p=0.01) and 600nM (p=0.01).  
Increasing  the  concentration  of  MK571  to  100 M  in  the  K-WT  cell  line  also 
demonstrated a significant accumulation at 10nM (p=0.01) and 50nM (p=0.02), as 
well  as  at  150  and  300nM  (p<0.02).  Increasing  the  concentration  of  MK571  to 
100 M in the transduced cell line K-MRP demonstrated significant accumulation at 
50nM (p=0.001).  
These  results  demonstrated  that  although  30µM  MK571  resulted  in  significant 
accumulation in the wild-type cell line, it was insufficient to inhibit the MRP1 in the 
transduced  cell  line.  This  correlates  to  the  increased  concentration  of  MK571 
required in the substrate  displacement  assay (figure 4-3) whereby the elevated 
MRP1  expression  was  maximally  inhibited  by  100µM  MK571.  These  results 
demonstrated that dasatinib was a substrate for MRP1. Jordanides Niove, 2008     Chapter 5 175 
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Figure 5-9 Assessment of radiolabelled dasatinib accumulation in the 
presence of MRP1 protein  
Cellular  concentration  of 
14C-dasatinib  in  the  presence  and  absence  of 
30µM MK571 (A) or 100µM Mk571 (B). K-WT (MRP1+ve) (red lines) and K-
MRP (MRP1++ve) cell line (blue lines) in the presence (black symbols) and 
absence  (white  symbols)  of  30µM  (solid  lines)  or  100µM  (dashed  lines, 
squares) MK571. All data are mean of duplicate analyses of n=3; *=p<0.05. 
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Despite the addition of 100 M MK571 in the transduced cell line, the accumulation 
in this cell line remained significantly lower than the wild-type cell line (p<0.05 for 
50-600nM). This may suggest that there is another transporter on the transduced 
cell line contributing to the reduced accumulation.    
The low specific activity of 
14C-dasatinib prevented this assay from being repeated 
in CML CD34
+ cells as the reduced radiolabelled 
14C counts accumulated in the 
low  cell  numbers  available  for  each  determination  would  not  be  above  the 
threshold of detection. 
5.10 Effect  of  MRP1  inhibition  on  CML  CD34
+  cells 
following 72hrs culture 
The  combination  of  substrate  displacement  assays  and  cellular  concentration 
measurements  demonstrated  that  nilotinib  was  an  inhibitor,  dasatinib  was  a 
substrate  and  IM  had  no  effect  on  MRP1.  To  determine  the  effect  of  MRP1 
inhibition  on  the  capacity  of  these  TKIs  to  kill  CML  cells,  CD34
+  cells  were 
incubated for 72hrs in the presence of TKIs alone or TKI and MK571 to inhibit 
transport via MRP1. 
As  in  the  previous  chapters  (chapters  3  and  4),  treatment  with  the  TKIs  alone 
resulted in a reduction in the total number of cells in comparison to cells in 5GF 
alone. Blocking the MRP1 transporter by the addition of 30 M MK571 resulted in 
no  reduction  of  the  total  number  of  viable  cells  compared  to  5GF  alone 
(20.1±1.6x10
5  with  MRP1,  17.7±2.2  alone;  p=ns),  indicating  that  MK571  alone 
does not reduce proliferation. Jordanides Niove, 2008     Chapter 5 177 
When the cells were co-treated with IM, nilotinib or dasatinib and MK571, there 
was no difference in the total number of cells remaining in comparison to TKIs 
alone  (IM  90.3±17.4%  vs.  IM  +  MK571  88.5±22.9%,  nilotinib  61.7±9.2%  vs. 
nilotinib  +  MK571  59.5±12%,  dasatinib  80±12.5%  vs.  dasatinib  +  MK571 
81.3±21.4%, p=ns for all combinations). This suggested that blocking the MRP1 
protein does not further enhance the effect of TKI in reducing total cells.  
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Figure 5-10 Inhibition of MRP1 in total viable cells 
Total number of cells following 3 days in culture, in the presence of TKIs 
alone (dark-grey fill) or combined with MK571 (light grey fill). In addition, 
total number of cells in 5GF alone (ND, black fill), or MK571 alone (white fill) 
are plotted. CD34
+ cells were seeded at 1x10
5 cells at d0 (dotted line); n=4 
for IM, n=4 for nilotinib, n=3 for dasatinib. All data are mean of duplicate 
analysis, *=p<0.01 
 
5.11 Assessment of q34
+ cells following 72hrs culture 
The quiescent population remaining following 72hrs of culture was examined for 
further reduction in 2 CML patients. There was no reduction in the presence of Jordanides Niove, 2008     Chapter 5 178 
MK571  alone  (ND  4.6±1%  vs.  MK571  4.6±3.2%)  suggesting  blocking  the 
transporter alone does not reduce the quiescent population. The co-treatment of 
MK571 with IM, nilotinib or dasatinib did not further reduce the accumulation of 
q34
+ cells (IM 11.7±8.3% vs. IM + MK571 12.2±8.5%, nilotinib 8±4.4% vs. nilotinib 
+ MK571 15±10.5%, dasatinib   5.2±1.7%  vs.  5.6±2.9%,  p=ns  for  all 
combinations), suggesting that blocking MRP1 does not enhance the reduction of 
the quiescent population. 
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Figure 5-11 Inhibition of MRP1 on quiescent CD34
+ CML cells 
Percentage of q34 following 72hrs of culture as a percentage of input in 
5GF alone (ND, black fill), with MK571 (white fill), in the presence of TKIs 
alone (dark grey fill) or combined with PSC 833 (light grey fill). n=4 for IM, 
n=6 for nilotinib, n=7 for dasatinib 
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5.12 Effect  of  MK571  on  cell  division  in  CML  cells 
following 72hrs culture  
The effect of MK571 in CD34
+ cells following 72hrs culture was examined further 
using the stain CFSE to track cell division. The data was analysed as previously, 
measuring  the population remaining following  treatment (Figure  5-12A) and the 
cells that are still CD34
+ (Figure 5-12B). There was no significant difference either 
in the absolute number of cells or CD34
+ cells remaining compared to 5GF alone 
either in the proliferating or non-proliferating cells (p=ns for all combinations). In 
addition there was no further difference at each division, suggesting that MK571 
alone is not toxic to the cells and does not alter the divisional kinetics of the cells.  Jordanides Niove, 2008     Chapter 5 180 
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Figure 5-12 Effect of MK571 on cell division in CML cells following 
72hrs culture 
Cells were labelled with CFSE to allow tracking of their proliferative history. 
The  number  of  (A)  total  cells  or  (B)  CD34
+  cells  that  remain  undivided 
(U.D), have divided once (Div 1), twice (Div 2) etc. were calculated using 
the % of cells detected in each division, the cell number and % CD34
+ cells 
within each division. Cells treated with 5GF alone (black fill) compared with 
cells treated with 30mM MK571 alone (grey fill), n=3 
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5.13 Assessment of CrkL phosphorylation 
To further define the effects of MRP1 inhibition on the efficacy of TKI to inhibit 
BCR-ABL  activity,  the  phosphorylation  of  the  downstream  substrate  CrkL  was 
examined  at  16  and  72hrs.  As  demonstrated  earlier,  p-CrkL  was  significantly 
reduced at 16hrs with the addition of TKIs, with p-CrkL reduction maintained at 
72hrs with nilotinib and dasatinib (see section 3.13). Combining IM or nilotinib with 
MK571 did not further reduce p-CrkL, demonstrating that MRP1 inhibition does not 
enhance the effect of TKIs at 16hrs (IM 52.5±11.3% vs. IM + MK571 59.4±6.9%, 
nilotinib 46±5.2% vs. nilotinib + MK571 43.5±6.6%, p=ns) or 72hrs (p=ns for all 
combinations). Surprisingly however, the combination of dasatinib with TKI also 
did not further reduce p-CrkL either at 16hrs (dasatinib 45.4±5.5% vs. dasatinib + 
MK571 38.5±3.7%, p=ns) or 72hrs (p=ns), despite being shown to be a substrate 
for this transporter. The inhibition of MRP1 with MK571 alone also demonstrated 
no difference in the activity of CrkL at 16 or 72hrs (n=3, p=ns at both timepoints), 
suggesting that inhibition of MRP1 does not further reduce BCR-ABL activity.   Jordanides Niove, 2008     Chapter 5 182 
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Figure 5-13 BCR-ABL inhibition as a measure of percentage of p-CrkL 
in CML CD34
+ cells 
Percentage  p=CrkL  remaining  relative  to  no  drug  control  (ND)  at  16hrs 
(black bars) or 72hrs (grey bars) n=3 
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5.14 Assessment of apoptosis  
In  order  to  fully  investigate  the  effect  of  blocking  the  MRP1  transporter,  CML 
CD34
+  cells  were  stained  with  annexin  and  viaprobe  to  determine  apoptosis. 
Increased apoptosis was observed in the presence of nilotinib as demonstrated 
earlier (see section 3-14). In contrast to FTC though, there was also a small but 
significant increase in apoptosis in the presence of MK571 compared to growth 
factor alone (23.9±4.4% vs. 19±4.69%, p=0.004), demonstrating slight toxicity to 
the cells. The co-treatment with TKI however did not further increase apoptosis (IM 
31.8±2.6% vs. IM + MK571 33.2±3.3%, nilotinib 37.7±3% vs. nilotinib + MK571 
36.1±4%,  dasatinib  31.3±2%  vs.  32.8±3.7%,  p=ns  for  all  combinations), 
suggesting that the effect of TKI was not further enhanced by inhibition of MRP1.  
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Figure 5-14 Apoptosis in the presence and absence of MK571 
Percentage of apoptosis in the presence (dark grey) or absence (black) of 
MK571 and TKIs; n=3. ND-no drug, MK-MK571 
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5.15 Summary 
The above experiments conclusively  demonstrate that  MRP1 was expressed in 
both CML CD34
+ and normal CD34
+ at similar levels. In addition, the protein was 
functional demonstrating effective translation. 
Replacing the known inhibitor, MK571, with TKIs demonstrated an interaction with 
nilotinib, although this did not reach statistical significance. Further analysis with 
radiolabelled nilotinib demonstrated no additional accumulation in the presence of 
the known MRP1 inhibitor, suggesting that nilotinib is at best a weak inhibitor of 
MRP1.  
In contrast, replacing the known inhibitor, MK571, with either IM or dasatinib had 
no  effect,  suggesting  that  these  agents  were  not  inhibitors  of  MRP1.  Further 
analysis  with  radiolabelled  IM  demonstrated  no  additional  accumulation  in  the 
presence of MK571, concluding that IM is neither a substrate nor an inhibitor for 
this  protein.  However,  blocking  the  transporter  with  MK571  in  the  cell  lines 
significantly increased the accumulation of dasatinib, suggesting that dasatinib is 
indeed a substrate for, and not an inhibitor of, MRP1.  
The effect of blocking the transporter either in the presence or absence of TKIs 
was  then  studied.  The  treatment  with  MK571  alone  did  not  affect  the  overall 
number  of cells  remaining  and  the proportion of  cells in each division  was  not 
altered,  indicating  that  MK571  does  not  have  an  anti-proliferative  effect  like 
PSC833. However, there was a small increase in apoptosis observed at 72hrs, 
demonstrating that MK571 alone was slightly toxic to the cells. Jordanides Niove, 2008     Chapter 5 185 
However, the co-treatment of MK571 with IM, nilotinib or dasatinib did not further 
reduce the cells in comparison to TKIs alone, despite dasatinib being a substrate 
for  this  transporter.  Furthermore,  the  inhibition  of  MRP1  did  not  enhance  the 
reduction  of  total  cells  and  more  importantly  did  not  reduce  the  quiescent 
population. In addition, the co-treatment of MK571 and TKIs did not further reduce 
p-CrkL  or  increase  apoptosis  compared  to  TKIs  alone.  These  results  therefore 
suggest  that  although  MRP1  is  functional  and  dasatinib  is  a  substrate,  the 
expression  does  not  mediate  resistance  in  CML  CD34
+  cells.  It  may  therefore 
suggest that, as detailed in chapter 3 (section 3.19) the maximal concentration 
required for full inhibition is limited by active efflux of dasatinib by ABCG2 and 
possibly other transporters as yet unidentified. Indeed, the co-treatment of FTC 
and MK571 with dasatinib may further enhance the overall cell kill of the progenitor 
and quiescent population and further limit BCR-ABL activity. Alternatively, these 
data may again suggest that dasatinib may be inhibiting BCR-ABL to its maximum, 
such that increasing the cellular concentration will not further reduce p-CrkL. 
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6  Results 4- Drug transporters in cell lines and 
CML CD34
+ cells 
The results presented in the previous chapters have investigated the three main 
clinically  relevant  drug  transporters  in  CML  CD34
+  cells  and  compared  their 
expression to normal counterparts. Following confirmation of protein function, their 
interaction with the TKIs was determined. Nilotinib was identified as an inhibitor for 
every drug transporter examined, while IM was an inhibitor for ABCG2 and MDR1. 
In contrast dasatinib was found to be a substrate for ABCG2 and MRP1, which 
were the two transporters that were highly expressed in CML CD34
+ cells.  Yet 
despite this, co-treatment of TKIs in the presence of drug transporter inhibitors did 
not further reduce the total number of cells or further reduce p-CrkL. This suggests 
that either dasatinib is inhibiting BCR-ABL activity to its maximum efficiency such 
that  increasing  the  concentration  will  not  further  reduce  p-CrkL,  or  that  the 
dasatinib  concentration  is  still  being  limited  by  the  active  efflux  of  other 
transporters. Indeed, the previous three chapters have only investigated the effect 
of inhibiting each transporter in isolation and have only looked at the 3 clinically 
relevant transporters. The transporter family have many members and they are 
inherently promiscuous, sharing many substrates. It is therefore likely that other 
transporters, perhaps not yet identified, may also mediate resistance by actively 
effluxing the TKIs. In addition, treatment of cells with TKIs may induce expression 
of  transporters  that  are  inactive  at  initial  diagnosis,  or  may  stimulate 
overexpression of the currently active transporters. This chapter therefore looked 
at a wider selection of transporters, including the solute carrier family SLC22a, 
which  might  be  expressed  on  CML  CD34
+  cells,  either  at  diagnosis  or  post 
treatment with TKIs and which may have a role in drug resistance. The first three Jordanides Niove, 2008     Chapter 6 187 
members of this family (SLC22a1-3) are organic cation transporters and are also 
known as OCT1-3, the following 2 members (SLC22a4 and SLC22a5) are organic 
cation/carnitine transporters and are also known as OCTN1 and OCTN2 and the 
next  4  members  are  organic  anion  transporters  (OAT1-4).  For  clarity  and 
elimination of confusion due to their similarity in nomenclature, in figures the first 3 
members will be referred to as OCT1-3 and the remaining will be referred to by 
their family gene names SLC22a4-9.    
6.1 Experimental variation of TLDA cards 
The expression of drug transporters was investigated by designing a custom-made 
TLDA card with a range of drug transporter genes. The advantage of analysis by 
this method is the small amount of material required. Each card possesses 384 
wells of which 48 are supplied by 1 port (i.e. 8 ports in total) and each port requires 
only  100ng  of  RNA  converted  to  cDNA  for  optimum  experimentation,  which 
therefore amounts to only ~2ng per well.  
Prior to any sample testing, the technique was validated in our hands. Firstly, the 
layout of the TLDA card was such that each gene for every sample was tested in 
duplicate. Table 6-1 represents an example from one of the cell lines showing the 
change in crossing thresholds ( Ct) between the endogenous control (GAPDH) 
and  gene,  and  the  corresponding  standard  deviation  (S.D.),  generated  by  the 
Taqman  software  “RQ  Manager  1.2”.  A   CT  value  that  is  lower  in  one  gene 
compared  to  another  represents  a  higher  relative  expression  and  vice  versa. 
Similarly, when comparing genes from two samples, the sample with the lower 
value will have higher gene expression. Negative values, as demonstrated with 
18S and β-ACTIN, represent genes that had a signal detected earlier than GAPDH Jordanides Niove, 2008     Chapter 6 188 
and hence have higher expression than this endogenous control. Genes that have 
no  signal  after  40  cycles  were  termed  “nd”  demonstrating  an  expression  level 
below the threshold of detection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6-1 A representative example of one sample tested in duplicate 
with the corresponding S.D. 
GAPDH was used as the endogenous control, nd=not detected 
 
Secondly, in excess of 3 samples were tested on different days in different port 
positions to determine inter-experimental variation. Table 6-2 details the CT and 
 Ct of K-WT tested on TLDA cards on different days with the corresponding S.D. 
  Plate 1 
Detector  Avg  Ct   Ct S.D. 
18S  -13.16  0.03 
MDR1  nd  nd 
MRP1  6.38  0.13 
MRP4  6.46  0.09 
ABCG2  0.84  0.03 
ABL1  5.19  0.06 
Β-actin  -0.91  0.09 
AKT1  3.09  0.19 
BCR  6.91  0.24 
CASP3  6.82  0.06 
CD34  nd  nd 
CD38  2.61  0.31 
GAPDH  Endogenous control 
HIF1A  4.43  0.03 
PROM1  nd  nd 
SLC22a1 (OCT1)   nd  nd 
SLC22a2 (OCT2)  nd  nd 
SLC22a3 (OCT3)  nd  nd 
SLC22a4 (OCTN1)  8.35  0.35 
SLC22a5 (OCTN2)  8.19  0.09 
SLC22a6 (OAT1)  nd  nd 
SLC22a7 (OAT2)  nd  nd 
SLC22a8 (OAT3)  nd  nd 
SLC22a9 (OAT4)  nd  nd Jordanides Niove, 2008     Chapter 6 189 
The analysis from the combined data in the two tables confirmed that the data 
obtained from the TLDA cards was optimised and valid for comparative analysis. 
  Plates 1-3 
Detector  Mean Ct  Ct S.D.  Mean  Ct   Ct S.D. 
18S  6.56  0.12  -14.07  0.13 
MDR1  21.08  0.05  0.60  0.11 
MRP1  24.49  0.05  3.87  0.28 
MRP4  25.84  0.02  5.22  0.23 
ABCG2  25.22  0.26  4.59  0.48 
ABL1  27.40  0.14  6.78  0.39 
β-actin  19.56  0.09  -1.07  0.30 
AKT1  24.99  0.38  4.37  0.49 
BCR  26.37  0.31  5.74  0.08 
CASP3  27.25  0.20  6.62  0.18 
CD34  >40.00  N/A  Nd  nd 
CD38  >40.00  N/A  Nd  nd 
GAPDH  20.62  0.25  Endogenous control 
HIF1A  24.94  0.14  4.32  0.34 
CD133  >40.00  N/A  19.38  0.25 
SLC22a1 (OCT1)   33.47  1.89  12.85  1.85 
SLC22a2 (OCT2)  >40.00  N/A  Nd  nd 
SLC22a3 (OCT3)  >40.00  N/A  Nd  nd 
SLC22a4 (OCTN1)  27.88  0.18  7.26  0.22 
SLC22a5 (OCTN2)  27.59  0.09  6.96  0.33 
SLC22a6 (OAT1)  >40.00  N/A  nd  nd 
SLC22a7 (OAT2)  >40.00  N/A  nd  nd 
SLC22a8 (OAT3)  >40.00  N/A  nd  nd 
SLC22a9 (OAT4)  >40.00  N/A  nd  nd 
 
Table 6-2 An example of one sample tested in duplicate on different 
plates representing the S.D. both at Ct and  CT 
The experiment was completed in 40 cycles. A value of greater than 40 
cycles  suggested  either  expression  was  below  the  level  of  detection  or 
there was no expression. GAPDH  was used as the endogenous control; 
n=3, nd=not detected, n/a= not applicable 
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6.2 Expression of drug transporters in cell lines 
Following validation, the cell lines used as models for optimisation of experiments 
in  the  previous  chapters  were  analysed.  Table  6-3  details  the   Ct  of  the  drug 
transporters in the cell lines. 
  K-WT  Ct  K-MDR  Ct  K-MRP  Ct  AML3  Ct  AML6.2  Ct 
Detector  Mean  S.E  Mean  S.E  Mean  S.E  Mean  S.E  Mean  S.E 
MDR1  nd  nd  0.51  0.56  15.91  0.56  nd  nd  nd  nd 
MRP1  4.71  0.21  3.93  0.09  -0.03  0.09  6.42  0.02  6.54  0.16 
MRP4  4.76  0.20  5.22  5.28  4.30  0.20  7.09  0.12  6.47  0.02 
ABCG2  8.77  0.28  4.73  0.26  6.13  0.26  nd  nd  0.81  0.03 
GAPDH  Endogenous control 
SLC22a1 
(OCT1)  
2 of 5  12.85  1.07  1 of 2  1 of 3  5.46  6.98 
SLC22a2 
(OCT2) 
nd  nd  nd  nd  nd  nd  nd  nd  nd  nd 
SLC22a3 
(OCT3) 
nd  nd  nd  nd  nd  nd  nd  nd  nd  nd 
SLC22a4 
(OCTN1) 
8.20  0.15  7.27  0.02  7.08  0.02  9.98  0.23  8.62  0.27 
SLC22a5 
(OCTN2) 
6.11  0.34  7.05  0.09  6.60  0.09  8.98  0.05  8.17  0.01 
SLC22a6 
(OAT1) 
nd  nd  nd  nd  nd  nd  nd  nd  nd  nd 
SLC22a7 
(OAT2) 
nd  nd  nd  nd  nd  nd  nd  nd  nd  nd 
SLC22a8 
(OAT3) 
nd  nd  nd  nd  nd  nd  nd  nd  nd  nd 
SLC22a9 
(OAT4) 
nd  nd  nd  nd  nd  nd  nd  nd  nd  nd 
 
Table 6-3 Expression of drug transporters in parental and transfected 
cell lines 
n=5  for  K-WT,  n=3  for  K-MDR,  n=2  for  K-MRP,  n=3  for  AML3,  n=3  for 
AML6.2. All samples were carried out in duplicate, nd=not detected 
 
The genes analysed demonstrate effective MDR1 and MRP1 transduction of the 
parental cell line (K-WT) to produce the cell line K-MDR and K-MRP respectively Jordanides Niove, 2008     Chapter 6 191 
(MDR1 in K-WT  CT=nd vs. K-MDR  Ct=0.51; MRP1 in K-WT  Ct=4.71 vs. K-
MRP  Ct=
-0.03, p=0.02). Similarly, effective ABCG2 transduction of the parental 
AML3  cell  line  was  observed  to  produce  AML6.2  (AML3   CT=nd  vs.  AML6.2 
 Ct=0.81).  
However, in addition to the elevated expression of the transduced genes, other 
drug transporters also demonstrated significant differences of expression in these 
cell  lines  compared  to  the  parental  cell  line.  In  K-MDR  cell  line,  there  was  a 
significant  increase  in  the   CT  of  MRP1  (p=0.02),  ABCG2  (p=0.001)  and 
SLC22a4  (p=0.02),  compared  to  K-WT  cell  line.  The   CT  for  ABCG2  and 
SLC22a4 were also increased in the K-MRP cell line, compared to K-WT (p=0.003 
and p=0.008 respectively) and MDR1 was expressed in the transduced K-MRP 
cell line (K-MRP  Ct=15.91), compared to K-WT, where expression was below the 
threshold  of  detection  or  not  expressed  (K-WT   CT=nd).  Similarly,  the   Ct  of 
MRP4,  SLC22a4  and  SLC22a5  were  also  elevated  in  the  AML6.2  cell  line, 
compared to the AML3 parental line (p=0.03, p=0.03, p=0.001 respectively). These 
findings suggest that manipulation of one transporter resulted in the modulation of 
the  endogenous  levels  of  other  transporters.  This  therefore  emphasises  the 
necessity to fully characterise cell lines before interpreting results. 
The  Ct values were analysed with the RQ equation (see section 3-1), thereby 
translating the  CT values into relative differences, which allows the comparison 
of the target sample (i.e. transduced cell line) against the calibrator sample (i.e. 
parental  cell  line,  Figure  6-1).  Although  the  MDR1  cell  line  had  statistically 
elevated   Ct  values  for  MRP1,  ABCG2  and  SLC22a4,  only  the  gene  ABCG2 
demonstrated greater than 3 fold increase in K-MDR compared to K-WT (1.72 fold 
for MRP1, 16.39 fold for ABCG2 and 1.9 fold for SLC22a4).  Jordanides Niove, 2008     Chapter 6 192 
The RQ equation was also used to compare the  Ct values of drug transporters in 
the K-MRP cell line with K-WT. The transduction of MRP1 resulted in a 26.7 fold 
overexpression of the gene in the transduced cell line. In addition, ABCG2 was 6.2 
fold  higher  in  K-MRP  compared  to  K-WT.  However,  although  there  was  a 
significant difference in  CT values with SLC22a4, the relative difference resulted 
in only 2.2 fold increase in K-MRP compared to K-WT.  
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Figure 6-1 Relative expression of drug transporters in the transduced 
cell lines K-MDR and K-MRP relative to the parental cell line K-WT 
Relative expression of K-MDR (A) and K-MRP (B) relative to the parental 
cell line K-WT; nd=not detected, ++= signal, * CT=p<0.05, n=3 
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Similarly,  the  transduction  of  ABCG2  in  the  parental  AML3  cell  line  resulted  in 
differences in the  Ct values of MRP4, SLC22a4 and SLC22a5; although none 
demonstrated greater than 3 fold relative difference (1.5 fold, 2.6 fold and 1.8 fold 
greater expression in AML6.2 compared to AML3, Figure 6-2). 
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Figure 6-2 Relative expression of drug transporters in the transduced 
cell line AML6.2 relative to the parental cell line AML3 
nd=not detected, ++= signal, * CT=p<0.05, n=3 
 
6.3 Expression of drug transporter genes in a CML cell 
line (K562) following drug treatment with TKIs 
The  parental  cell  line  was  then  treated  with  TKIs  to  determine  whether  the 
exposure to these drugs modulated the expression of drug transporters (Figure 
6-3).  
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Figure 6-3 Relative expression of drug transporters in a K-WT cell line 
during treatment with TKIs. 
The relative expression of ABCG2 (A), OCT1 (B), SLC22a4 (C), SLC22a5 
(D), MRP1 (E), MRP4 (F) and MDR1 (G) in K-WT cell line treated with 5 M 
A. 
G. 
F.  E. 
D.  C. 
B. 
ABCG2  OCT1 
MRP1  MRP4 
SLC22a4  SLC22a5 
MDR1 
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IM (black fill), 5 M nilotinib (dark grey fill), or 150nM dasatinib (light grey 
fill), compared to no drug control (ND, white fill) at days 1, 2 and 3; n=1 in 
duplicate,  nd=not  detected,  ++=  signal.  Figure  G  has  a  larger  RQ  scale 
compared to the other figures 
The relative expression of ABCG2 (Figure 6-3A) was increased in the presence of 
TKIs  at  day  1,  2  and  day  3,  with  the  maximal  increase  observed  on  day  2 
compared  to  the  control.  Similarly,  this  trend  was  also  observed  with  MRP1 
(Figure 6-3E), although the fold change in MRP1 did not reach above 3 fold. In 
addition, there was maximal expression of MDR1 at day 2 (Figure 6-3G), although, 
in  contrast  to  the  trend  for  ABCG2  and  MRP1,  there  was  much  lower  relative 
expression of the treated arms compared to the untreated control at day 1.  
The  expression  of  OCT1  (Figure  6-3B)  was  elevated  at  day  1  with  active 
expression observed at day 2 with all three TKIs. However, at day 2 there was no 
expression of OCT1 detected in the control group after 40 cycles, suggesting that 
either  there  was  no  expression  or  the  expression  was  below  the  threshold  of 
detection. Therefore, although OCT1 was detected on day 2 in the presence of 
TKIs, the expression could not be quantified due to the absence in the untreated 
control. At day 3 the expression of OCT1 was reduced compared to the control 
with IM and reduced to less than 2 fold higher with nilotinib and dasatinib. This 
suggested that the TKIs maintain increased OCT1 expression in cells that may 
have very little or no expression otherwise.   
This suggested that TKIs  induced the  expression  of these  drug  transporters to 
varying degrees, with the maximal effect shown on day 2. It might be that this 
trend  was  related  to  cell  death  caused  by  the  TKIs,  which  may  affect  the 
expression  of  these  transporters.  Also  by  cells  dying  that  did  not  express  the 
transporters you would get an apparent increase in expression in the remaining 
cells.  Jordanides Niove, 2008     Chapter 6 196 
In  contrast  the  greatest  expression  of  SLC22a4  (Figure  6-3C)  and  SLC22a5 
(Figure 6-3D) were shown on day 1, which was increasingly reduced at days 2 and 
3. Indeed the expression of SLC22a5 was similar to the control group by day 3. 
This  suggested  that  the  TKIs  exert  their  maximal  effect  on  these  transporters 
earlier compared to transporters ABCG2 and MDR1 where the maximal effect was 
demonstrated on day 2. These transporters are present on the same chromosome 
and hence are co-regulated, which would support the similar trend.  
In  contrast  to  these  transporters  the  expression  of  MRP4  (Figure  6-3F)  was 
elevated slightly on day 1 and 2, but did not reach greater than 2 fold, suggesting 
there was minimal effect by TKIs on this transporter. 
The greatest elevation at each day was shown in the cells treated with dasatinib 
and indeed this trend was shown for every transporter with the exception of OCT1, 
suggesting  that  dasatinib  had  the  most  effect  in  modulating  the  regulation  or 
expression of drug transporters. 
6.4 Expression of drug transporters on CML and normal 
CD34
+ cells 
In  total,  11  CML  CD34
+  samples  were  analysed  and  compared  to  7  normal 
counterparts.  In  table  6-1,  the  values  presented  are  of  the  crossing  thresholds 
normalised to GAPDH.  
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  Normal  Ct  CML  Ct   
Detector  Mean  S.E.  Mean  S.E.    CT 
ABCG2  9.09  0.33  7.55  0.22  -1.54 
MDR1  5.44  0.24  8.33  0.47  2.89 
MRP1  4.70  0.39  4.81  0.35  0.11 
MRP4  6.55  0.22  4.31  0.20  -2.24 
SLC22a1 (OCT1)   nd  nd  nd  nd  nd 
SLC22a2 (OCT2)  nd  nd  nd  nd  nd 
SLC22a3 (OCT3  nd  nd  nd  nd  nd 
SLC22a4 (OCTN1)  10.28  0.22  8.68  0.26  -1.60 
SLC22a5 (OCTN2)  7.53  0.40  7.36  0.43  -0.17 
SLC22a6 (OAT1)  nd  nd  nd  nd  nd 
SLC22a7 (OAT2)  nd  nd  nd  nd  nd 
SLC22a8 (OAT3)  nd  nd  nd  nd  nd 
SLC22a9 (OAT4)  nd  nd  nd  nd  nd 
 
Table 6-4  CT values of drug transporters in CML and normal CD34
+ 
with their corresponding   CT values 
n=11 for CML, n=7 for normal, nd=not detected 
 
In  comparison  to  normal   CT  values,  CML  samples  demonstrated  significantly 
higher levels of ABCG2 (p<0.001), MRP4 (p<0.0001) and SLC22A4 (p<0.001) and 
significantly lower expression of MDR1 (p=0.0028). 
Using the RQ equation comparing the target CML sample against the calibrator 
sample  (normal  mPB),  the  difference  in  the  drug  transporters  was  calculated 
(Figure 6-4). The mRNA levels of ABCG2, MRP4 and SLC22A4 were 2.91 fold, 
4.72 fold and 3.03 fold higher respectively in CML CD34
+. In contrast CML CD34
+ 
cells  had 7.42 fold less MDR1  expression than the normal counterparts. There 
was no difference with either MRP1 or SLC22a5. Jordanides Niove, 2008     Chapter 6 198 
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Figure 6-4 Relative expression of drug transporters in CML CD34
+ 
The relative expression of the drug transporters in CML CD34
+ (light grey) 
relative to normal (black) counterparts, n=11 for CML, n=7 for normal 
 
In addition, 4 CML samples and 4 normal counterparts were also analysed on a 
separate TLDA card specific for another project. GAPDH was again used as the 
endogenous control (Table 6-5). 
 
  Normal  Ct  CML  Ct   
Detector  Mean  S.E.  Mean  S.E.    CT 
ABCA1  7.97  0.32  11.33  0.66  3.36 
ABCG1  6.1  0.13  9.67  0.48  3.57 
 
Table 6-5  CT values of drug transporters in CML and normal CD34
+ 
with their corresponding   CT value (second set) 
n=4 for CML, n=4 for normal, nd=not detected 
7.42x 
2.91x 
4.72x 
3.03x 
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In  comparison  to  normal   CT  values,  CML  samples  demonstrated  significant 
lower levels of ABCA1 and ABCG1 (p<0.001), two additional transporters from the 
ABC family that mainly efflux cholesterol. Using the RQ equation comparing the 
target  CML  sample  against  the  collaborator  sample,  the  mRNA  of  ABCA1  and 
ABCG1 were 10.27 and 11.88 fold lower in CML cells. 
ABCA1 ABCG1
R
Q
0
1
2
3
4
5
Normal
CML
 
Table 6-6 Relative expression of drug transporters in CML CD34
+, 
(second set) 
The relative expression of the drug transporters in CML CD34
+ (light grey) 
relative to normal (black) counterparts, n=4 for CML, n=4 for normal 
 
6.5 Expression of drug transporters following treatment 
with TKI 
Following expression analysis of drug transporters, CML CD34
+ cells were treated 
with  5 M  IM  for  72hrs  in  an  attempt  to  identify  the  drug  transporters  that  are 
modulated. 
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Significant differences of CT were observed with every drug transporter, however, 
significant differences of CT were also observed with the endogenous controls, 
which  were  not  consistent,  raising  the  possibility  of  technical  issues.  Further 
investigation  of  the  quality  of  the  RNA  demonstrated  significant  degrading  by 
72hrs  (Figure  6-5).  Indeed,  degradation  was  observed  as  early  as  24hrs  post 
culture  even in the absence of TKI treatment, preventing comparative analysis. 
This may be due to the high levels of proteases and endonucleases in CML cells 
which will decrease the possibility of isolating good quality RNA from these cells.   
 
 
Figure 6-5  Agilent gel of RNA extracted from CML CD34
+ cells ± IM 
treatment 
L-Ladder, 1- untreated CML CD34
+ at day 0, 2- untreated CML CD34
+ at 
day 3, 3- CML CD34
+ cell treated with 5 M IM, 4- K-WT, 5- AML3. 
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6.6 Summary 
This chapter demonstrated the expression of drug transporters in cell lines, CML 
CD34
+  and  normal  counterparts  and  attempted  to  investigate  the  expression 
following treatment with TKIs. Prior to any investigations however, the TLDA card 
was validated in our lab.  
The cell lines used as models for optimisation in the previous chapters were then 
analysed.  Surprisingly,  when  individual  transporters  were  overexpressed,  we 
observed  modulation  of  not  only  the  transduced  gene  but  also  other  related 
transporters.  Indeed  the   CT  of  ABCG2  was  significantly  lower  (demonstrating 
higher expression) when either MDR1 or MRP1 were transduced, demonstrating 
>6 fold increased expression by the relative quantification calculation. Similarly, 
the overexpression of MRP1 induced the endogenous expression of MDR1, which 
was either absent or below the level of detection in the wild-type cell line. This 
observation  may  be  due  to  two  possibilities.  It  may  suggest  that  the  induced 
expression of drug transporters in cell lines modulate the expression of other drug 
transporters, demonstrating a linkage between ABCG2, MDR1 and MRP1, which 
are  the  clinically  relevant  efflux  transporters  in  CML.  Alternatively,  the  induced 
expression  may  be  due  to  the  presence  of  GFP,  either  directly  acting  as  a 
substrate and hence inducing transporter activity, or indirectly inducing transporter 
expression via an unknown mechanism. In order to confirm whether GFP alone 
can  induce  the  expression  of  transporters,  the  same  K-WT  cell  line  used  to 
transduce  the  specific  transporters  should  also  be  transduced  with  an  empty 
vector containing only GFP to be tested as a control. Unfortunately, such a control 
was not available during this project and hence the cause of the modulation was 
not confirmed. These modulations however, do highlight the possible limitations of Jordanides Niove, 2008     Chapter 6 202 
relying on experiments directly comparing engineered cell lines to wild-type, and 
re-affirm the importance of using specific inhibitors that target only the gene in 
question.     
The treatment of the wild-type K562 with IM, nilotinib or dasatinib demonstrated an 
effect on the drug transporters tested. Indeed, modulation was shown in all the 
drug transporters with at least a 3 fold increase compared to the no drug control 
group in all transporters except for MRP4 during a 72hr period. Treatment with 
TKIs showed greatest modulation of MDR1, reaching >17 fold higher expression at 
48hrs.  These  data  suggest  that  the  presence  of  the  TKIs  induce  the  cell  to 
increase  the  expression  of  the  drug  transporters.  This  may  be  as  a  cellular 
defence mechanism as the role of transporters is to actively extrude foreign toxic 
compounds.  However,  these  results  are  only  based  on  one  experiment  and 
require several repeats for confirmation of these trends.   
The expression of drug transporters in CML CD34
+ cells was compared to normal 
counterparts. As detailed in the earlier chapters, there was a significant reduction 
of MDR1 mRNA in the CML cells compared to the normal counterparts and similar 
expression of MRP1 in both cohorts. In this population, the ABCG2 expression 
was  significantly  elevated  in  CML  cells  (2.91  fold)  compared  to  the  normal 
counterparts.  However  the  fold  change  was  much  lower  than  that  detailed  in 
chapter 3. The CD34
+ cells in this cohort were handled in the same manner yet it 
includes a different set of patients, which may explain the variation. 
The  comparison  of  drug  transporter  expression  in  CML  CD34
+  cells  following 
treatment with TKIs was not possible due to the problems faced in obtaining RNA 
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The isolation of RNA was attempted with several kits, including Qiagen (Qiagen, 
Crawley, United Kingdom) and PARIS RNA isolation (Ambion, Austin, USA), but 
the  problem  persisted.  This  outcome  was  also  faced  by  colleagues  in  a 
collaborative  laboratory  who  also  were  unable  to  extract  good  quality  RNA 
following  IM  treatment  (personal  communication),  and  other  laboratories, 
suggesting that this may not be achievable. 
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7  Discussion 
Although CML was probably first described as early as the nineteenth century, 
until recently there was little progress in understanding the biology of the disease, 
and  hence  the  treatment  options  available  were  limited  to  either  allogeneic 
transplantation, for a minority of patients, or a combination of IFNα and Ara-C; 
both of which were associated with risks and problems. However, the discovery of 
the Ph
+ chromosome in the 1960’s (Rowley 1973) and realisation that the resulting 
BCR-ABL fusion gene was the molecular cause of disease in >95% of patients 
(Druker et al. 2001), presented the opportunity for molecularly targeted therapy. 
The  first  targeted  small  molecule  drug  IM  was  the  result  of  this  insight  and 
dramatically altered the course of CML treatment. Following the success of Ph
+ 
tumour eradication in murine models, IM has been part of an ongoing multicentre 
phase III clinical trial (IRIS) designed to compare this agent to the previous best 
treatment of conventional IFNα and Ara-C. Within the first 18 months of the clinical 
trial, patients treated with IM demonstrated excellent cytogenetic responses and 
fewer patients progressed to more aggressive disease compared to conventional 
treatment (O'Brien et al. 2003). This resulted in the widespread use of IM for the 
initial treatment of CP CML and currently it is the first choice in patients, even for 
those who are eligible for transplantation. However, it is now becoming evident 
that only a few patients treated with IM achieve CMR, and another set of patients 
lose their initial cytogenetic and haematological response (Hochhaus et al. 2002; 
Hughes et al. 2003). The underlying reasons for this have not been resolved and 
are the topic of much debate (Figure 7-1). 
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Figure 7-1 Mechanisms of resistance 
 
One  of  the  most  described  mechanisms  of  resistance  observed  in  relapsed 
leukaemia patients is the development of point mutations within the kinase domain 
(Gorre et al. 2001). To date, there are approximately 50 different aa substitutions 
(Azam et al. 2003) described in IM resistant clinical samples and the emergence of 
these  mutations  generally  confers  a  poor  prognosis  (Branford  et  al.  2003). 
Although these mutations have been shown to exist prior to IM therapy (Roche-
Lestienne et al. 2002), it has been suggested that they offer no survival advantage 
until the cells are exposed to IM. In order to overcome such resistance, there has 
been the development of new generation agents that have successfully inhibited 
most of the kinase domain mutations and can bind to both the active and inactive 
conformations of BCR-ABL. However, the incidence of mutations as the underlying 
mechanism for resistance is uncertain. Some studies have detected a low level of 
BCR-ABL  kinase  mutations  in  CD34
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2007a)  and  post  IM  treatment  (Chu  et  al.  2005)  however  other  studies  have 
demonstrated no mutants in the resistant population in vitro (Copland et al. 2006).  
BCR-ABL amplification has also been described as a resistance mechanism, as it 
may lead to increased mRNA and protein concentration. Amplified transcripts have 
been shown in Ph
+ BC cell lines and patients with advanced disease (Gorre et al. 
2001).  Furthermore,  prolonged  IM  exposure  has  been  shown  to  increase  gene 
amplification  (le  Coutre  et  al.  2000).  However,  gene  amplification  has  not 
previously been reported in early CP. Indeed, it has been reported that primitive 
CD34
+ cells have higher transcript levels despite only having one copy of BCR-
ABL (Copland et al. 2006; Jiang et al. 2007b). Therefore, it is possible that high 
protein level is still important, but not as a result of gene amplification. 
Although many groups have described these mechanisms, resistance cannot be 
wholly attributed to gene mutations or amplifications, as IM does not eradicate all 
the leukaemic cells even in the best responders. Recently a small subpopulation of 
cells that remains resistant to IM has been detected; these qSC are resistant even 
at IM concentrations 10 fold higher than those achievable in vivo ((Holyoake et al. 
1999;  Graham  et al.  2002). It has therefore  been hypothesised  that it  is these 
primitive cells that are responsible for MRD and may form a pool of cells that can 
reactivate  and  cause  disease  relapse.  Indeed,  patients  who  stopped  IM  after 
achieving CMR relapsed rapidly (Cortes et al. 2004), demonstrating the existence 
of this population. Furthermore, in vitro studies have shown that these cells still 
persist with nilotinib treatment (Jorgensen et al. 2007a) and, although a little more 
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In  light  of  these  qSC  there  have  been  2  mathematical  models  proposed  that 
discuss  the  potential  ability  of  IM  to  eradicate  CML  cells,  including  this  qSC 
population, which may then also be applied to the activity of other TKIs. Michor et 
al (Michor et al. 2005) suggest that although IM can reduce the proliferating and 
differentiating  cells,  it  will  not  reduce  the  qSC  population.  This  assumption  is 
based on the initial biphasic decline in the BCR-ABL transcripts, whereby the initial 
rapid decline represents the death of the differentiated cells followed by the much 
slower  decrease  of  the  more  primitive  CML  progenitors.  Indeed  the  BCR-ABL 
transcripts  rapidly  increased  in  patients  who  discontinued  IM  therapy  following 
CMR (Cortes et al. 2004; Mauro et al. 2004). Therefore, this model suggests that 
IM is unlikely to eradicate CML. 
In contrast, the second hypothesis is based on the key assumption that stem cells 
will be recruited into cell cycle periodically (Roeder et al. 2006). When this occurs 
these cells will begin cycling and become sensitive to IM. Hence, over time, the 
qSC pool will be depleted, supporting the observation that levels of MRD continue 
to  fall  over  prolonged  periods  of  IM  treatment  (Branford  et  al.  2004).  Thus, 
assuming no IM resistant clone arises, this model predicts that IM may eventually 
completely eradicate the leukaemic cells, although it is estimated it  will take in 
excess of 20 years to achieve. They further propose however, that the IM effect 
may be accelerated using agents that induce cycling activity, producing a more 
efficient tumour load reduction.  
Based  upon  the  latter  proposal,  Jorgensen  et  al  (Jorgensen  et  al.  2006)  have 
investigated the effect of treating CML CD34
+ cells with IM in combination with the 
growth  factor  G-CSF.  A  significant  reduction  of  primitive  CD434
+  cells  was 
observed  following  intermittent  exposure  to  G-CSF  compared  to  continuous Jordanides Niove, 2008    Chapter 7 208 
treatment of IM alone, which was further enhanced when the cells were treated 
with  a  combination  of  IM  and  intermittent  G-CSF,  supporting  the  above 
mathematical  model.  Indeed,  the  enhanced  reduction  of  cells  in  vitro  led  to  a 
multicentre clinical trial that further investigated the potential clinical use of growth 
factors  in  combination  with  IM  to  improve  long-term  outcomes  in  CP  CML. 
However,  no  significant  difference  was  observed  in  patients  treated  with  the 
combination of G-CSF and IM  compared to continuous IM  alone,  indicating no 
further benefit compared to standard IM treatment (Heaney 2007). 
In addition, combinations of IM with other agents have been attempted to optimise 
established therapies, but  with limited success. However,  lonafarnib, a farnesyl 
transferase inhibitor (FTI), showed effects on the quiescent CD34
+ population in 
combination with IM (Jorgensen et al. 2005a) and as a single agent, lonafarnib 
improved treatment in a limited number of patients who failed IM (Borthakur et al. 
2006).  
However,  for  these  models  to  succeed,  optimal  TKI  plasma  and  intracellular 
concentrations are necessary. It has been suggested that suboptimal intracellular 
TKI concentration may contribute to drug resistance. Gambacorti et al suggested 
that  excessive  IM  binding  to  plasma  proteins  might  significantly  alter  the 
availability  of  active  drug.  Alpha-1  acid  glycoprotein  (AGP)  is  a  hepatic  acute 
phase protein that was shown to bind and inhibit IM (Gambacorti-Passerini et al. 
2000), although another study did not support this finding and demonstrated that 
CML-derived AGP does not contribute to the leukaemic resistance (Jorgensen et 
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Alternatively,  active  efflux  transporters  may  prevent  optimal  TKI  concentrations 
being achieved in the cell. It is well established that ABC transporters are present 
on normal stem cells and their role is to extrude toxic substances. Furthermore, 
these transporters have been shown to efflux chemotherapeutic substrates and 
small  molecule  drugs,  therefore  it  can  be  postulated  that  intracellular  TKI 
concentrations are limited by active transport by this family of transporters. Indeed, 
until recently, an option for patients failing IM was to increase the dose. Although 
some found that this improved or reinstated the previous response, (Kantarjian et 
al. 2003; Zonder et al. 2003) this was not universal (Marin et al. 2003). This thesis 
has concentrated on the role of ABC proteins in mediating drug resistance, with 
the aim of further enhancing the TKI effect in the CML CD34
+ cell population and 
the IM resistant qSC. 
7.1 Expression and function of drug transporters 
In this study, we compared the expression of the most clinically relevant of these 
transporters and demonstrated that, at the mRNA level, ABCG2 was significantly 
elevated  in  CML  samples  compared  to  normal  counterparts,  while  MDR1  was 
significantly  reduced.  This  is  in  partial  agreement  with  Jiang  et  al  (Jiang  et  al. 
2007b) who have reported elevated expression of both genes in leukaemic CD34
+ 
cells. However, the disparity in the results may be due to a number of factors that 
would render valid comparison of these two studies impossible. First and foremost, 
the choice of samples may influence the expression levels. Jiang et al examined 
only  the  specimens  in  which  long-term  culture  initiating  cells  (LTC-ICs)  were 
predominately  Ph
+/BCR-ABL
+  and  may  therefore  be  preferentially  selecting  the 
samples with more aggressive CML. Secondly, it seems that all of the Jiang et al 
samples were subject to cell sorting into different populations by Hst and Py prior Jordanides Niove, 2008    Chapter 7 210 
to experimental analysis. Both stains are actively effluxed by the ABCG2 and MDR 
proteins (Goodell et al. 1996) thus this selection protocol may preferentially select 
the  CD34
+  cells  with  the  more  active  transporters  or  induce  their  expression. 
Indeed,  as  demonstrated  in  chapter  6,  the  expression  of  drug  transporters  are 
often  linked,  hence  the  induced  efflux  by  the  use  of  substrate  dyes  of  one 
transporter may also alter or induce the expression of another. In contrast, in our 
study  we  randomly  selected  a  number  of  CML  samples  from  the  cell  bank  for 
investigation, which were then thawed and the RNA was immediately extracted for 
analysis. Hence, the  cohort analysed in  this project  was selected in a different 
manner, without manipulation or subfractionation, other than CD34
+ enriching by 
positive immunomagnetic selection. We consider that our data will therefore better 
reflect the  baseline  expression in  standard CML CP CD34
+ cells, as  increased 
MDR1 may be a sign of aggressive disease or sample manipulation. We would 
also suggest that caution should be employed in using substrate dyes for selection 
of samples to be used in transporter assays. 
In addition we determined that the mRNA level of MRP1 in CML CD34
+ cells was 
similar to that in normal mPB CD34
+ cells. The transcript levels of MRP1 in CML 
CD34
+ cells has not previously been reported by other groups, although Carter et 
al (Carter et al. 2001) have demonstrated equal mRNA transcripts in MNCs from 
healthy donors and CML patients. However, these populations had less than 3% 
CD34
+ content so, again, a direct comparison cannot be made.  
Further  analysis  confirmed  that  these  drug  transporters  were  also  functional  in 
these cells, suggesting that it is reasonable to propose that active efflux of TKIs 
from cells may take place and may have a role in drug resistance. Interestingly, 
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observed  in  AML  patient  samples.  In  this  study  we  observed  that  a  greater 
proportion of the cell population had active ABCG2 expression rather than higher 
expression on a small subpopulation, suggesting that ABCG2 expression is not 
only restricted to the primitive CD34
+38
- population as in normal cells (Figure 7-2).  
 
Figure 7-2 ABCG2 expression in normal and CML haemopoietic cells 
ABCG2 is normally highly expressed in CD34
+38
- HSC and switched off in 
the more maturing cell lineages. In CML we propose that the expression of 
ABCG2  may  be  found  on  the  majority  of  the  CD34
+  cells,  suggesting  a 
greater proportion have the active transport rather than a high expression 
level  restricted  to  a  small  subpopulation;  SC-multipotent  stem 
cell/haemangioblast,  HSC-  haemopoietic  stem  cell,  HPC-haemopoietic 
progenitor,  CPC-  CML  progenitor.  Green  shading  indicates  ABCG2 
expression levels. 
 
Our observation that ABCG2 expression was also detected in the more mature 
CD34
+ cells suggests that the activity is regulated by BCR-ABL in the CML cells. 
Indeed, it has been shown that BCR-ABL phosphorylates the tyrosine kinase AKT 
(Mayerhofer et al. 2002) and that AKT also increases the translocation of ABCG2 Jordanides Niove, 2008    Chapter 7 212 
(Mogi et al. 2003; Takada et al. 2005), supporting this hypothesis. In addition, the 
activation of AKT induces HIF1a (Mayerhofer et al. 2002), which has also been 
shown  to  up-regulate  the  expression  of  ABCG2  mRNA  (Mogi  et  al.  2003; 
Krishnamurthy et al. 2004), suggesting that BCR-ABL driven AKT activity would 
both upregulate ABCG2 mRNA and increase translocation to the surface. More 
recently, Nakanishi et al (Nakanishi et al. 2006) have confirmed this connection 
and  demonstrated  that  BCR-ABL  enhances  the  expression  of  ABCG2  via 
activation of the AKT pathway; although this work was carried out in cell lines, it 
complements our data that ABCG2 is up-regulated in CML CD34
+ cells (Figure 
7-3). 
 
Figure 7-3 ABCG2 regulation by BCR-ABL activity 
BCR-ABL  phosphorylates  the  tyrosine  kinase  AKT,  which  in  turn  may 
increase the translocation of ABCG2. In addition, phosphorylated AKT may 
induce HIF1a, which in turn regulates ABCG2 mRNA. 1. (Mayerhofer et al. 
2002). 2. (Mogi et al. 2003). 3. (Takada et al. 2005), 4. (Krishnamurthy et al. 
2004) 
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Furthermore, we can postulate that ABCG2 may be regulating the expression of 
the CD34 protein itself as inhibition of this transporter resulted in a reduction of 
proliferating  CD34
+  cells  by  a  mechanism  other  than  apoptosis  or 
maturation/differentiation.  Indeed,  over-expression  of  ABCG2  in  HSC  has  been 
shown  to  result  in  an  accumulation  of  CD34
+  cells  (Krishnamurthy  et  al.  2004; 
Takada et al. 2005) and over-expression in human BM cells has resulted in an 
increase in proliferation of progenitor cells and myeloid engraftment in NOD/SCID 
mice (Ahmed 2005). If ABCG2 therefore does regulate CD34
+ expression, then it 
may further question whether all the CML cells that are ABCG2
+ and CD34
+ are 
immature  or  whether  the  expression  of  both  these  “stem  cell”  markers  are 
aberrantly  regulated  by  BCR-ABL.  Indeed,  some  CML  CD34
+  cells  have  been 
shown to have aberrant expression of other surface proteins such as CD56 (Lanza 
et al. 1993) and CD7 (Yong et al. 2006), so it may therefore not be unrealistic to 
postulate that BCR-ABL has an effect on the expression of such surface proteins. 
These  suggestions  could  be  confirmed  using  murine  transplantation  assays  to 
investigate  the  reconstituting  capacity  and  tumourgenicity  of  CML  CD34
+  cells 
treated with FTC, an inhibitor of ABCG2, in comparison to control CML and normal 
cells. 
7.2 Interaction of TKIs with drug transporters 
7.2.1 Influx transporters 
Having confirmed that the transporters are expressed and functional in these cells 
we aimed to further establish their role with regard to TKIs. There has been much 
debate  as  to  the  role  of  both  influx  and  efflux  transporters  in  limiting  the 
intracellular  concentration  of  IM  and  other  TKIs.  Several  recent  studies  have Jordanides Niove, 2008    Chapter 7 214 
identified that the active transport of IM is dependent upon OCT1 (Thomas et al. 
2004; White et al. 2006). Indeed, low activity of OCT1 has been identified as a 
cause of suboptimal clinical response to IM in CML patients (White et al. 2007), 
which may be overcome by increasing the IM dose. Surprisingly, nilotinib is not 
transported by OCT1, despite being highly structurally related to IM (White et al. 
2006), therefore suggesting that there may be other transporters not yet identified 
that also play a role in TKI transport. Alternatively, the increased lipophilic nature 
of  nilotinib  compared  to  IM  may  also  suggest  that  uptake  may  be  a  passive 
process (unpublished data). 
However,  there  is  controversy  as  to  whether  the  baseline  expression  of  OCT1 
prior to therapy correlates with disease progression. Wang et al (Wang et al. 2007) 
showed  high  baseline  OCT1  mRNA  and  demonstrated  that  expression  of  this 
transporter was a powerful indicator of CCR within 6 months. However, most of 
these  patients  had  prior  treatment  or  were  in  the  late  stages  of  CP.  Similarly, 
Crossman  et  al  (Crossman  et  al.  2005a)  also  demonstrated  OCT1  expression 
although their cohort also comprised of patients who had undergone prior therapy. 
In contrast, White et al (White et al. 2007) demonstrated that despite a correlation 
with OCT1 mRNA and activity, the expression of OCT1 alone is not itself a strong 
indicator of molecular response. The limiting factor of all these expression studies 
however, was that they were all examined in MNCs of PB or BM and Jiang et al 
(Jiang et al. 2007b) have previously shown that the expression differs in the cell 
populations,  with  the  highest  OCT1  mRNA  expression  in  the  lin
+CD34
-  subset. 
Therefore, the varying level of expression in the different lineages may conceal the 
correlation of OCT1 expression and activity in the primitive progenitor population. 
We examined the expression of OCT1 in CD34
+ cells from newly diagnosed CP 
patients prior to commencement of IM treatment, but demonstrated the level to be Jordanides Niove, 2008    Chapter 7 215 
below the threshold of detection. We have not monitored these patients during 
their treatment, but can say that due to the lack of expression of OCT1 levels prior 
to  onset  of  therapy  in  CP  patients,  this  is  unlikely  to  be  a  useful  indicator  of 
molecular response at onset of treatment. It is probable that the expression may 
develop with disease progression and/or it may be induced by therapy. Indeed, 
although only demonstrated once, we have shown that treatment with TKIs in K-
WT cell lines induced the expression  of  OCT1. If this is  confirmed  with further 
testing, then induction of OCT1 may prove to be a valuable prognostic tool in late 
CP patients and for disease monitoring rather than as a predictive tool prior to 
treatment commencement.  
In  addition  to  OCT1,  there  are  many  other  influx  transporters  that  may  also 
mediate TKI transport. To date, the studies reported on influx transporters have 
been  limited  to  OCT1-3.  In  our  study,  we  also  included  other  members  of  the 
SLC22  family.  Our  data  showed  that  the  cation  and  carnitine  transporters 
SLC22A4  and  SLC22A5  (OCTN1  and  OCTN2)  were  also  expressed  on  the 
primary CML CD34
+ cells, with 3 fold higher expression of SLC22a4 compared to 
expression levels on their normal counterparts. This suggests that they may have 
a role in TKI transport. Future studies of TKI uptake should be extended to include 
these transporters in addition to OCT1-3. 
7.2.2 Efflux transporters 
There  have  also  been  many  reports  investigating  the  interaction  of  efflux 
transporters  with  the  current  TKIs,  but  with  strongly  contrasting  results.  The 
interaction of IM with ABCG2 was first examined by Houghton et al (Houghton et 
al. 2004), who reported that IM is not a substrate but rather a potent inhibitor for Jordanides Niove, 2008    Chapter 7 216 
this  transporter.  However,  shortly  after,  Burger  et  al  (Burger  et  al.  2004) 
demonstrated  that  ABCG2  over-expressing  cell  lines  were  resistant  to  IM, 
concluding IM to be a substrate for ABCG2. This was supported by another report 
describing the active transport of IM across transepithelial layers of MDCKII cells 
that have been transfected with ABCG2 (Breedveld et al. 2005). However, there 
has been a recent study that has suggested the interaction between ABCG2 and 
IM is more complex and concentration dependent so IM may be both acting as an 
inhibitor and a substrate due to its high affinity for ABCG2 (Hegedus et al. 2002; 
Nakanishi et al. 2006; Shukla et al. 2007). At very low concentrations, IM behaves 
like  a  substrate,  but  becomes  an  inhibitor  at  high  concentrations.  Shukla  et  al 
(Shukla  et  al.  2007)  have  demonstrated  that  IM  does  not  interact  at  the  ATP 
binding site of ABCG2, but that it stimulates ATP hydrolysis, which is coupled with 
efflux function. However, IM can effectively inhibit the binding of a known ABCG2 
substrate with an IC50 value of 0.47 M (Shukla et al. 2007) and another group has 
further  reported  that  0.8 M  IM  can  effectively  inhibit  ABCG2-mediated  Hst 
transport  (Brendel  et  al.  2007).  Therefore,  the  high  affinity  of  IM  for  ABCG2, 
suggests that there is a narrow concentration range in which ABCG2 can transport 
IM, and that it can inhibit the protein at a higher concentration (Shukla et al. 2007). 
This may therefore explain why Burger et al observed active IM efflux when they 
used 200nM 
14C IM in their transport studies, where as Houghton et al confirmed 
inhibition with a higher IM concentration of 1 M. 
Nevertheless, the observation that IM is a substrate at <0.8 M is not relevant in a 
clinical scenario as a standard 400mg once-daily administration of IM produces 
plasma  cellular  concentration  ranging  between  1.2 g/ml  (2 M)  at  trough  to 
2.6 g/ml  (4.8 M)  at  peak  levels  (Peng  et  al.  2005).  Therefore,  in  vivo,  the 
concentration of IM will be 2-3 fold higher than that required for ABCG2 inhibition, Jordanides Niove, 2008    Chapter 7 217 
even at trough levels. Also, it has been shown that the IM concentration is similar 
in  plasma  and  BM  (unpublished  data),  therefore,  in  compliant  patients,  IM  will 
never be at a level at which active efflux will occur, but instead IM will inhibit this 
transporter.  
Although these reports hint at the interaction of IM with ABCG2, the limitation of all 
these transport studies is that they have not been carried out in primary tumour 
cells, hence do not resemble in vivo conditions. Indeed, they have not even been 
performed in the correct cell lines that represent the clinical targets for IM - that is 
CML  or  gastro-intestinal  stromal  tumour  (GIST)  lines,  but  instead  in  cell  lines 
engineered  to  over-express  ABCG2.  Furthermore,  the  interaction  of  IM  with 
ABCG2 should be tested at a clinically relevant therapeutic concentration. In our 
studies, we investigated the interaction of IM with ABCG2 and initially established 
the  assays  in  CML  cell  lines  that  had  not  previously  been  selected  for  drug 
resistance,  which  is  closer  to  the  situation  found  in  clinical  settings,  and  then 
confirmed  all  the  findings  in  primitive  CD34
+  CML  cells,  harvested  from  newly 
diagnosed patients prior to therapy. We observed that, at 5 M, IM is an inhibitor of 
ABCG2, which is in agreement with the current view of the IM/ABCG2 interaction. 
In addition, we have performed HPLC analysis of IM levels in our laboratory on 
CML CD34
+ cells and have observed no difference in cellular accumulation in the 
presence  or  absence  of  the  specific  ABCG2  inhibitor,  FTC,  confirming  these 
findings (unpublished data).  
However,  with  hindsight,  the  experimental  procedure  chosen  to  determine  the 
interaction  of  TKIs  with  drug  transporters  could  be  criticised  and  might  be 
improved  by  a  different  approach.  We  compared  the  cellular  concentration  of 
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FTC, to determine whether IM is a substrate of ABCG2. The washed cells were 
then lysed and counted. With this experiment therefore, any residual radiolabelled 
drug that may have attached to the external surface of the cell membrane that may 
not have been washed off was also counted. It may therefore be suggested that 
any differences in the two treatments in terms of genuine intracellular levels may 
have  been  masked  by  excessive  amounts  of  cell-bound  IM,  hence  the  similar 
cellular IM concentrations in the presence or absence of FTC. A more accurate 
analysis  would  require  a  HPLC  measurement  of  the  IM  concentration  in  the 
cytoplasm derived from a membrane-free preparation of the cells. However, not 
only is this difficult, if not impossible to achieve with current laboratory techniques, 
but there is also every chance that the agents such as IM will be lost with the 
membrane. 
However,  our  conclusion  that  IM  is  an  inhibitor  of  ABCG2  at  therapeutic 
concentration corresponds with the recent reports. Furthermore, we also tested 
the effect of drug transporter inhibition in the presence of IM and further confirmed 
no increase in apoptosis or in BCR-ABL inhibition. The activity of BCR-ABL cannot 
be directly measured, but may be assessed by detection of CrkL phosphorylation 
(Hamilton et al. 2006), either by flow cytometry or by Western blotting. Due to the 
low  cell  numbers  available  however,  we  were  restricted  to  measuring  by  flow 
cytometry  and  although  this  has  the  advantage  of  separating  and  observing 
different  subpopulations,  recent  comparative  experiments  carried  out  in  our  lab 
demonstrate that Western blotting is more sensitive. Therefore, small differences 
in BCR-ABL inhibition may have been present, but were not detected with the less 
sensitive  flow  technique.  In  addition,  CrkL  has  also  been  suggested  to  be  a 
substrate for SRC kinases (Qiao et al. 2006), therefore IM, which does not inhibit 
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SRC kinase signalling is active. It may therefore be that a different indirect target 
for  measuring  BCR-ABL  activity,  or  a  few  alternative  methods  to  allow 
confirmation, may be preferable, such as inhibition of STAT5 phosphorylation. 
Regardless  of  these  potential  weaknesses  in  our  approach,  our  investigations 
demonstrated  no  further  IM  effect  in  the  presence  of  FTC,  using  a  range  of 
methods and hence, in our opinion conclusively demonstrate that IM is an inhibitor 
of ABCG2 in primary CML CD34
+ cells when used at therapeutic levels. Therefore, 
inhibiting ABCG2-mediated substrate efflux will  not further enhance the cellular 
concentration  of  IM;  hence,  the  increased  expression  of  ABCG2  on  CML  cells 
compared to their normal counterparts is not relevant in the context of this drug. 
A similar debate has been ongoing regarding the interaction of IM with MDR1. The 
over-expression of MDR1 in K562 cell lines resulted in increased IM resistance 
(Mahon et al. 2003) and a reduced intracellular drug concentration (Widmer et al. 
2003). Indeed, RNAi mediated knockdown of MDR1 in IM-resistant CML cell lines 
has been shown to restore IM sensitivity (Rumpold et al. 2005). These data are 
consistent with other reports suggesting that IM is a substrate for MDR1 (Mukai et 
al. 2003; Illmer et al. 2004). However, in contrast, other groups have shown that 
over-expression of MDR1 in K562 cells does not confer resistance to IM (Ferrao et 
al. 2003). The recent study by Shukla et al (Shukla et al. 2007) though suggests 
that, like ABCG2, IM may interact with MDR1 as a substrate at low concentrations, 
but as an inhibitor at higher concentrations. Yet again, as with the reports with 
ABCG2,  these  studies  were  limited,  as  they  have  been  performed  in  cell  lines 
engineered  to  over-express  MDR1,  achieved  by  in  vitro  passaging  of  cells  in 
progressively  increasing  doses  of  chemotherapeutic  agents.  In  addition,  the 
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not  be  wholly  attributed  to  enhanced  intracellular  concentrations  of  IM.  Indeed, 
clinical trials that have administered PSC 833 (valspodar) as a MDR1 modulator 
have  had  to  terminate  early  due  to  increased  morbidity  and  mortality  in  the 
patients (Baer et al. 2002). We investigated the effect of PSC 833 in CML CD34
+ 
cells alone in vitro and demonstrated that PSC 833 alone  was profoundly anti-
proliferative  and  caused  significant  apoptosis.  Therefore,  we  can  postulate  that 
previous reports demonstrating increased overall kill by MDR1 inhibition with PSC 
833 in combination with IM may not be due to increased IM effect, but either due 
to the inhibition of MDR1 leading to anti-proliferative effects or to off target toxicity. 
Surprisingly, PSC 833 as a single agent also demonstrated significant reduction in 
p-CrkL  at  16hrs.  This  may  reflect  either  the  increased  concentration  of  an 
endogenous  substrate  that  has  p-CrkL  inhibitory  activity,  caused  by  blocking 
MDR1, or the direct inhibition of p-CrkL by PSC 833. However, as PSC 833 is a 
cyclosporin,  we  do  not  anticipate  that  it  is  the  latter,  although  the  underlying 
mechanism has not been resolved and will need further investigation.  
In our studies we also investigated the interaction of IM with MDR1. In our studies, 
we demonstrated that IM was an inhibitor of MDR1 and although the combination 
with PSC 833 reduced total cell  numbers,  this  did not appear to be due to an 
enhanced IM  effect. Therefore, like ABCG2, the  expression  of  MDR1  does not 
appear to mediate IM resistance in CML cells. This is in agreement with in vitro 
studies by Ferrao et al (Ferrao et al. 2003) and in vivo studies by Zong et al, who 
demonstrated  that  IM  response  in  a  CML  murine  model  was  not  improved  by 
inhibiting MDR1 (Zong et al. 2005). Indeed, they suggested one of the reasons 
leukaemia initiating cells were not sensitised to IM by loss of MDR1 might be due 
to  the  inhibitory  effect  of  IM  on  this  drug  transporter.  Furthermore,  a  previous 
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from patients who responded to IM compared to those that had not (Crossman et 
al. 2005b), and showed that low levels of MDR1 gene expression in CML blast 
cells was not a predictor of response to IM (Lange et al. 2003). 
For  completeness,  the  interaction  of  IM  with  MRP1  was  also  investigated. 
Previously, Mukai et al had demonstrated that IM was not a substrate for MRP1 in 
cell  lines  (Mukai  et  al.  2003).  We  confirmed  this  finding  and  additionally 
demonstrated  that  IM  is  not  an  inhibitor  of  MRP1,  nor  does  MRP1  modulation 
increase  the  IM  effect  in  vitro.  The  difference  in  interaction  between  the  drug 
transporters and IM may be due to the mechanism of action of MRP1. In contrast 
to  ABCG2  and  MDR1,  MRP1  cannot  transport  or  interact  with  unmodified 
substrates, but requires them to be conjugated to glutathionine. It may therefore 
be that IM is not conjugated to glutathionine in these cells and hence is neither 
transported by, nor interacts with, MRP1.  
The  interaction  of  nilotinib  with  the  drug  transporters  has  previously  been 
investigated, although to a much lesser extent than IM. A recent publication has 
demonstrated that, like IM, nilotinib was as effective as the known specific inhibitor 
FTC in preventing Hst transport by ABCG2 (Brendel et al. 2007). Indeed, nilotinib 
was more potent than IM and only 100nM was required for complete inhibition in 
mouse SP cells. This is in agreement with our results, which confirmed that at 
therapeutic  concentrations,  nilotinib  is  a  potent  inhibitor  of  ABCG2.  In  addition, 
Brendel et al observed that at very low molecular concentrations, nilotinib interacts 
at the substrate binding site of ABCG2 in K562 cell lines. This suggests that like 
IM, nilotinib may be a substrate at very low doses. However, as discussed with IM, 
these concentrations are considerably lower than those in compliant CML patients, 
with  peak-trough  levels  of  3.6-1.7 M  when  treated  with  a  standard  twice-daily Jordanides Niove, 2008    Chapter 7 222 
dose  of  400  mg  (Kantarjian  et  al.  2007),  therefore  nilotinib  concentrations  will 
always  be  in  the  range  that  cause  inhibition. We  have  also  demonstrated  that 
nilotinib is an inhibitor for MDR1 and MRP1 at therapeutic concentrations. This 
finding is in agreement with White et al (White et al. 2006), who also demonstrate 
that  inhibition  of  MDR1  in  MNCs  from  CP  CML  patients  did  not  increase  the 
intracellular nilotinib concentration.  
Surprisingly, the addition of PSC 833 resulted in a reduction in the accumulation of 
14C-nilotinib.  In  support  of  this White  and  colleagues  also  reported  unexpected 
results when treating CML cells with PSC 833 (White et al. 2006), with significant 
reduction in nilotinib uptake. It may suggest that PSC 833 is directly competing 
with  nilotinib  uptake,  or  down-regulating  the  nilotinib  uptake  mechanism. 
Alternatively, PSC 833 might be forming a complex  with nilotinib, which in turn 
reduces the active transport into the cells. 
As with IM, the effect of drug transporter inhibition in combination with nilotinib was 
investigated  and  resulted  in  no  further  cell  kill  or  BCR-ABL  inhibition.  We  can 
therefore conclude that the ABC transporters do not mediate resistance to IM or 
nilotinib in these primary CML CD34
+ cells. Hence, in a clinical setting, the effect of 
IM  or  nilotinib  cannot  be  further  enhanced  by  the  inhibition  of  these  drug 
transporters. 
In contrast to the Novartis agents above, there have been fewer studies of the 
Bristol-Myers  Squibb  agent  dasatinib.  Kamath  et  al  (Kamath  et  al.  2007)  have 
demonstrated that the absorption of dasatinib in MDR1 knock-out mice was no 
different compared to the wildtype, and that dasatinib did not alter the absorption 
or disposition of known MDR1 substrates, suggesting that dasatinib is neither a Jordanides Niove, 2008    Chapter 7 223 
substrate nor an inhibitor of MDR1. This is in agreement with our studies, which 
have also demonstrated that dasatinib is neither a substrate nor an inhibitor of this 
drug transporter.  
However,  Kamath  et  al  (Kamath  et  al.  2007)  did  observe  that  dasatinib  was 
actively  effluxed  from  Caco-2  cells,  suggesting  that  it  may  be  a  substrate  for 
another efflux transporter. We investigated dasatinib further and observed that, in 
contrast to IM and nilotinib, dasatinib was a substrate for both ABCG2 and MRP1. 
These results are of great interest, as they would suggest that in clinical practice, 
the cellular concentration of dasatinib might be increased and the potency of this 
drug may  be enhanced by blockade of these transporters. This is an attractive 
possibility and one that could efficiently be put into practice with specific inhibitors. 
There  are  now  clinically  safe  drug  transporter  inhibitors  such  as  Ko  143  for 
ABCG2, or alternatively a second TKI that inhibits the transporter, such as nilotinib 
or IM, could also be used. The use of the latter would then also provide a dual hit 
against  BCR-ABL,  although  caution  is  also  advisable  in  using  these  agents  as 
transporter inhibitors in patients, as nilotinib has been associated with detrimental 
side effects, including QT prolongation, which may result in an increased risk of 
developing ventricular arrhythmias. Furthermore, the combination of two TKIs may 
lead to an increased antiproliferative effect (Copland et al. 2006; Jorgensen et al. 
2007b), therefore, secondary usages may not be permitted. 
However,  before  clinical  application  becomes  feasible  there  are  a  number  of 
questions that need to be addressed. Although dasatinib has been identified as a 
substrate for ABCG2  and  MRP1, there is  no confirmation that drug transporter 
blockade will increase BCR-ABL inhibition and cell kill. In this study, we tested the 
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not observe any enhanced kill with either ABCG2 or MRP1 inhibition, and, more 
importantly, no further BCR-ABL inhibition or reduction in q34
+ cells.  
The studies that were carried out only examined one transporter at a time though, 
and therefore it may be that a combination of inhibitors may alter the outcome. If 
the combination of inhibitors with dasatinib produced further BCR-ABL inhibition 
and reduced q34
+ cells, then it may provide a basis for increased effect. 
However, caution must still be employed, as targeting these transporters will also 
have an effect on normal primitive progenitor cells. Indeed, the role of these drug 
transporters is to actively extrude toxic substances from essential sites such as the 
blood  brain  barrier  and  the  kidney.  If  this  role  is  inhibited  in  normal  cells,  and 
especially stem cells, then the effect may have disadvantageous consequences. It 
is  reasonable  to  assume  that  there  may  be  no  short  term  problems  with  the 
inhibition of ABCG2, as abcg2 null mice show normal haematological response 
with no developmental or observable organ defects (Zhou et al. 2002). However, it 
is not confirmed that ABCG2 functionality is not required for normal human stem 
cell  function  or  whether  the  activity  of  this  transporter  is  substituted  by  other 
transporters; a point that requires further investigation. 
Furthermore, this hypothesis is reliant upon there being the only two transporters 
involved in dasatinib efflux. It is not improbable that as both ABCG2 and MRP1 
actively efflux dasatinib, then there may be other, as yet, unidentified transporters 
that  may  also  actively  efflux  the  TKI,  which  would  therefore  still  maintain  a 
suboptimal  intracellular  concentration.  Our  expression  studies  identified  MRP4 
mRNA to be significantly elevated in CML CD34
+ cells compared to their normal 
counterparts, and it is extremely likely there are other transporters present. Thus, Jordanides Niove, 2008    Chapter 7 225 
the concentration of dasatinib within the cell may still be suboptimal even with the 
combination of ABCG2 and MRP1 inhibitors. Our pilot data in chapter 6 may also 
indicate that dasatinib and other TKIs induce the expression of other transporters; 
hence we can speculate that the cell may still find a way to extrude these drugs. 
This  is  in  agreement  with  Burger  et  al  (Burger  and  Nooter  2004),  who  also 
observed induced mRNA and protein expression of ABCG2 and MDR1 in Caco2 
cells when exposed to IM. 
However, it may be revealed that, even if all the transporters that efflux dasatinib 
are identified and inhibited, and the intracellular concentration is further increased, 
the activity of BCR-ABL and cell kill may still not be reduced. It may be that, even 
with  active  efflux,  the  current  cellular  concentration  of  dasatinib  is  such  that 
maximal inhibition of BCR-ABL is already achieved. Indeed, significant inhibition of 
CrkL phosphorylation is already achieved in primitive progenitor CD34
+38
- cells at 
the  IC50  dose  of  10nM  (Copland  et  al.  2006).  Furthermore,  we  have  recently 
treated  2  CML  CD34
+  samples  with  >1000nM  dasatinib  compared  to  10nM 
dasatinib  for  72  hrs  and  shown  no  measurable  difference  in  p-CrkL  inhibition, 
suggesting  that  even  extreme  doses  still  do  not  fully  inhibit  this  pathway 
(unpublished data). Thus, the very low effective dose range of this agent suggests 
that a low cellular concentration will still have a strong inhibitory effect on BCR-
ABL,  with  no  further  demonstrable  effect  at  much  higher  doses.  Therefore,  as 
supported by our inhibition data from ABCG2/MRP1, further increasing the cellular 
concentration of dasatinib may not further enhance BCR-ABL inhibition after all. 
An alternative explanation for the persistence of CML stem cells may be that TKI 
such as dasatinib do maximally inhibit BCR-ABL activity, but that the cells are no 
longer reliant upon BCR-ABL for survival. Indeed, the residual p-CrkL observed Jordanides Niove, 2008    Chapter 7 226 
may not be due to suboptimal inhibition, but may be residual normal p-CrkL levels 
which are not dependent on either BCR-ABL or SRC activity. In addition, it may be 
that  the  cells  have  acquired  secondary  genetic  abnormalities  that  provide 
alternative pathways for proliferation. If this is the case even complete inhibition of 
BCR-ABL  by TKI  will  never eradicate these cells. Indeed, despite the ability  of 
dasatinib  to target  BCR-ABL cells deeper  in to the stem cell  compartment, the 
quiescent CML cells still appear to be intrinsically resistant to dasatinib (Copland 
et al. 2006). It may be suggested therefore that BCR-ABL has a minimal effect on 
the qSC population. Evidence for BCR-ABL independence has been demonstrated 
in  a  murine  model,  whereby  inactivation  of  p190
BCR-ABL  did  not  rescue  the 
malignant  phenotype,  suggesting  that  p190
BCR-ABL  is  not  required  for  disease 
maintenance  (Perez-Caro  et  al.  2007)  once  initiated.  It  was  hypothesised  that 
other  epigenetic  changes  or  mutations  in  the  LSCs  may  have  rendered  them 
insensitive  to  inactivation  of  p190
BCR-ABL.  In  contrast  however,  there  have  been 
other  studies  clearly  demonstrating  the  requirement  of  BCR-ABL  for  disease 
maintenance  and  a  recent  study  has  demonstrated  that  dasatinib  treatment 
achieved complete remission of Ph
+ B-ALL in a murine model (Hu et al. 2006). 
Therefore  to  confirm  whether  CML  SCs  are  oncogene  dependent,  studies  are 
currently  been  undertaken  to  combine  siRNA  knockdown  of  BCR-ABL  with 
dasatinib to completely inhibit the oncogenic protein.    
7.3 Summary and future directions 
Overall,  based  on  these  findings,  there  are  avenues  to  continue  this  study  to 
identify new drug transporters involved in active TKI transport. There is evidence 
that there will be other influx transporters in addition to OCT1 that mediate the 
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exploit this effect in vivo, as methods of increasing the expression and function of 
these  transporters  are  not  yet  established.  However,  identifying  which  influx 
transporters are involved in the uptake of the TKIs may be utilised as prognostic 
tools to direct treatment by allowing the clinician to select the most suitable TKI 
and also monitoring for treatment response. In contrast, there is more scope to 
actively manipulate efflux transporters using specific inhibitors. The data presented 
here  indicate  that  with  the  current  drug  transporters,  the  effect  of  the  Novartis 
agents cannot be enhanced. However the cellular concentration of dasatinib can 
be  increased  and  may,  with  a  suitable  combination  of  inhibitors,  further  inhibit 
BCR-ABL  activity  and  increase  overall  cell  kill.  Hence  a  more  comprehensive 
analysis of all the transporters in primitive CML cells would be of interest, which 
may then lead to combination studies with specific inhibitors and TKIs to maximise 
the cellular TKI concentration and determine whether resistance can be overcome. 
However,  it  is  my  opinion  that  even  after  identifying  all  the  transporters  that 
actively efflux TKIs and maximal BCR-ABL inhibition by these agents is achieved, 
the TKI effect will not be enhanced, nor will it prove to be a cure for CML. The 
evidence suggests to me that the resistance of progenitor and primitive cells is not 
the result of limiting intracellular concentration of dasatinib. This is certainly not the 
case  for  IM  and  nilotinib  and  yet  disease  still  persists.  I  believe  the  primary 
direction for future therapy lies in conclusively confirming whether the cells are 
addicted to BCR-ABL as this will impact on the development of agents or protocols 
to combat this disease. If the qSC population are not oncogene dependent, then 
there  will  be  a  need  to  identify  and  develop  agents  that  target  other  essential 
aspects of SC maintenance for effective eradication and cure.  
One such novel agent that has shown promising results in CML is the farnesyl 
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activity in patients with acute leukaemias (Cortes et al. 2005) and preferentially 
targets the non-proliferating cells in tumour models (Rose et al. 2001). Copland et 
al  (Copland  et  al.  2005)  have  demonstrated  induction  of  apoptosis  in  both 
CD34
+38
+ progenitors and the more primitive CD34
+38
- CP CML cells, including 
the quiescent population, with synergism when combined with TKIs. LTC-IC data 
has  also  demonstrated  almost  total  ablation  of  CML  SC  and  preferential 
cytotoxicity for these cells compared to their normal counterparts, demonstrating 
novel and potent activity in eliminating quiescent CML stem cells. Furthermore, 
BMS-214662 was equally cytotoxic in cell lines harbouring the mutant BCR-ABL 
with T315I kinase domain mutation (Copland et al. 2007), demonstrating superior 
activity to IM and nilotinib. However the mode of action of this novel agent is to 
date unknown. Elucidation of this mechanism is essential, as it will prove a useful 
tool for developing novel therapeutic strategies for targeting cancer stem cells. 
An alternative novel approach to efficiently target the leukaemic SC may be by 
working in partnership with BCR-ABL. Instead of attempting to eradicate SC by 
actively  inhibiting  this  oncogene  itself,  its  presence  in  SC  may  be  used  as  a 
marker to deliver an apoptotic agent that is only activated in a BCR-ABL cell. For 
example, this apoptotic agent may  be delivered in two  inactive  halves that are 
completely harmless to normal cells. However, upon binding to BCR-ABL, the two 
separate  halves  may  be  brought  in  close  proximity  such  that  they  may  bind, 
causing activation and subsequent apoptosis only in the cell with the oncogene. 
This  will  therefore  specifically  target  the  tumour  population,  while  avoiding  the 
normal  SC.  Furthermore,  this  form  of  targeting  will  be  effective  regardless  of 
whether the SC is found to be dependent or independent upon BCR-ABL activity, 
as  this  technique  only  requires  the  oncogene  to  be  present.  Indeed,  such  a 
mechanism  for  delivering  an  agent  that  can  specifically  target  an  oncogenic Jordanides Niove, 2008    Chapter 7 229 
marker  will  also  prove  to  be  useful  in  other  cancers  with  a  SC  origin.  Such 
technology is currently being developed in mitochondrial RNA (Ozawa et al. 2007; 
Valencia-Burton  et  al.  2007),  but  will  prove  extremely  useful  if  it  can  be 
manipulated to target specific oncogenes such as BCR-ABL. 
Overall, this thesis provides a comprehensive study of the current TKIs and their 
interaction with transporters. Although there have already been numerous studies 
on this interaction, the reports have been conflicting and the experiments carried 
out have been in unsuitable cell lines that have been engineered to over-express 
the transporter. This thesis has significantly improved upon the existing literature 
as the interaction of TKIs and transporters has been investigated in drug naïve 
primary CML CD34
+ cells and tested at clinically relevant doses. Therefore, the 
results more closely reflect the true interaction of TKIs with these transporters and 
their effect on these cells. Furthermore, this thesis presents a promising lead for 
drug  transporter  modulation  in  combination  with  dasatinib  for  overcoming  TKI 
resistance,  although further  testing is  required. Finally,  we can  summarise  with 
conviction  that  although  ABC  transporters  are  present  and  functional  in  CML 
CD34
+ cells, blockade of these proteins by specific inhibitors do not increase IM 
and  nilotinib  accumulation  or  enhance  their  effect,  providing  evidence  that 
resistance to these agents is not mediated by active drug efflux. More importantly, 
neither  inhibitor  was  able  to  target  the  quiescent  population,  highlighting  the 
importance  of finding  agents  that  specifically  target  the  cancer  stem  cells.  It  is 
likely therefore, that future directions will most likely focus on understanding the 
biology of the CSC to identify other characteristics specific for the leukaemic cell 
and to develop agents with a different mechanism of action, or to develop novel 
approaches  of  delivering  agents  that  specifically  target  the  known  oncogenic 
markers. Jordanides Niove, 2008    Chapter 7 230 
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